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Degenerative aortic stenosis is a progressive disease with a peak in the elderly population (1). One-and-
a-half decade ago professor Alain Cribier pioneered  a less invasive strategy, with the first in human 
transcatheter aortic valve implantation (TAVI) (2). TAVI was initially tested and approved in patients who 
were inoperable or at high risk for death or complications with surgical aortic valve replacement (SAVR) 
(3-5), but the landscape has changed. While TAVI is maturing, adoption and penetration has expanded 
to patients at intermediate surgical risk (6-8). Although the concept of TAVI is appealing and intuitively 
less invasive than SAVR, the procedure still comes with a penalty of complications. Firstly, this thesis 
summarizes the principle periprocedural complications and evaluates possible solutions in order to push 
new frontiers in TAVI. Secondly, the focus of this thesis shifts toward expanding the technology to new 
indications. 
The introduction of uniform clinical endpoint definitions has led to a comprehensive overview of TAVI 
related complications (9). TAVI involves implantation by radial or balloon expansion of a stented frame 
within the aortic root. The anatomical position of the cardiac conduction system lies in close proximity to 
the aortic valve. Consequently, radial expansion of a transcatheter heart valve might affect cardiac con-
duction (10). When this damage is permanent, patients might need a pacemaker. Some patients might 
be more prone to conduction disturbances and in some instances they might resolve. Part I of this thesis 
zooms in on this concept. 
In contrast to percutaneous coronary intervention, TAVI requires large bore vessel access with an in-
crease in vascular complications such as bleeding, dissection, pseudoaneurysms. Newer device iterations 
have a smaller profile and thus require through smaller arteriotomies. Percutaneous arteriotomy closure 
systems are based on sutures. Part II of this thesis will address vascular complications and introduces 
collagen plug based closure devices for large bore arteriotomies.
Up to 5% of patients experience a clinically significant stroke after the TAVI procedure (11), in particular 
within the first 48 hours (12). With TAVI, interaction of the delivery system across the aortic arch and 
within the aortic root may dislodge tissue, which may embolize to the brain, causing ischemic stroke (13). 
Part III of this thesis discusses cerebral embolization and the value of cerebral embolic protection devices 
to reduce its incidence.
Multi-modality imaging is essential for procedural planning in terms of transcatheter heart valve design 
and size selection. The success of TAVI has stimulated product refinement and has brought competitive 
valve designs and implantation technologies. Part IV of this thesis will touch upon pre-procedural plan-
ning and the use of imaging strategies in optimizing the interplay between a transcatheter heart valve 
and the anatomical landing zone of the patient.
The final chapter of this thesis explores new indications for TAVI. The aortic valve typically contains three 
leaflets (tricuspid). Aortic stenosis is a degenerative disease characterized by valvular endothelial dam-
age, inflammation and calcification. Aortic valve degeneration develops over many years and typically 
becomes apparent in the elderly population. In up to 2 to 5% of the population the aortic valve has only 
2 leaflets (bicuspid) (14). Bicuspid valves are more prone to degeneration and aortic stenosis thus affects 
patients at an earlier age (15). The landmark randomized trials on TAVI excluded patients with bicuspid 
aortic stenosis (3-5). TAVI may be more challenging in bicuspid AS. Finally, even moderate aortic stenosis 
may be relevant in patients with heart failure and a depressed left ventricular function. The cornerstone 
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of heart failure therapy is after load reduction with medical therapy (16,17). It is conceivable that mod-
erate aortic stenosis may be detrimental to a failing ventricle. This thesis takes a deeper dive into these 
2 entities – severe bicuspid AS and moderate AS with depressed LV function – as interesting targets for 
TAVI and expanding future indications.
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ABSTRACT
Transcatheter aortic valve implantation (TAVI) has evolved from an exclusive, highly complex and 
hazardous procedure into a mature, safe and streamlined therapy for patients with severe aortic stenosis 
(AS). Various successive device iterations and product refinements have created a dynamic and compet-
itive field with a spectrum of different CE-marked transcatheter heart valve (THV) designs. This review 
provides a practical overview of current CE-marked THVs with a focus on respective sizing algorithms 
and delivery strategies.
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INTRODUCTION
Transcatheter aortic valve implantation has 
evolved from an exclusive, highly complex and 
hazardous procedure into a mature, safe and 
streamlined therapy for patients with severe 
aortic stenosis. TAVI uptake and adoption have 
increased exponentially and the annual TAVI rate 
has already surpassed SAVR in selected nations 
(1). More liberal patient selection and the explo-
ration of new indications, such as asymptomatic 
severe AS, moderate AS with heart failure and 
aortic regurgitation, may further broaden the 
TAVI landscape. This remarkable clinical success 
has stimulated successive device iterations and 
product refinement, resulting in a dynamic and 
competitive field with a spectrum of different 
CE-marked THV designs (2). This review provides 
a practical overview of current CE-marked THVs 
with a focus on respective sizing algorithms and 
delivery strategies.
Overview of CE-marked transcatheter heart 
valves 
Medtronic Evolut R
The CoreValve Evolut R device (Medtronic, Min-
neapolis, MN, USA) consists of a trileaflet porcine 
pericardial valve housed in a nitinol self-expanding frame and builds on the properties of its CoreValve 
predecessor (3). A fluoroscopic image of the Evolut R is shown in Figure 1A. The valve leaflets are in a su-
pra-annular position to maximise the effective orifice area and the redesigned nitinol frame has a larger 
cell size with a smaller frame height of 45 mm. Its inflow has a more consistent radial force to achieve opti-
mal conformation to the aortic annulus. The mid segment is narrower and the outflow segment abuts the 
aortic wall above the sinotubular junction for improved alignment between valve housing and the native 
sinus. A 12 mm porcine pericardium fabric skirt surrounds the inflow segment and is continuous with the 
valve leaflets to protect against paravalvular leakage. The valve is fully repositionable and retrievable up 
to approximately 80-90% of total deployment. Three valve sizes are currently available covering a range of 
aortic annular diameters from 18 to 26 mm (Figure 2). The novel EnVeo delivery system and integrated 14 
Fr InLine sheath (Medtronic) have significantly reduced the overall profile and are compatible with vessel 
sizes 5 mm and above. This smaller profile makes a transfemoral approach possible for a wider spectrum 
of patients, including those with more challenging iliofemoral anatomy including small, tortuous or ath-
erosclerotic vessels. 
Figure 1. Fluoroscopic views of new-generation transca-
theter heartvalves after implantation. A) Medtronic Evo-
lut R. B) Boston Lotus.C) Edwards SAPIEN 3. D) Direct 
Flow Medical. E) SymetisACURATE. F) St. Jude Portico.
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Boston Lotus
The Lotus valve system (Boston Scientific, Marlborough, MA, USA) is a trileaflet bovine pericardial valve 
supported on a braided nitinol frame which is deployed through active mechanical expansion, gradu-
ally decreasing in size from 70 mm ( fully sheathed) to 35 mm upon unsheathing and 19 mm at release 
(Figure 1B). The nitinol frame expands upon unsheathing and valve function is almost instant. A central 
radiopaque marker facilitates positioning of the prosthesis within the aortic root. The inflow segment is 
covered with an adaptive seal to conform to aortic root irregularities and reduce paravalvular leakage. 
The delivery catheter is attached to the bioprosthesis with three coupling fingers. The valve has a unique 
locking mechanism that connects the posts to the corresponding buckles and is completely deployed 
at this point. Valve function and position can be assessed in terms of implantation depth, paravalvular 
leakage, and location relative to the coronary ostia, and can still be fully repositioned or retrieved when 
deemed necessary. The Lotus valve comes in three sizes, covering a range of annular diameters from 19 to 
27 mm (Figure 2). The delivery system has an 18-20 Fr profile and requires a minimum vessel size of 6 mm.
Edwards Sapien 3
The SAPIEN 3 represents the fourth iteration in the balloon-expandable SAPIEN series (Edwards Life-
sciences, Irvine, CA, USA) (4). The cobalt-chromium frame houses three bovine pericardial leaflets and has 
a polyethylene terephthalate (PET) skirt at its inflow portion and an outer PET sealing cuff to reduce para-
valvular leakage (Figure 1C). The novel Commander delivery system consists of an outer deflectable flex 
catheter and an inner balloon catheter with radiopaque alignment markers. A central radiopaque balloon 
marker  and an additional small wheel for fine alignment of the transcatheter heart valve increase accuracy 
in positioning. The valve is loaded on the balloon in the abdominal aorta, which helps downsize the overall 
introduction profile. Furthermore, a dedicated 14 or 16 Fr expandable eSheath temporarily expands as the 
device passes through the iliofemoral vessels (minimum diameter 5.5 mm) and then recoils to its smaller 
caliber. There are four available valve sizes to accommodate aortic annular diameters ranging from 18.5 to 
29.5 mm (Figure 2). 
Figure 2. Combined sizing chart of new CE-marked transcatheter heart valves.
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Direct Flow Medical
The Direct Flow Medical device (Direct Flow Medical, Santa Rosa, CA, USA) is an 18 Fr compatible trileaf-
let bovine pericardial valve attached to a non-metallic frame covered by a polyester fabric (Figure 1D) (5). 
Flexible pillars connect the aortic and ventricular rings which are inflated with a radiopaque solution. 
The system is unsheathed in the left ventricle followed by inflation of the ventricular ring and retraction 
of the device into the aortic root. Three positioning wires allow final manipulation before inflation of the 
aortic ring. The device can be repositioned or retrieved by deflating both rings if device depth, proximity 
to the coronaries or residual paravalvular leakage are unsatisfactory. Once the correct device position is 
confirmed, a quick curing polymer is instilled instead of the radiopaque solution to secure permanent 
implantation and the valve is released by detaching the positioning wires. The Direct Flow Medical valve 
comes in four sizes, covering annular diameters from 21 to 29 mm (Figure 2). 
Symetis Acurate
The ACURATE TA ( for transapical) and neo ( for transfemoral) valves (Symetis SA, Ecublens, Switzerland) 
consist of a nitinol self-expanding frame with three stabilisation arches at the distal/aortic edge, an upper 
and a lower crown (Figure 1E) (6). The lower inflow crown is covered by a polyethylene terephthalate seal-
ing skirt while the upper crown segment provides supra-annular anchoring and houses three pericardial 
leaflets (ACURATE neo supra-annular; ACURATE TA intra-annular). Transfemoral deployment follows a 
top-down approach. The upper crown is released first to capture the native leaflets followed by release of 
the stabilisation arches and unsheathing of the lower crown. There is no need for rapid right ventricular 
pacing during deployment. During transapical deployment, the stabilisation arches and upper crown are 
released first before pulling the system down to embrace and compress the native leaflets. The lower crown 
is then unsheathed and self-detaches from the delivery system. There are three available valve sizes cover-
ing annular diameters from 21 to 27 mm (Figure 2), and the delivery system fits within an 18 Fr transfem-
oral sheath. 
St. Jude Portico
The Portico device (St. Jude Medical, St. Paul, MN, USA) is an intra-annular trileaflet bovine pericardial 
valve housed in a nitinol self-expanding frame with a height of 47 mm (7). The tubular inflow portion (9 mm 
height) has a porcine pericardial sealing cuff and the outflow segment (38 mm height) consists of large cells 
extending the frame towards the ascending aorta to provide stability (Figure 1F). The Portico is fully reposi-
tionable and resheathable until approximately 85% of deployment. Implantation starts with expansion and 
sealing of the inflow segment, with the valve functioning early during deployment. There are four available 
sizes for annular diameters ranging from 19 to 27 mm (Figure 2). The transfemoral delivery system is a 
flexible 18 Fr ( for smaller valve sizes) or 19 Fr catheter ( for larger sizes). The valve can be implanted using 
dedicated sheaths or via a 19 Fr SoloPath sheath (Terumo Europe NV, Leuven, Belgium). 
Delivery strategies 
The transfemoral route is the access site of first choice for transcatheter aortic valve delivery and has con-
sistently shown the best outcomes, especially compared to the transapical approach (8). The smaller pro-
file of latest-generation devices has increased the proportion of patients who are eligible for femoral access 
with a minimum required vessel size currently down to 5 mm. Nevertheless, selected patients may fare 
better with an alternative access route due to excessive calcification, atherosclerotic disease, tortuosity or 
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insufficient vessel caliber. Various options exist, including transapical, trans-subclavian/axillary, transca-
rotid, direct aortic and, more recently, transcaval. 
Transapical delivery is possible for SAPIEN 3 and ACURATE TA and the self-expanding systems are com-
patible with trans-subclavian/axillary access. Direct aortic TAVI can be performed with virtually any device 
platform and the transcarotid route has been successfully applied in selected centers. The transcaval tech-
nique is the newest way of bypassing heavily diseased iliac arteries but requires a non-calcified segment of 
Figure 3. Stepwise analysis of multislice CT with automatic 3mensio software. A) Segmentation and centrelining 
of aortic root. B) Prediction of optimal C-arm projection. C) Aortic root in a longitudinal view which can be rotated 
360 degrees for appreciation of root dimensions and distance to coronaries. D) Smooth tracing of the annular 
border for calculation of perimeter, area and mean diameters. E) Appreciation of the aortic valve anatomy (in this 
case a bicuspid aortic valve). F) Three-dimensional reconstruction of peripheral arteries and aorta. G) Estimation of 
tortuosity and calcium load in the common femoral artery with cross-sectional measurements of vessel diameters 
at any level.
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the abdominal aorta (9). Briefly, the inferior vena cava is connected with the abdominal aorta by punctur-
ing through the venous and arterial walls with a 0.014” “chronic total occlusion” stiff coronary guidewire. 
Upon entering the aorta, this guidewire is snared and eventually replaced by a stiff 0.035” guidewire. The 
TAVI procedure is then completed as a typical retrograde transfemoral procedure. After valve delivery, the 
aorto-caval communication is typically closed with St. Jude AMPLATZER™ nitinol closure devices (VSD or 
PDA occluders). The fate and adoption of alternative access strategies remains unclear. Indeed, relatively 
straightforward execution without the need for general anesthesia is arguably the most attractive feature 
of the standard retrograde transfemoral approach. Multislice computed tomography (MSCT) angiography 
is currently the preferred imaging tool for comprehensive assessment of the entire arterial tree relevant to 
TAVI. Conventional angiography may provide additional information given its superior spatial resolution 
or when CT imaging is suboptimal. A major limitation of ultrasound examination is its inability to visualise 
the retroperitoneal space. 
Valve size selection 
Pre-procedural imaging planning is key for any successful TAVI programme. Access site, transcatheter 
heart valve and consequent device sizing typically rely on MSCT (Figure 3). Inaccurate sizing may have 
important clinical consequences. Undersizing can result in prosthesis-patient mismatch, paravalvular 
leakage, device migration and embolisation, all of which can adversely influence prognosis after TAVI. 
Conversely, oversizing may lead to annular rupture, prosthesis underexpansion with subsequent risk of 
central transvalvular regurgitation, and conduction abnormalities due to excessive compression of the 
conduction system in the LVOT. An integrated sizing chart for current CE-marked THVs is displayed in 
Figure 2. Of note, self-expanding devices typically require more oversizing relative to the native anatomy, 
as opposed to closer matching with the SAPIEN 3, Direct Flow and Lotus devices. Several imaging modali-
ties are available to measure native annular dimensions and help guide THV size selection.
Multislice computed tomography (MSCT) 
A single MSCT study can offer vital information concerning the aortic root and entire relevant arterial 
trajectory, including the aorta, subclavian and iliofemoral system. MSCT has become the standard for 3D 
assessment of the aortic root in terms of dimensions, calcium distribution and height of the coronary ostia 
relative to the virtual annulus (10). Various dedicated software packages (3mensio (Pie Medical Imaging, 
Maastricht, The Netherlands), Philips Heart Navigator (Philips Medical Systems, Eindhoven, The Nether-
lands), Siemens syngo Aortic Valve Guide (Siemens AG, Munich, Germany) and GE Innova (GE Healthcare 
Ltd, Little Chalfont, Buckinghamshire, UK)) simplify the process of multiplanar reconstruction and make 
these advanced analyses accessible to interventionalists without extensive radiological training. Interest-
ingly, sizing charts for self-expanding systems rely on aortic annular perimeter (and derived diameters) 
whereas area is the preferred parameter for balloon and mechanically expandable THVs. Derived diam-
eters will not differ much in principle although the perimeter is less influenced by anatomic variation 
during the cardiac cycle and may result in larger derived diameters. 
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Echocardiography 
Transthoracic echocardiography is not as accurate as transoesophageal echocardiography and 2D echo-
cardiography requires expert interpretation to ensure that the aortic annulus is viewed in the correct plane 
to avoid underestimation of minimum and maximum diameters. The advent of 3D echocardiography may 
fix this important limitation, although the spatial resolution of 3D TOE remains inferior to MSCT and aor-
tic calcification may negatively affect imaging quality. Controversy surrounds the correlation between 3D 
TOE and MSCT sizing. Importantly, TOE quality depends on the experience of the echocardiographer and 
is characterized by wider inter-observer variability. In a recent study, aortic annulus measurements were 
significantly smaller with TOE versus MSCT, particularly in more oval annular anatomy (11). Three-di-
mensional TOE is a valid alternative to MSCT in patients with severe renal insufficiency (to avoid contrast 
exposure) or a suboptimal MSCT study (e.g., motion artefacts, out-of-phase contrast injection). 
Magnetic resonance imaging 
Cardiac magnetic resonance imaging (CMR) is a valid alternative to MSCT for device sizing. CMR is effec-
tive to determine aortic root dimensions and evaluate thoracic arterial structures yet struggles with calci-
um and cannot be used in patients who have an MRI non-compatible pacing device or are claustrophobic. 
Other modalities
Rotational angiography (R-angio) is a novel technique performed in the catheterisation laboratory using 
simultaneous C-arm rotation and diluted contrast injection. R-angio provides CT-like reconstruction of 
the aortic root with accurate sizing; however, patient characteristics (e.g., BMI >29 kg/m2) and a significant 
learning curve hamper its adoption in clinical practice (12). 
Simultaneous balloon aortic valvuloplasty and supra-aortic contrast angiography may help in root sizing 
and demonstrate the interaction of native aortic valve leaflets with the coronary ostia. This ancillary tech-
nique may be particularly helpful when MSCT sizing is ambiguous between two consecutive device sizes 
(13,14). 
CONCLUSION
Multiple CE-marked options for TAVI exist and MSCT is now the cornerstone to determine the optimal 
selection of the appropriate access site, transcatheter valve design and size.
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DESCRIPTION OF THE VALVE AND DELIVERY SYSTEM
The Lotus valve system (Boston Scientific, Marlborough, MA, USA) 
consists of a trileaflet bovine pericardial valve supported on a braid-
ed nitinol frame (Figure 1). A central radiopaque marker facilitates 
positioning of the prosthesis within the aortic root. The frame is 
covered with an Adaptive Seal at the inflow segment that adapts to 
aortic root irregularities and minimizes paravalvular leak (Figure 2). 
This transcatheter heart valve is currently available in three sizes 
- 23, 25, and 27 mm (Figure 3) - covering a range of annulus diame-
ters from 19 to 27 mm. In fully deployed state, all sizes have a frame 
height of 19 mm. The 23 mm model can be delivered through an 18 Fr 
sheath (small), while the 25 and 27 mm valves require a 20 Fr (large) 
sheath. 
Lotus is typically inserted with a transfemoral approach, though direct aortic and transaxillary alterna-
tive access is possible. Implantation of a Lotus valve requires the following components:
– A support guidewire: either a manually curved Super/Extra Stiff 0.035” guidewire (260 cm for 23 mm 
and 275 for 25 and 27 mm) or a pre-shaped Safari guidewire with an extra-small, small, or large curve 
(Figure 4).
Figure 1. The Lotus Valve.
Figure 2. The Adaptive Seal technology covers the 
inflow segment of the Lotus valve frame and adapts 
to aortic root irregularities and, hence, minimizes 
paravalvular leak.
Figure 3. The three available Lotus valve sizes —23, 25, 
and 27 mm— accommodating annulus diameters ran-
ging from 20 to 27 mm.
Figure 4. The pre-curved Safari wire comes in three curve sizes to 
facilitate stability for valve implantation in small and large ventricles.
27Boston Lotus
In
tr
od
uc
tio
n
– Lotus introducer—small for 23 mm and large for 25 and 27 mm 
(Figure 5).
– Lotus valve delivery system, with pre-mounted Lotus valve
—103 cm for 23 and 113 cm for 25 and 27 mm (Figure 6). The 
pre-shaped angulated delivery system should help negotiate the 
thoracic aorta.
- Prostar or double Perclose ProGlide (Abbott Vascular, Abbot 
Park, Illinois, USA) suture-based closure for transfemoral access 
(Figure 7).
The bioprosthesis is coupled to the delivery system with three coupling 
fingers (Figure 8). The three fingers hatch with the buckles at the top of the 
frame. Initially the frame expands during unsheathing. The unique feature 
of Lotus is the locking mechanism that follows after the frame is fully un-
sheathed but still elongated. The locking mechanism implies connecting 
the buckles (top of the frame) with the posts (level of valve leaflets), similar 
to fastening a seatbelt. 
Figure 5. Lotus introducer (small). 
The light blue 18 Fr Lotus introducer 
accommodates transfemoral 
access for the small Lotus delivery 
system (23 mm valve).
Figure 6. Lotus delivery system. Top, the pre-mounted 
Lotus valve; bottom, the intuitive delivery handle with 
the blue control knob for unsheathing/re-sheathing 
and locking and the black release cover for release of 
the valve.
Figure 7. Double Perclose ProGlide systems. ProGlide provides percutaneous 
suture-based closure of femoral access arteriotomies, ranging from 5 Fr to 21 Fr. Figure 8. Three fingers 
connect the Lotus valve to the 
delivery system throughout 
the entire implantation pro-
cess. The fingers are attached 
to the buckles on the frame 
and can be released when the 
result after complete locking is 
satisfactory.
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The valve shortens and expands radially during 
the locking process (Figure 9). After locking, the 
valve is fully deployed, and its position relative to 
the coronary ostia and presence of paravalvular 
aortic regurgitation can be assessed. Still, at this 
stage, the bioprosthesis can be repositioned or 
retrieved.
The delivery handle of the delivery system is 
ergonomic and intuitive (Figure 6). A large blue 
control knob regulates unsheathing and locking 
by rotating counterclockwise. Clockwise rotation 
will lead to re-sheathing. The release cover prox-
imal to the blue control knob can be slid forward 
to release the valve from the catheter.
PROSTHESIS LOADING
The loading procedure for the 23, 25, and 27 mm valves is identical. When removed from the package, 
the valve is sealed within a bottle stopcock at the distal end of the delivery system. The stopcock contains 
glutaraldehyde for valve conservation:
1. Remove the Luer cap from the bottle stopcock, and attach it to the waste bag to drain the glutaralde-
hyde solution.
2. Flush the guidewire port at the distal end of the delivery system.
3. Remove the valve from the stopcock (Figure 10).
4. Visually inspect the valve for abnormalities (catheter tip and finger connection, collar and buckle inter-
action, sheathing aids, nosecone, valve leaflets), and flush the system (Figure 11).
Figure 9. When fully sheathed, the Lotus valve frame 
has a height of 70 mm. During unsheathing the height of 
the valve frame shrinks to 35 mm, while the diameter of 
the valve increases. During the locking process, the frame 
shrinks to a height of 19 mm and reaches its final configu-
ration with maximal sealing of the annulus.
Figure 10. The pre-mounted Lotus valve is conser-
ved in a bottle stopcock containing glutaraldehyde.
Figure 11. Before delivery, the valve is visually 
screened for abnormalities by checking the catheter 
tip and finger connection, collar and buckle inter-
action, sheathing aids, nosecone, and valve leaflets, 
followed by flushing of the system.
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5. Lock the valve by turning the blue control knob 
counterclockwise, to ensure post and
buckles engage without a gap and there is no twist-
ing (Figure 12).
6. Turn the blue control knob clockwise to ensure 
post and buckles disengage symmetrically.
7. Rinse the valve with agitation 2 × 60 s.
8. Insert a stylet in the nosecone and flush the sys-
tem with saline.
9. Remove air bubbles from the leaflets by agitating 
the valve.
10. Submerge the valve in saline, and wait until the 
valve can be delivered.
11. Once the valve can be delivered, gently start sheathing the valve by turning the blue control knob 
clockwise.
12. Remove the stylet and inspect the catheter tip. The delivery system is ready.
Figure 12. The blue control knob on the delivery 
handle facilitates unsheathing/locking of the Lotus 
valve (rotating counterclockwise) and re-sheathing 
(rotating clockwise). This mechanism is checked 
before valve delivery.
Figure 13. Echo-guided puncture of the right common femoral artery. On an axial plane 
the location of the vessel can be accurately determined.
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TYPICAL TRANSFEMORAL IMPLANTATION 
PROCEDURE
Obtaining Vascular Access
1. Obtain controlled access to the left and right 
common femoral arteries, preferably under fluo-
roscopy or ultrasound guidance (Figure 13).
2. Obtain venous access for a temporary right 
ventricular pacing wire.
3. Position the temporary pacing wire in the apex 
of the right ventricle, and test the pacemaker.
4. Insert a pigtail catheter through the left femoral 
artery, and position at the level of the non-cor-
onary cusp; confirm a coaxial C-arm projection 
with a contrast injection to have all cusps in one 
plane (Figure 14).
5. Preclosure with two 6 F Perclose ProGlide sys-
tems (or 1 Prostar) in the right femoral artery.
6. Insert the 18 F introducer (small) or 20 F (large), depending on the bioprosthesis size (Figure 5).
7. Cross the aortic valve with a 0.035 straight tip wire, and advance a catheter in the left ventricle.
8. Confirm ventricular pressures and transaortic gradient.
9. Exchange for a Safari wire (Figures 4 and 15). Ensure the pre-shaped curve of the Safari wire is posi-
tioned in the apex, and the soft part of the wire is entirely curled in the ventricle. This will provide enough 
safe migration space for the nosecone (see below).
10. Decide whether to perform balloon predilatation. In our practice, balloon predilatation is performed 
only exceptionally.
Valve Delivery
1. Hold the pre-shaped delivery system in an 
S-curve, and insert over the Safari wire into 
the body (Figure 16a).
2. Advance the assembly gently, under 
fluoroscopic guidance, keeping guidewire 
control and checking proper orientation 
along the descending aorta (Figure 16b). 
The radiopaque marker should be facing the 
right side of the delivery system on an AP 
fluoroscopic view before entering the aortic arch (Figure 17).
3. Smoothly advance the system along the aortic arch (Figures 16b and 17).
4. Cross the native aortic valve and ensure the nitinol braid is below the aortic annulus (Figure 18a1).
5. Determine the final landing zone of the radiopaque marker.
6. Start unsheathing the valve by turning the blue control knob counterclockwise (Figures 16c and 18A2/
A3/A4).
Figure 14. Angiogram of the aortic valve in a perpendi-
cular plane with all cusps aligned (NCC-RCCLCC). An 
optimal working projection contributes to an accurate 
valve implantation.
Figure 15. Animation of a Safari wire positioned in the left 
ventricle.
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7. Avoid excessive device migration into the left ventricle. The Lotus valve functions early during deploy-
ment; there should be no hemodynamic compromise.
8. As the valve deployment evolves, a waist will appear, and the radiopaque marker is displaced toward 
the ventricle.
9. The framework shortens from 70 to 35 mm upon unsheathing.
Figure 16. Stepwise Lotus valve implantation: (a) delivery system is held in the pre-shaped S-curve 
before introduction; (b) delivery system is smoothly advanced by pushing forward through the Lotus 
introducer; (c) when the tip of the delivery system is in the correct position (with the nitinol braid below 
the native annulus), the valve can be unsheathed and locked by turning the blue knob counterclockwise; 
(d) release cover is slid toward the patient and turned clockwise to release the valve; (e) blue control knob 
is turned counterclockwise to re-sheath the disconnected fingers and nosecone; ( f ) delivery system is 
pulled back gently through the introducer.
Figure 17. During crossing of the aortic arch (in approximately 8 s), the delivery system is carefully 
monitored to ensure that the radiopaque marker follows the outer curve of the arch.
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Locking
The next step is locking the valve by connecting the buckles (cranial) and posts (caudal). 
1. Before initiating the final locking process, confirm that the fluoroscopy projections show all three buck-
les and posts (Figure 18B1).                   
2. Gently turn the blue control knob counterclockwise while confirming that the buckles and posts ap-
proach symmetrically. During this process, the frame height will shrink from 35 to 19 mm (Figure 18B2).
3. The valve is completely locked, resistance is felt, and a force limiter is tripped. An audible sound is 
heard.
4. Final valve positioning relies on the 
confirmation that the distal braid is 
below the annulus (this may allow for 
a high position) or by landing the ra-
diopaque marker at its predetermined 
location.
5. After locking the valve, a contrast 
injection may help confirm valve posi-
tioning in terms of implantation depth, 
position relative to the coronary ostia, 
and paravalvular regurgitation (Figures 
19 and 18B3).
Figure 18. Unsheathing: (a1) fully sheathed Lotus valve ( frame height 70 mm) with the distal tip 
of the nitinol frame below the native annulus; (a2/3) unsheathing of the valve. The valve functi-
ons early during deployment; (a4) fully unsheathed valve ( frame height 35 mm). Locking: (b1) 
locking of the frame in a correct fluoroscopic image with all buckles and posts visible; (b2) fully 
locked frame ( frame height shrinks to 19 mm); (b3) angiogram to confirm correct positioning 
after locking and absence of significant paravalvular regurgitation. At this stage, the valve is still 
fully repositionable and re-sheathable. Release: (c1/2) disconnecting the fingers from the frame 
buckles; (c3) final angiogram to evaluate position and paravalvular regurgitation.
Figure 19. Fully locked Lotus valve before release on fluoroscopy 
(a) and reconstructed (b). The valve can be repositioned at this 
stage.
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Release
1. Slide the release cover (located distal to the blue knob) in 
the direction of the patient (Figure 16D).
2. Turn the release cover clockwise. The release pin moves 
upward. The valve is released (Figure 18C1/2).
3. When the valve is completely released, start re-sheathing 
the fingers and nosecone by turning the blue control knob 
clockwise. Gently pull the nosecone back into the descend-
ing aorta and fully re-sheath.
4. The final position of the Lotus valve can be properly 
visualized by transthoracic or transesophageal echocardiog-
raphy (Figure 20) and on fluoroscopy (Figure 21).
Figure 20. Long-axis transesophageal echo-
cardiographic view of the Lotus valve after 
final release.
Figure 21. The Lotus valve after final locking and release: (a) lotus valve with central radio-
paque marker and Adaptive Seal; (b) reconstruction of a Lotus valve in the correct anatomi-
cal position; (c) fluoroscopic image of the Lotus valve.
Figure 22. Fluoroscopic image of a 
fully locked Lotus valve in an extremely 
horizontal aorta with an angle of 72°.
Figure 23. Repositioning of the Lotus valve on fluoroscopy: (a1) aortic 
angiogram pre-repositioning,moderate paravalvular aortic regurgitati-
on; (b1) aortic angiogram post-repositioning, no aortic regurgitation. 
(a2/b2) Angle and depth measurements before and after implantation 
confirming a slight tilting of the frame between pre- and post-repositi-
oning, with a similar depth of implantation; (c) final aortic angiogram 
with no aortic regurgitation.
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Repositioning
The repositionability/retrievability feature allows 
for precise valve delivery even in complex anat-
omies (e.g., horizontal aorta (Figure 22)) and 
readjustment when paravalvular regurgitation is 
present (Figures 23 and 24). The Lotus bioprosthe-
sis is fully repositionable and retrievable until the 
valve is fully locked and the release pin is removed. 
Re-sheathing is done by turning the blue control 
knob clockwise.
PROCEDURE AND SIZING TIPS AND TRICKS
The Lotus delivery system requires a minimum ar-
terial vessel diameter of 6 mm. The Lotus valve can 
be implanted in a wide range of native valve diam-
eters (19–27 mm). Figure 25 illustrates the sizing 
matrix. The 23 mm Lotus fits annulus and LVOT 
diameters ranging from 20 to 23 mm, the 25 mm Lotus from 23 to 25 mm, and the 27 mm Lotus from 25 
to 27 mm. The Adaptive Seal of the Lotus valve can help eliminate the incidence of paravalvular regurgita-
tion. In our opinion, the left ventricular outflow tract dimensions are equally important for Lotus sizing. 
Excessive oversizing relative to the LVOT and overall depth of implantation may affect the occurrence of 
conduction disorders and need for 
pacemakers. It is important to bear 
in mind that the bioprosthesis will 
dominate the anatomy, suggesting a 
more circular final geometry. Coro-
nary obstructions can be avoided by 
pre-procedure MSCT planning and 
by checking the Lotus position before 
release. The bioprosthesis can be 
repositioned when needed.
Figure 24. Repositioning of the Lotus valve on 
transesophageal echocardiography: there was a mild 
paravalvular leak (at 11 o’clock on short axis), which 
was resolved after repositioning.
Figure 25. Lotus valve sizing guidelines.
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Part I 
Conduction disorders
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ABSTRACT
Background
Right bundle branch block is an established predictor for new conduction disturbances and need for a 
permanent pacemaker (PPM) after transcatheter aortic valve replacement. The aim of the study was to 
evaluate the absolute rates of transcatheter aortic valve replacement related PPM implantations in pa-
tients with pre-existent right bundle branch block and categorize for different transcatheter heart valves.
Methods and Results
We pooled data on 306 transcatheter aortic valve replacement patients from 4 high-volume centers in 
Europe and selected those with right bundle branch block at baseline without a previously implanted 
PPM. Logistic regression was used to evaluate whether PPM rate differed among transcatheter heart 
valves after adjustment for confounders. Mean age was 83±7 years and 63% were male. Median Society of 
Thoracic Surgeons score was 6.3 (interquartile range, 4.1–10.2). The following transcatheter valve designs 
were used: Medtronic CoreValve (n=130; Medtronic, Minneapolis, MN); Edwards Sapien XT (ES-XT; 
n=124) and Edwards Sapien 3 (ES-3; n=32; Edwards Lifesciences, Irvine, CA); and Boston Scientific Lotus 
(n=20; Boston Scientific Corporation, Marlborough, MA). Overall permanent pacemaker implantation 
rate post-transcatheter aortic valve replacement was 41%, and per valve design: 75% with Lotus, 46% with 
CoreValve, 32% with ES-XT, and 34% with ES-3. The indication for PPM implantation was total atrioven-
tricular block in 98% of the cases. Lotus was associated with a higher PPM rate than all other valves. PPM 
rate did not differ between ES-XT and ES-3. Ventricular paced rhythm at 30-day and 1-year follow-up was 
present in 81% at 89%, respectively.
Conclusions
Right bundle branch block at baseline is associated with a high incidence of PPM implantation for all 
transcatheter heart valves. PPM rate was highest for Lotus and lowest for ES-XT and ES-3. Pacemaker 
dependency remained high during followup.
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INTRODUCTION
Patients with severe aortic stenosis and a higher operative risk for mortality are good candidates for tran-
scatheter aortic valve replacement (TAVR) (1-4). TAVR involves placement of a transcatheter heart valve 
(THV) that protrudes into the left ventricular outflow tract. As such, the THV radial force may impose on 
the adjacent conduction system and result in conduction disturbances (5,6). Incidence of new left bundle 
branch block (LBBB) and high-grade atrioventricular block (AV block) varies according to patient demo-
graphics, anatomical characteristics, and selected THV. New LBBB and permanent pacemaker (PPM) im-
plantation post-TAVR varies from 4% to 81% and from 0% to 49%, respectively, and is consistently higher 
with the self-expanding CoreValve compared to balloon-expandable Sapien valves (5,7,8).
New THV designs have focused on profile refinement, paravalvular leak prevention, and the intrinsic 
feature of partial or complete repositionability and retrievability (9-11), yet conduction disorders remain 
common. Right bundle branch block (RBBB) at baseline is considered a dominant predictor for high 
degree AV block and PPM post-TAVR (7,12-16). Frequency of RBBB at baseline in current TAVR practice 
ranges from 4% to 21% (7). Knowledge of the respective PPM rates for different THV designs in patients 
with RBBB may guide patient-tailored THV selection. This multicenter collaboration sought to further 
elucidate TAVR-related PPM rates in patients with pre-existent RBBB and categorize for different THV 
designs. 
METHODS
Patient Selection
Between May 2008 and February 2016, 2845 patients under-
went TAVR in 4 tertiary care European institutions. All pa-
tients were screened for RBBB (and absence of a PPM) before 
the TAVR procedure and were included in a joint database 
collecting: baseline demographics; TAVR procedure char-
acteristics; new conduction disorders within 24 hours; PPM 
at 30 days; and electrocardiographic and clinical-follow-up 
data at 30 days and 1 year. THV selection was per institution’s 
discretion. A minimum of 10 available cases per THV was a 
predefined requirement for further analysis, to secure solidity 
of data. The 4 THVs used were CoreValve (Medtronic, Minne-
apolis, MN), Sapien XT (ES-XT) and Sapien 3 (ES-3; Edwards 
Lifesciences, Irvine, CA), and Lotus (Boston Scientific Corpo-
ration, Marlborough, MA). Figure 1 displays the patient flow 
diagram. All patients provided written informed consent for 
the procedure and data analysis for research purposes per 
institutional review board approval. 
Figure 1. Flow chart of study inclusion. 
Abbreviations: ES-3 = Edwards Sapien 3; 
ES-XT = Edwards Sapien XT; PPM = per-
manent pacemaker; RBBB= right bundle 
branch block; THVs = transcatheter heart 
valves.
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Outcomes
The primary outcome was implantation of a PPM within 30 days after the TAVR procedure. Secondary 
outcomes were new-onset conduction disturbances within 24 hours: (1) third-degree atrioventricular 
block (AV3B) and (2) alternating bundle branch block (i.e. change from RBBB to LBBB). The decision for 
PPM was per treating physician’s discretion, but, in general, in compliance with contemporary European 
Society of Cardiology Guidelines on PPM (17). Clinical outcomes were reported using the revised Valve 
Academic Research Consortium criteria (18). 
Statistical Analysis
Continuous variables are presented as mean ± SD or median (interquartile range; IQR). Distribution of 
continuous variables was assessed for normality with histograms and the Shapiro–Wilk test. Continuous 
variables were compared using a Student t test or Mann–Whitney U test, when applicable. Categorical 
CoreValve ES-XT Lotus ES-3 Overall
P-value
(N=130) (N=124) (N=20) (N=32) (N=306)
Age. mean ± SD 83 ± 6 83 ± 8 83 ± 6 81 ± 6 83 ± 7 0.301
Male sex. n (%) 79 (61) 83 (67) 12 (60) 20 (63) 194 (63) 0.761
BMI in kg/m2. mean ± SD 26 ± 5 27 ± 4 29 ± 7 27 ± 4 27 ± 5 0.319
Diabetes Mellitus. n (%) 33 (25) 38 (31) 9 (45) 13 (41) 93 (30) 0.161
STS-score in %. median [IQR]
6.5 7.0 5.9 4.5 6.3
0.186
[4.5-10.4] [4.0-10.1] [5.2-7.8] [3.0-10.5] [4.1-10.2]
PVD. n (%) 28 (22) 36 (29) 6 (30) 7 (22) 77 (22) 0.526
COPD. n (%) 41 (32) 40 (33) 5 (25) 7 (22) 93 (30) 0.634
Atrial fibrillation. n (%) 21 (16) 27 (22) 4 (20) 8 (25) 60 (20) 0.584
NYHA-class ≥ III. %  (n) 101 (78) 103 (83) 14 (74) 17 (53) 235 (77) 0.005
History of stroke. n (%) 18 (14) 12 (10) 4 (20) 3 (9) 36 (12) 0.613
History of CABG. n (%) 15 (12) 19 (15) 5 (25) 10 (31) 49 (16) 0.033
History of PCI. n (%) 49 (38) 53 (43) 6 (30) 10 (31) 118 (39) 0.513
History of SAVR. n (%) 4 (3) 3 (2) 0 (0) 2 (6) 9 (3) 0.581
Digoxin use. n (%) 4 (3) 5 (4) 2 (13) 0 (0) 11 (4) 0.187
Amiodarone use. n (%) 18 (14) 16 (13) 2 (13) 2 (7) 38 (13) 0.792
Access. n (%)
0.005
Transfemoral 119 (91) 98 (79) 20 (100) 25 (78) 262 (86)
Transsubclavian 10 (8) 14 (11) 0 (0) 1 (3) 25 (8)
Transapical 1 (1) 12 (10) 0 (0) 6 (19) 19 (6)
Table 1. Patient characteristics. Categorical variables are displayed as counts (percentages) and differences 
were tested using a chi-square test for trend. Continuous variables are displayed as mean ±  SD or median 
[IQR] and were tested with a student T-test or Mann Whitney-U test. depending on distribution. Abbre-
viations: CABG = coronary artery bypass grafting; COPD = chronic obstructive pulmonary disease; ES-3 = 
Edwards Sapien 3; ES-XT = Edwards Sapien XT; IQR = interquartile range; NYHA = New York HeartAsso-
ciation; PCI = percutaneous coronary intervention; PVD = Peripheral vascular disease; SAVR = surgical 
aortic valve replacement; STS = Society of Thoracic Surgeons; SD = standard deviation.
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variables are expressed as percentages plus absolute numbers and were tested with the chi-square test for 
trend. Logistic regression was performed to identify predictors for the primary outcome (i.e. PPM). THVs 
were included in the univariate analysis plus potential confounders in regard to the primary outcome. 
The number of variables in the univariate model was limited by the established rule of thumb of 10 events 
per variable (19). All selected variables were evaluated using univariate logistic regression for inclusion in 
the multivariate model, considering a P value of <0.20 as an entry criterion. These variables remained in 
the multivariate model, regardless of P value after adjustment. We controlled for the interaction between 
valve type and alternative access, because alternative access was seldom used with CoreValve and Lotus. 
All statistical analyses were performed with SPSS software (version 21.0.01; IBM Corp, Armonk, NY). A 
2-sided value of P<0.05 was considered statistically significant.
RESULTS
A total of 2845 consecutive patients underwent TAVR at 4 European centers. For the purpose of this study, 
306 (11%) patients with pre-existent RBBB (without a PPM in situ) were extracted and further analyzed 
(Figure 1). Patient characteristics are listed in Table 1. Mean age was 83 ± 7 years, the majority was male 
(194; 63%), and the median predicted risk of mortality (Society of Thoracic Surgeons (STS) score) was 
6.3% (IQR 4.1–10.2). The CoreValve and Sapien-XT were used in the majority of patients (42% and 41%, 
respectively). An alternative access was used in ≈20% with the balloon expandable ES-XT and ES-3 and 
9% with CoreValve and not with Lotus. Antiarrhythmic agents were commonly used; 13% of patients used 
amiodarone and 4% digoxin.
CoreValve ES-XT Lotus ES-3 Overall
P-value
(N=130) (N=124) (N=20) (N=32) (N=306)
New AV3B <24h. n (%) 48 (39) 30 (27) 13 (68) 10 (39) 101 (36) 0.004
Alternating BBB <24h*. n (%) 10 (8) 7 (6) 3 (17) 3 (12) 23 (8) 0.457
New PPM. n (%) 60 (46) 40 (32) 15 (75) 11 (34) 126 (41) 0.001
Days to PPM. median [IQR] 2 [1-5] 3 [1-5] 1 [1-2] 2 [1-5] 2 [1-5] 0.546
Indication for PPM. n (%)†
0.489
  AV3B 59 (98) 39 (97) 14 (93) 11 (100) 123 (98)
  AV2B 1 (2) 0 (0) 1 (7) 0 (0) 2 (2)
  Sick sinus syndrome 0 (0) 1 (3) 0 (0) 0 (0) 1 (1)
Ventricular paced rhythm at 30 
days‡. n (%) 38 (81) 24 (92) 9 (69) 8 (73) 79 (81) 0.275
Ventricular paced rhythm at 1 
year‡. n (%) 21 (91) 15 (94) 2 (67) 3 (75) 41 (89) 0.415
Table 2. Permanent pacemaker implantations and conduction related outcomes. Categorical variables are 
displayed as counts (percentages) and differences were tested using a chi-square test for trend. Continuous 
variables are displayed as median [IQR] and were tested with a Mann Whitney-U test. * Alternating bundle 
branch block was considered as a new left bundle branch block in this patient population with pre-existent 
RBBB. † Percentage indicate the proportion of patients who received a permanent pacemaker ‡ Follow-up 
ECGs were missing in 29 patients (23%) at 30 days and in 80 patients (64%) at 1 year. Abbreviations: AV2B = 
second degree atrioventricular block; AV3B = third degree atrioventricular block; BBB = bundle branch block; 
ES-XT = Edwards Sapien XT; ES-3 = Edwards Sapien3; IQR = interquartile range; PPM = permanent pacema-
ker.
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Clinical Outcomes
All-cause mortality—within 48 hours following the procedure—was 3% (n=10). Thirty-day mortality rate 
was 7% (n=20) and 30-day stroke rate was 2% (n=5). One-year mortality rate was 18% (n=44).
PPM Implantation
Conduction changes are summarized in Table 2. The primary outcome—PPM implantation within 30 
days—occurred in 41% of patients. The univariate analysis is summarized in Supplemental Table 1. The 
following variables were included in the multivariate analysis: valve type; alternative access; body mass 
index (BMI); sex; and an interaction term for valve type x alternative access (because alternative access 
was not applied with Lotus). Results from the multivariate analysis are displayed in Figure 2. By multivar-
iate analysis, PPM was more common with Lotus than with the other THVs. Lotus was associated with 
a significantly higher PPM rate than all other individual transcatheter heart valves (Lotus versus CoreV-
alve: odds ratio (OR), 3.69 (95% CI 1.13–12.04); P=0.030; Lotus versus ES-XT: OR 6.79 (95% CI 2.05–22.52); 
P=0.002; Lotus versus ES-3: OR 5.24 (95% CI 1.30–21.25); P=0.020). On the contrary, PPM rate was low-
er with the ES-XT valve versus CoreValve and Lotus (ES-XT vs CoreValve: OR 0.54 (95% CI 0.31–0.95); 
P=0.033; ES-XT vs Lotus: OR 0.15 (95% CI 0.04–0.49); P=0.002). PPM rate between the balloon expandable 
valves did not differ (ES-XT vs ES-3: OR 0.91 (95% C 0.40–2.07); P=0.820). Another independent predictor 
for PPM in the multivariable model was a higher BMI before TAVR (multivariate OR 1.08 per 1 kg/m2 
increment (95% CI 1.02–1.14); P=0.013). Alternative access was associated with a lower rate of PPM in the 
univariate model (OR 0.32 (95% CI 0.15–0.69); P=0.004), but not in the multivariate model (OR 0.26 (95% 
CI 0.05–1.27); P=0.095). There was an important interaction between alternative access and valve type, 
attributed to the fact that Lotus was not performed with alternative access. The association between 
Figure 2. Forest plot displaying odds ratios (OR) for permanent pacemaker implantation after multivariate 
analysis. The following variables were included in the multivariate model: valve type, sex, body mass index (BMI), 
alternative access, and an interaction term valve type x alternative access. *Odds ratio per 1 kg/m2 increment of 
BMI. †An interaction term for the interaction between alternative access and valve type was included in the model 
to adjust for the fact that alternative access was not applied with Lotus. Abbreviations: ES-3 = Edwards Sapien 3; 
ES-XT = Edwards Sapien XT; NA = not applicable; PPM = permanent pacemaker.
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alternative access and PPM was nonsignificant with any of the valve types (CoreValve: OR 0.234 (95% CI 
0.048–1.128); P=0.070; with ES-XT: OR 0.565 (95% CI 0.207–1.539); P=0.264; with ES-3: OR 0.250 (95% CI 
0.0262–2.403); P=0.230).
New-Onset Conduction Disturbances
Alternating bundle branch block within 24 hours was documented in 23 patients (8%). New-onset AV3B 
within 24 hours was documented in 101 patients (36%). Univariate and multivariate analysis addressing 
new AV3B are summarized in Supplemental Table 2. New AV3B was more common with Lotus than with 
other individual THVs by multivariate analysis (Lotus vs ES-XT: OR 6.01 (95% CI 1.93–18.67); P=0.002; 
Lotus vs ES-3: OR 3.88 (95% CI 1.02–14.82); P=0.047; Lotus vs CoreValve: OR 3.80 (95% CI 1.25–11.52); 
P=0.018). New AV3B was less common with the ES-XT valve than with Lotus (OR 0.17 (95% CI 0.05–0.52); 
P=0.002). New AV3B rate between the balloon expandable valves was similar (ES-XT vs ES-3: univariate 
OR 0.59 (95% CI 0.24–1.43); P=0.240). Of all patients with new AV3B within 24 hours of the TAVR proce-
dure, 91% received a PPM. One in 4 of these permanent pacemakers were implanted more than 4 days 
after the TAVR procedure. The documented indication for PPM implantation was almost exclusively AV3B 
(98%). Follow-up electrocardiograms at 30 days and 1 year confirmed ventricular pacing in 81% and 89%, 
respectively.
DISCUSSION
The present study showed that tailored valve choice may reduce rates of PPM implantations in patients 
with pre-existent RBBB. Overall PPM rate post-TAVR in patients with RBBB was 41% and was highest with 
Lotus (75%). More than 80% of patients with a PPM remained pacemaker dependent at 30-day and 1-year 
follow-up. 
Prevalence of RBBB in the general population ranges from 0.5% to 1.5%, has a male predominance, and 
increases with age to 2.2% in patients above 55 years old (20,21). Prevalence of pre-existent RBBB is 4% 
in patients undergoing surgical aortic valve replacement (SAVR) with a mean age of 69 years (22), and is 
10% in patients undergoing TAVR with a mean age of 81 (7). RBBB is a dominant predictor for PPM after 
both TAVR and SAVR (7,9,11,23,24). Not unexpectedly, patients with pre-existent RBBB are more vulnera-
ble for high-grade AV block given that the conduction system is already impaired. With TAVR, the radial 
force of a stented frame may impose pressure on the conduction system embedded in the interventricular 
septum within a couple of millimeters from the aortic annulus and may further compromise the left bun-
dle branch (14). Before patients with RBBB evolve toward total AV block, an alternating bundle branch 
can sometimes be recognized, as illustrated in Figure 3. In our population, an alternating bundle branch 
block within 24 hours post-TAVR could be detected in 8% of patients. 
According to a recent meta-analysis, TAVR with the selfexpanding CoreValve is associated with a higher 
PPM rate compared with the balloon expandable ES-XT (7). PPM rate with newer-generation THVs varies 
and definitely remains a clinical issue, in particular with the mechanically expanded Lotus. Also, the lat-
est balloon expandable ES-3 THV has a higher reported PPM rate compared with its predecessor, ES-XT 
(25). 
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Prevalence of RBBB in this study was similar to what has 
been reported in the literature. Our findings demonstrate 
a higher incidence of PPM in patients with pre-existent 
RBBB compared to what generally is reported in a random 
TAVR population. In patients with pre-existent RBBB 
treated with CoreValve in this study, almost half required a 
PPM as compared to 20% in the randomized US CoreValve 
High Risk Study and 28% in the meta-analysis by Siontis 
et al (7,26). PPM rate in patients with ES-XT was 31% and 
is significantly higher than the 6% in the meta-analysis 
and 9% in the randomized PARTNER 2 (Placement of 
Aortic Transcatheter Valves 2) trial (3). In our study, also 
with newer generation THVs in patients with pre-existent 
RBBB, the PPM rate was consistently higher than what is 
reported in high-risk TAVR patients: ES-3 34% versus 10% 
(27) and Lotus 75% versus 27% (9), respectively. 
Multivariate analysis confirmed a higher incidence of PPM 
with Lotus than with other THV designs. Conversely, ES-
XT was associated with the lowest PPM risk. Interestingly, 
a higher BMI before TAVR also predicted PPM implantation, although the effect was modest. Previous 
studies reported the impact of BMI on outcomes post-TAVR, but did not show an enhanced rate of PPM 
implantations (4,28). The exact  pathophysiology is unclear. However, BMI may pose particular hurdles 
from a procedure execution perspective and maybe result in less accurate (and maybe deeper) valve 
implants. Alternative access (i.e. transsubclavian or transapical access) was associated with a lower PPM 
rate in the univariate model. However, this effect was absent in the multivariate model, suggesting the 
effect of the balloon expandable valves that were used in the majority (75%) of alternative access proce-
dures. 
The high rate of PPM with Lotus could hypothetically be caused by (1) a higher radial force of the stented 
frame compared to other THVs, which potentially forces the native annulus in a circular shape, and (2) 
the Lotus frame remains in contact with the wall of the left ventricular outflow tract throughout the 
process of foreshortening and locking, which could be more harmful to the conduction system. Depth 
of transcatheter valve implantation is an established predictor for CoreValve, ES-XT, and ES-3 (29-31), in 
particular with an implantation depth of more than 6 mm below the native aortic valve. Methodology to 
determine depth of implantation is not standardized and was not collected in this study. However, depth 
of implantation could affect the need for PPM with any THV and warrants further detailed analysis. 
Previous reports suggested the transient nature of TAVR induced conduction disorders given that up 
to half of patients with new pacemakers post-TAVR were no longer pacemaker dependent at follow-up 
(13,32,33). In contrast, our study demonstrates a paced rhythm in 89% of patients at 1 year in patients 
who received a PPM,  underscoring a less-resilient conduction system in these patients. Similarly, patients 
with pre-existent RBBB who developed AV3B within 24 hours after the procedure received a PPM in 
91% of the cases, with 1 in 4 receiving the pacemaker more than 4 days post-TAVR, underscoring the 
Figure 3. Two-lead electrocardiogram de-
rived from continuous rhythm monitoring 
within 24 hours after transcatheter aortic 
valve replacement, illustrating the typical 
cascade from RBBB to a total atrioventri-
cular block. *Intermittent sinus beats with 
LBBB. Abbreviations: BBB = bundle branch 
block; LBBB = left bundle branch block; 
RBBB = right bundle branch block.
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persistence of this conduction disorder. In aggregate, conduction recovery post-TAVR in patients with 
pre-existent RBBB is unlikely, and therefore the decision to proceed with PPM implantation could be 
made early after TAVR to minimize hospital stay. 
In our study—involving patients with pre-existent RBBB and a relatively high rate of PPM implanta-
tions—the mortality rate (7% at 30 days and 18% at 1 year) is on par with recently published trials and 
registry data (26,31,34-38).  Conflicting data link new conduction disorders in general and PPM implan-
tation in particular to impaired TAVR-related outcome, including less improvement in LV function or 
quality of life, more rehospitalizations, and increased 1-year mortality (13,39-41). Hypothetically, PPM 
implantation in patients with RBBB levels out mortality attributed to the high incidence of - potentially 
lethal - total heart blocks. 
Limitations 
This multicenter study has an observational design and may suffer from inherent bias in terms of THV 
selection and confounders. Depth of implantation—which is known to be associated with PPM—was not 
collected in this study. Indeed, given that balloon expandable devices have less TAVR-related conduction 
disorders, operators may already favor this THV for patients with pre-existent RBBB and avoid mechani-
cally expanded valves on the other hand. Nonetheless, only THVs with at least 10 patients in the database 
were eligible for further analysis, and the number of events was sufficient to allow for adequate multivari-
ate analysis to adjust for confounders. We acknowledge that the Lotus valve is relatively under-represent-
ed in the present study, and therefore avoidance of this valve cannot be strongly recommended. However, 
we believe that there is a clear signal that this valve is associated with the highest PPM rate. The decision 
to implant a PPM was at the treating physician’s discretion, but was most often for high-degree AV block 
and thus conforms to current international guidelines (17). 
CONCLUSION
Postprocedural PPM rate in this cohort of patients with pre-existent RBBB was consistently higher than 
described in the literature for all THVs. PPM rate was highest with Lotus and lowest with the balloon 
expandable ES-XT and ES-3. Pacemaker dependency remained high at both 30-day and 1-year follow-up.
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SUPPLEMENTAL MATERIAL
Univariate OR [95% CI] P-Value
Type of THV
Lotus vs. CoreValve 3.50 [1.20-10.20] 0.022
Lotus vs. ES-XT 6.30 [2.14-18.55] 0.001
Lotus vs. ES-3 5.73 [1.65-19.94] 0.006
CoreValve vs. ES-XT 1.80 [1.08-3.00] 0.024
CoreValve vs. ES-3 1.64 [0.73-3.67] 0.232
ES-XT   vs. ES-3 0.91 [0.40-2.07] 0.820
Patient characteristics
Alternative access 0.32 [0.15-0.69] 0.004
Baseline atrial fibrillation 0.79 [0.44-1.42] 0.429
Body mass index* 1.08 [1.02-1.14] 0.006
Female gender 1.49 [0.93-2.39] 0.098
Medication Amiodarone 0.87 [0.43-1.75] 0.690
Medication Digitalis 0.86 [0.25-3.00] 0.813
NYHA - class ≥ III 0.92 [0.54-1.58] 0.765
Prior SAVR 0.40 [0.08-1.95] 0.256
Supplemental Table 1. Predictors for permanent pacemaker by univariate logistic regression. Variables in italic 
were included in the multivariate analysis. *Odds ratio per 1 kg/m2 increment of body mass index. Abbreviations: 
CI = confidence interval; ES-3 = Edwards sapien valve 3; ES-XT = Edwards Sapien XT; NYHA = New York Heart 
Association; SAVR = surgical aortic valve replacement; THV = transcatheter heart valve.
Univariate OR 
P-Value
Multivariate OR 
P-Value
[95% CI] [95% CI]
Type of THV
Lotus vs. CoreValve 3.43 [1.22-9.63] 0.019 3.80 [1.25-11.52] 0.018
Lotus vs. ES-XT 5.92 [2.06-16-99] 0.001 6.01 [1.93-18.67] 0.002
Lotus vs. ES-3 3.47 [0.99-12.09] 0.051 3.88 [1.02-14.82] 0.047
CoreValve vs. ES-XT 1.73 [0.99-3.00] 0.053 1.58 [0.88-2.85] 0.128
CoreValve vs. ES-3 1.01 [0.42-2.41] 0.981
ES-XT   vs. ES-3 0.59 [0.24-1.43] 0.240 0.17 [0.05-0.52] 0.002
Patient characteristics
Alternative access 0.51 [0.21-1.23] 0.133 0.48 [0.13-1.81] 0.281
Baseline atrial fibrillation 1.00 [0.53-1.86] 0.987
Body mass index 1.04 [0.99 -1.10] 0.126 1.04 [0.98-1.10] 0.218
Female gender 1.39 [0.84-2.29] 0.200 1.30 [0.77-2.20] 0.326
Prior surgical aortic valve 
replacement 0.89 [0.22-3.63] 0.868
Supplemental Table 2. Predictors for new total atrioventricular block <24h. Results from uni- and multivariate lo-
gistic regression for new onset third degree atrioventricular block within 24 hours. Variables in italic were included 
in multivariate regression. Abbreviations: CI = confidence interval; ES-XT = Edwards Sapien XT; ES-3 = Edwards 
Sapien 3; OR = Odds Ratio; THV= transcatheter heart valve.
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ABSTRACT
Aims
To correlate dynamics in electrical conduction after transcatheter aortic valve implantation (TAVI) with 
need for permanent pacemaker implantation (PPM) and assess implications for early discharge.  
Methods
Daily ECG’s after TAVI were analyzed for rhythm and conduction times and were correlated with PPM.
Results 
TAVI was performed in 291 consecutive patients with three contemporary transcatheter heart valve 
designs: Medtronic CoreValve (n=111), Edwards Sapien XT (n=29) and Sapien 3 (n=72), and Boston Lotus 
(n=79). We considered two cohorts: A. Patients with normal baseline conduction; and B. patients with 
pre-existent conduction disturbances. Based on QRS dynamics, three patterns were discerned: stable 
normal QRS duration, transient QRS prolongation and persistent QRS prolongation. In cohort B QRS 
dynamics did not correlate with PPM. In contrast, in cohort A QRS dynamics and PPM appeared highly 
correlated. Neither patients with stable normal QRS duration (0/47), nor patients with transient QRS 
prolongation required PPM (0/26). All PPMs occurred in patients with persistent QRS prolongation until 
discharge (27/85). Persistent QRS prolongation was typically seen with Lotus and CoreValve, whereas 
stable normal QRS duration was typically seen with Sapien XT and Sapien 3.
Conclusion
Three distinct patterns of QRS dynamics can be discerned after TAVI and their predictive probabilities for 
PPM strongly relate to the baseline conduction status. Patients with normal conduction at baseline and 
stable QRS duration after TAVI are potentially eligible for early discharge.
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has evolved into an attractive, minimally invasive alter-
native to surgical aortic valve replacement for patients with severe aortic stenosis and intermediate or 
greater surgical risk (1-3). Not only the procedure itself, but also hospital stay has shortened to extremes 
of same day discharge in some instances (4). Electrical conduction disturbances and need for permanent 
pacemaker implantation (PPM) are frequent after TAVI (5), and imposes an important obstacle for early 
discharge after TAVI. 
Conduction disturbances are more common with self-expanding and mechanically expanded transcath-
eter heart valves (THVs) compared to balloon-expandable valves (6, 7). Apart from THV design, several 
baseline predictors for post-procedural conduction disturbances have been identified (e.g. pre-existing 
conduction disturbances, excessive device oversizing relative to the annular root dimensions, and depth 
of implantation) (6, 8).  
Newly acquired conduction disturbances do not always persist since half of patients who received a PPM 
are no longer pacemaker-dependent at long-term follow up (8, 9). Therefore the decision for either safe 
early discharge or monitoring by telemetry and potential PPM implantation poses a current challenge. 
Electrical conduction after TAVI may be dynamic and device dependent. Proper understanding of these 
dynamics is clinically relevant and may help guide patient management and facilitate early discharge. The 
ECG immediately after TAVI already provides information to determine whether patients might be eligi-
ble for early discharge (10). The purpose of the present study was to assess conduction times (i.e. QRS-du-
ration) during the entire admission after TAVI, in order to identify dynamic patterns and to correlate with 
need for permanent pacemaker dependency. 
METHODS
All consecutive patients who underwent transarterial 
(transfemoral or transsubclavian) TAVI between January 
2012 and December 2015 in our center were entered in a 
prospective database. This study complied with the Decla-
ration of Helsinki. All patients provided written informed 
consent for the procedure and data analysis for research 
purposes per Institutional Review Board approval. This 
study was not subject to the Dutch Medical Research 
Involving Human Subjects Act, which was confirmed by 
the local medical ethics committee of the Erasmus MC 
Rotterdam. 
An overview of inclusion is illustrated in Figure 1. Pa-
tients who died within 72 hours after the procedure were 
excluded from the analysis. Three THV-designs were used: 
Corevalve (n=111) (Medtronic, Minneapolis, Minnesota), 
Figure 1. Flowchart of study inclusion. Abbre-
viations: ES-XT = Edwards Sapien XT; ES-3 = 
Edwards Sapien 3; PPM = permanent pacema-
ker implantation.
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Sapien XT (n=29) and Sapien 3 (n=72) (Edwards Lifesciences, Irvine, California), Lotus (n=79) (Boston 
Scientific Corporation, Marlborough, Massachusetts).
For the purpose of this study, we considered two cohorts: cohort A consisted of patients with untainted 
conduction, whereas cohort B consisted of patients with pre-existent conduction disturbances (i.e. 1st or 
degree AV-block, hemiblock or bundle branch block).
Twelve-lead ECGs were collected prior to TAVI and daily afterwards up to discharge to a maximum of 
14 days and at one-month follow-up at the outpatient clinic visit. ECGs were interpreted by dedicated 
clinical researchers (LVG, HK and YA). If necessary, an experienced cardiologist (NVM) was consulted for 
consensus. The ECGs were analyzed for rhythm, conduction times, and the presence of AV block or bun-
dle branch block. Conduction times were derived from digitalized ECGs with a chart speed of 25mm/s. 
Computer-calculated conduction times were used, since they show less variability compared to manual 
caliper methods (11). Only ECGs without pacemaker intrusion were included in our analysis. In presence 
of multiple ECGs on the same day, the ECG with the longest calculated QRS-duration was selected. 
QRS-prolongation of 20 ms was considered a significant change. Three conduction patterns were dis-
cerned: (1) Stable: QRS-duration after TAVI did not prolong by > 20 ms; (2) Transient: QRS duration after 
TAVI prolonged by > 20 ms but at the discharge ECG the QRS duration narrowed again within 20 ms; (3) 
Persistent: QRS duration after TAVI prolonged by > 20 ms and the QRS duration at discharge persisted at 
least 20 ms beyond baseline.
The primary outcomes of this study were 1. New onset high degree AVB and 2. need for PPM. The decision 
for PPM was per treating physician’s discretion, although agreed by an electrophysiologist and in general 
in compliance with contemporary ESC Guidelines on PPM (12). Patients who receive a permanent pace-
maker in our institution systematically visit the pacemaker technician at 10 days and 6 months after im-
plantation at the outpatient clinic. At 10 days the anterograde and retrograde properties of the atrioven-
tricular conduction are assessed with pacing maneuvers, after which the pacemaker settings are adapted 
in order to prioritize the native conduction system. A PPM interrogation at 6 months assesses pacing 
percentage. For the purpose of this study, patients with less than 20% ventricular pacing over 6 months of 
follow-up – which is suggestive for independency of ventricular pacing (13) - were then re-adjudicated by 
an electrophysiology expert (DT) for pacemaker dependence. Depending on whether there was normal 
intrinsic atrioventricular conduction pacing was labeled as ‘dependent’ or ‘independent’. 
Continuous variables were presented as mean (±SD) or median (interquartile range). The distribution of 
continuous variables was assessed for normality with histograms and the Shapiro-Wilk test. Comparisons 
between the ECG conduction patterns for repeatedly measured continuous variables were done using 
a repeated measures analysis of variance (ANOVA) with post-hoc Tukey adjustment. The assumption 
of homogeneity of variances was tested with the Levene’s test. Categorical variables were expressed as 
absolute counts plus percentages and were compared by use of the Pearson’s square test and Z-test for 
proportions. 
All statistical analyses were performed with SPSS version 21.0.1 (IBM Corp, Armonk, NY). A two-sided 
value of P<0.05 was considered statistically significant. 
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RESULTS
A total of 291 consecutive patients underwent transfemoral (94%) or transsubclavian (6%) TAVI with Cor-
eValve (38%%), Sapien XT or Sapien 3 (35%), or Lotus (27%). Mean age was 79 ± 8 years, 46% were female. 
Balloon predilatation was performed in 51% of patients. Half of the patients (54%) did not have pre-ex-
istent conduction disturbances (cohort A) whereas the other half (46%) did (cohort B). Baseline charac-
teristics between cohort A and B were well balanced (Table 1). AV1B was the most common conduction 
disturbance (21%), followed by left anterior fascicular block (16%), left bundle branch block (12%) and 
right bundle branch block (11%). 
Cohort A (N=158) Cohort B (N=133) Overall (N=291) P-value
Age in years 78 ± 8 80 ± 7 79 ± 8 0.116
Male gender 77 (49%) 79 (59%) 156 (54%) 0.069
Body mass index in kg/m2 27 ± 5 27 ± 5 27 ± 5 0.860
Body surface area in m2 1.86 ± 0.20 1.86 ± 0.20 1.86 ± 0.20 0.966
Creatinin level in µmol/L 99 [74-128] 94 [77-117] 96 [77-122] 0.463
Renal dialysis 7 (5%) 4 (4%) 11 (4%) 0.759
DM 50 (32%) 48 (36%) 98 (34%) 0.424
Hypertension 134 (85%) 104 (78%) 238 (82%) 0.145
Log EuroSCORE in % 11 [7-18] 12 [9-19] 12 [8-19] 0.102
NYHA-class I 4 (3%) 3 (2%) 7 (3%)
0.987
II 36 (24%) 28 (23%) 64 (23%)
III 95 (63%) 80 (65%) 175 (64%)
IV 16 (11%) 12 (10%) 28 (10%)
Atrial fibrillation 48 (30%) 32 (24%) 80 (28%) 0.229
Conduction 
disturbance* 
None 158 (100%) 0 (0%) 158 (54%)
NA
AV1B 0 (0%) 61 (46%) 61 (21%)
LBBB 0 (0%) 35 (27%) 35 (12%)
RBBB 0 (0%) 33 (25%) 33 (11%)
LAFB 0 (0%) 47 (35%) 47 (16%)
LPFB 0 (0%) 6 (5%) 6 (2%)
Access Transfemoral 152 (96%) 122 (92%) 274 (94%) 0.105
Transsubclavian 6 (4%) 11 (8%) 17 (6%)
Predilatation 79 (50%) 70 (53%) 149 (51%) 0.651
THV CoreValve 58 (37%) 53 (40%) 111 (38%) 0.813
ES-XT or ES-3 55 (35%) 46 (35%) 101 (35%)
Lotus 45 (49%) 34 (26%) 79 (27%)
 Table 1. Baseline characteristics. Categorical variables are displayed as counts (percentages. Continuous vari-
ables are displayed as mean ± SD or median [interquartile range]. * Patients without conduction disturbances at 
baseline represent Cohort A and patients with conduction disturbances represent Cohort B. Abbreviations: CABG 
= coronary artery bypass grafting; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; MI = 
myocardial infarction; PCI = percutaneous coronary intervention; THV = transcatheter heart valve.
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Conduction related outcomes are displayed in Table 2. Intraprocedural LBBB and high degree AVB were 
common (67% and 33%, respectively). Delayed high degree AVB (i.e. high degree AVB that first presented 
after the patients had left the catheterization laboratory) occurred in 8% of patients. At 30-days, over-
all 23% required PPM; 17% in cohort A compared to 29% in cohort B (p=0.013). Indication for PPM was 
almost exclusively a high degree AVB (94%). None of the patients had a documented high degree AVB 
after discharge nor did any of them need a PPM during 1-year follow-up. In the majority, the percentage of 
pacing that was provided was either less than 10% or more than 90% of the time (Table 2, Supplemental 
Figure 1). Pacemaker interrogations at 6 months follow-up were completed in 74% of patients (17 patients 
were lost to follow-up). The interrogation revealed <20% paced rhythm (i.e. pacemaker independent) in 
39% of patients. The amount of ventricular pacing did not differ between cohort A and B (p=0.459). 
In cohort A, conduction patterns correlated with PPM, regardless of THV type (Figure 2). In cohort B, high 
degree AVB and PPM appeared unrelated to QRS patterns (Figure 3). 
Changes in QRS duration for the three discerned patterns in cohort A are displayed in Supplemental 
Table 4 and Figure 2. In patients with a stable QRS duration, the mean QRS duration at baseline was 95 ± 
11 ms. In patients with transient QRS prolongation, mean QRS duration at baseline was 100 ± 9 ms and 
prolonged up to 144 ± 15 ms, after which it narrowed to 103 ± 10 ms at discharge. On aggregate, mean 
QRS duration at follow-up was 102 ± 11 ms. In patients with persistent QRS prolongation, the mean QRS 
duration at baseline was 97 ± 11 ms and prolonged up to 157 ± 15 ms and it remained broad (152 ± 17) 
until discharge. At follow-up, the QRS-duration was still broad (137 ± 23 ms).  It took 1 day to reach the 
maximum QRS duration in the majority of patients (61%) irrespective of THV design or the transient or 
Cohort A 
(N=158)
Cohort B 
(N=133) Overall (N=291) P-value
Number of days to discharge 8 [6-11] 8 [6-12] 8 [6-11] 0.905
Thirty day mortality 8/157 (5%) 6/133 (5%) 14/290 (5%) 0.817
One year mortality 23/151 (15%) 19/121 (16%) 42/272 (15%) 0.915
Intraprocedural new LBBB 105/133 (74%) 48/84 (57%)* 153/217 (67%) 0.007
Intraprocedural new AV3B 35/133 (25%) 47/133 (43%) 82/291 (33%) 0.002
PPM at 30 days† All THVs 27/158 (17%) 39/133 (29%) 66/291 (23%) 0.013
CoreValve 15/58 (26%) 16/53 (30%) 31/111 (28%) 0.621
ES-XT or ES-3 5/55 (9%) 11/46 (24%) 16/101 (16%) 0.042
Lotus 7/45 (16%) 12/34 (35%) 19/79 (24%) 0.042
Indication for 
PPM‡
High degree AVB 26/27 (96%) 36/39 (92%) 62/66 (94%)
0.094Sick sinus syndrome 1/27 (4%) 2/39 (5%) 3/66 (5%)
Trifascicular block 0/27 (0%) 1/39 (3%) 1/66 (2%)
Number of days to PPM 6 [1-8] 4 [1-8] 5 [1-8] 0.377
Percentage pacing 
at 6 months inter-
rogation§
0% 2/22 (9%) 4/27 (15%) 6/49 (12%)
0.459
1-20% 7/22 (32%) 6/27 (22%) 13/49 (27%)
21-99% 6/22 (27%) 12/27 (44%) 18/49 (37%)
100% 7/22 (32%) 5/27 (19%) 12/49 (25%)
 Table 2. Conduction related and clinical outcomes. Categorical variables are displayed as counts (n/N) (percenta-
ges. Continuous variables are displayed as median [interquartile range]. * patients with LBBB at baseline are herein 
excluded.† N is total number of patients treated with that particular valve. ‡ N is total number of patients with a 
PPM. §Pacemaker interrogations were performed in 49 of 66 patients (17 patients were lost to follow-up).
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persistent nature (Transient: 0.5 (IQR 0-4) day; Persistent: 1 (IQR 0-3) day). The transient pattern became 
apparent at 1 day post TAVI (IQR 1-4), and the QRS interval normalized up to day 6.
 Implantation of a Lotus valve was typically followed by persistent QRS prolongation (69%), in contrast 
to stable normal QRS duration (7%) or transient QRS prolongation (24%). Conversely, half of the patients 
treated with the Sapien XT and Sapien 3 had a stable normal QRS duration (51%) compared to transient 
QRS prolongation (13%) and persistent QRS prolongation (36%). With CoreValve, persistent QRS pro-
longation was most common (57%) in contrast to stable normal QRS duration (28%) or transient QRS 
prolongation (16%). 
In cohort A, patients with a stable normal QRS duration and patients with transient QRS prolongation 
never required a PPM, although high degree AVB appeared and resolved in 28% and 35%, respectively. In 
patients with a persistent QRS prolongation high degree AVB appeared in 52% (44/84) and 32% (27/84) 
required a PPM. At the 6-month pacemaker interrogation 41% was independent of their pacemaker.
QRS-patterns determined at daily intervals and subsequent conduction related events are listed in Sup-
plemental Figure 2. Patients with a stable normal QRS pattern 1 day post TAVI have a low likelihood for 
high degree AVB or PPM with pacemaker dependency. Conversely, patients with a transient/persistent 
QRS prolongation may develop high degree AVB or pacemaker dependency up to day 6.
Mortality at 30-days and 1-year were 5% and 15% respectively, and were similar between cohort A and 
B. Supplemental Table 2 shows an overview of death causes during 1 year follow-up. Notably, one-year 
mortality in patients from cohort A with stable conduction occurred in 7 patients in total, and none were 
related to late conduction disorders. These deaths were caused by cerebral stroke, hepatic failure, hospi-
tal-acquired pneumonia, sepsis, terminal heart failure, rectum carcinoma and in one patient the cause 
was unknown. 
Figure 2  and Figure 3 . Dynamics of QRS-duration in cohort A (left) (i.e. patients with normal conduction 
atbaseline) and cohort B (right)(i.e. patients with conduction disturbances at baseline), with associated high degree 
AVB and PPM rates. QRS-interval times are plotted as a difference from baseline up to 14 days after TAVI (depen-
ding on date of discharge). The grey lines represent individual patients who did not require PPM, red lines represent 
patients who required PPM, and the bold black line is a smoothed line that connects mean QRS durations to reflect 
the general trend of the groups. Abbreviations: AVB = atrioventricular block; ms = milliseconds.
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DISCUSSION
The present study demonstrates that QRS dynamics following TAVI may have clinical implications. The 
main findings can be highlighted as follows: 1) Three distinct patterns of QRS dynamics can be identified 
after TAVI:  stable normal QRS-duration, transient QRS-prolongation and persistent QRS-prolongation. 
2) Patients with newly acquired QRS prolongation after TAVI require longer telemetric monitoring than 
those with stable normal QRS duration and if persistent they have a high need for PPM. 3) In patients 
with pre-existing conduction disturbances before TAVI, high degree AVB and PPM occur irrespective of 
QRS dynamics. 4) QRS prolongation typically peaks within 1 day after TAVI. 5) Balloon expandable TAVI 
is associated with more stable QRS duration. 6) Up to 40% of patients are no longer pacemaker depen-
dent during follow up.
The vicinity of the atrioventricular His bundle to the aortic valve contributes to the risk for conduction 
disturbances and PPM after aortic valve replacement in general and TAVI in particular (5, 14). Past 
research has mainly focused on baseline predictors of conduction disturbances (6, 8), enabling to identify 
those patients who are at high risk for PPM. In addition, choice of THV is a main contributor, as PPM 
rates are consistently higher with the self-expanding CoreValve, reported to be ~30% (15, 16) compared 
to 10-15% with the balloon-expandable Sapien XT and Sapien 3 (15-17) and ~30% with the mechanically 
expanded Lotus (7). 
Currently, daily practice is proceeding rapidly by discharging patients early at the expense of missing 
emerging conduction disorders (4). In the present study QRS-prolongation typically peaked within 1day 
after TAVI. Patients with normal baseline conduction and stable QRS duration or transient QRS pro-
longation never required PPM. When observed at daily intervals it appears that a stable QRS duration 
1 day post TAVI may justify safe early discharge. The opposite is true for patients with normal baseline 
conduction and persistent QRS prolongation, since they are at risk for high degree AVB, which impedes 
early discharge. Therefore our data strongly recommends to keep these patients admitted on telemetric 
monitoring for a minimum of 6 days. We hypothesize that a persistent QRS-prolongation may identify 
more permanent and explicit damage to the atrioventricular bundles. 
On the other hand, in patients with pre-existent conduction disturbances QRS prolongation can be de-
ceiving, since patients with stable QRS duration and transient QRS prolongation also required PPM in the 
present study. Therefore patients with pre-existent conduction disorders have an eminent risk for PPM 
and thus warrant longer telemetric monitoring. 
Recently, Toggweiler et al. reported that ECGs after TAVI can be helpful to identify patients who need 
telemetric monitoring (10). The authors concluded that patients without conduction disorders or a stable 
ECG for 48 hours after TAVI can be safely discharged. Our data may refine this concept by adding that 
patients with pre-existent conduction disturbances (i.e. prior to TAVI) may need longer clinical observa-
tion to rule out need for PPM. 
In patients with normal conduction at baseline, QRS prolongation – either persistent or transient – was 
more frequent with CoreValve and Lotus. This is consistent with the higher reported PPM rates with these 
devices. It is intriguing that QRS-prolongation occurred less with balloon-expandable valves, suggesting 
patients treated with these devices are more suitable for early discharge (provided that other complica-
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tions have been ruled out). 
Whether TAVI patients remain pacemaker dependent is subject of ongoing debate. QRS prolongation 
after TAVI is sometimes transient as in more than one third of the patients bundle branch blocks recover 
(8). Pacemaker rhythm on follow-up ECGs can give a rough impression for at least partial pacemaker 
dependency. Data from the PARTNER-trial reported ventricular paced rhythm in 50% of patients 30-days 
after TAVI(8). Moreover, at 1-year follow-up more than half of the patients appear no longer pacemaker 
dependent (9). Outside the field of TAVI, the ‘Inhibition of Unnecessary RV Pacing With AVSH in ICDs’-
study (INTRINSIC RV) aimed to inhibit the rate of unnecessary right ventricular pacing with implantable 
cardioverter defibrillators. The authors reported that patients with less than 20% right ventricular pacing 
had 0% pacing when switched to VVI-mode (13). Unnecessary pacing is mostly related to premature 
atrial and ventricular contractions or pacemaker dysfunction (18), which implicates that 0% pacing is 
rare, even in patients with normal conduction. In the present study, 41% of the patients with a permanent 
pacemaker were paced less than 20% during 6 months follow-up. Dedicated interrogation of these pace-
makers revealed that none of these patients were truly pacemaker dependent at follow up. This supports 
the theory that the threshold for PPM after TAVI may be (too) low. Future devices may enable continuous 
rhythm monitoring at home in the form of self-adhesive patches, with wireless transmission to the physi-
cian (19). This may be a cost-effective way for safe early discharge and avoiding needless PPM.
Our findings may have clinical implications. PPM in the elderly is not harmless, for early complications 
are common in patients above 75 years (5%) (20). Most frequent complications include lead dislodge-
ment/loss of capture, pneumothorax and infection. Moreover, unnecessary right ventricular pacing may 
contribute to heart failure.
The rate of delayed high degree AVB in 
the present study was similar to what 
has been reported by Toggweiler et al. 
(Figure 4). In addition, newly acquired 
QRS prolongation that persisted for 
6 days announced events that would 
oppose safe discharge in 12% of patients 
with normal QRS at baseline and un-
derscores the importance of prolonged 
telemetric monitoring. Duration of 
telemetric monitoring and timing for 
safe discharge in patients with newly 
acquired or pre-existing conduction 
disorders requires further study and 
validation in a larger prospective cohort. 
Limitations
This was a single-center observational study and may suffer from inherent bias. Pre-existent conduction 
disorders were not equally distributed among different THVs and combinations of various conduction 
Figure 4. Overview of first presentation of high degree AVB in the 
present study and the study by Toggweiler et al (10). * Note that 
in the present study high degree AVB during the procedure was 
also noted, whereas the study by Toggweiler et al. only noted high 
degree AVB present at the moment the patient left the catheteriza-
tion laboratory.
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disorders were present. Our study represents a real world TAVI population and it therefore enhances 
generalizability. The decision to implant a PPM was at the treating physician’s discretion but was almost 
exclusively high degree AVB and thus conform current international guidelines (12). ECG with analyzable 
conduction times (i.e. not intruded by a ventricular pacing) was available for 66% of total hospitalized 
days and was thus incomplete, yet reflects retrospective analysis of current clinical practice. Our study 
represents the most elaborate sample of conduction times after TAVI reported to date. The missing ECGs 
were equally distributed over time and among the different devices and conduction patterns, therefore 
we believe the described patterns are valid. 
CONCLUSIONS
Three distinct patterns of QRS dynamics can be discerned after TAVI and their predictive probabilities 
strongly relate to the baseline conduction status. Patients with normal conduction before and after TAVI 
do not develop need for PPM and may be pre-eminently eligible for early discharge. Patients with pre-ex-
isting or newly acquired QRS prolongation need prolonged telemetric monitoring because need for PPM 
is high.  
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SUPPLEMENTAL MATERIAL
Stable              
(n=47)
Dynamic 
transient (n=26)
Dynamic 
persistent (n=85) P-value
Baseline QRS duration 95 ± 11 100 ± 9 97 ± 11 0.129
Δ QRS baseline – maximum +8 ± 6* +48 ± 16 +57 ± 15 <0.001
Δ QRS maximum – discharge -3 ± 6 -45 ± 17* -6 ± 12 <0.001
Δ QRS discharge – follow-up 30 days -5 ± 6 -1 ± 10 -15 ± 20* <0.001
Δ QRS baseline – follow-up 30 days 0 ± 5 +3 ± 9 +39 ± 23* <0.001
Follow-up 30 days QRS duration 98 ± 10* 102 ± 11* 137 ± 23* <0.001
Supplemental table 1. QRS dynamics from baseline to 30 days follow-up in Cohort A. * denotes significant differ-
ences compared to both other subgroups at a p<0.05 confidence level.
Cohort A Cohort B
PPM + PPM - PPM + PPM -
Mortality at 30 days 1 / 27 (4%) 7 / 130 (5%) 1 / 39 (3%) 5 / 94 (5%)
Mortality at 1 year* 1 / 26 (4%) 22 / 125 (18%) 7 / 36 (18%) 12 / 85 (13%)
Death cause - Stroke - Sepsis (2x) - Sepsis - Sepsis
- Multi-organ failure - Subdural 
hematoma
- Stroke (2x)
- Pneumonia (2x) - Pneumonia - Multi-organ failure
- Stroke (3x) - Unknown (4x) - Hemothorax
- Pulmonary 
embolism
- Valve embolization
- Liver cirrhosis - Colitis
- Heart failure - Liver cirrhosis
- Cancer (2x) - Unknown (4x)
- Myocardial 
infarction
- Unknown (8x)
Supplemental table 2. Overview of death causes during follow-up for Cohort A and B. Incidence is shown as 
counts (n/N) and percentages. *19 patients were lost to follow-up. Abbreviatons: PPM = permanent pacemaker 
implantation. 
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ABSTRACT
Background
The interaction of left ventricular outflow tract (LVOT) and transcatheter heart valve (THV) is complex 
and may be device design specific. We sought to study LVOT characteristics and its relation with perma-
nent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR).
Methods
We studied 302 patients with a median age of 81 years (IQR 75–84). Computed tomography was used to 
assess LVOT in terms of amount of calcium, perimeter and device size relative to LVOT.
Results
We implanted a Medtronic CoreValve (MCS) in 203 patients, Edwards-Sapien XT (ESV-XT) in 38, Ed-
wards-Sapien S3 (ESV-S3) in 26 and Lotus in 35 patients. Sixty-eight patients (22.5%) received a new PPI 
within 30 days after the index procedure. The incidence of PPI was 22.7% with MCS, 10.5% with ESV-
XT, 26.9% with ESV-S3 and 31.4%with Lotus. By multivariate analysis RBBB at baseline (OR 2.9 (95% CI 
1.2–6.9, p=0.014), second generation valves (OR 2.1 (95% CI 1.0–4.5), p=0.048), DOI (OR 1.20 per 1 mm 
increment, (95% CI 1.09–1.31), p < 0.001) and LVOT sizing (OR per 1% increment 1.03 (95% CI 1.01–1.07), 
p=0.022) were associated with need for PPI. Sensitivity analyses suggest that a lesser degree of LVOT over-
sizing triggers PPI with second generation THVs vs. first generation THVs.
Conclusions
More LVOT oversizing is associated with a higher need for permanent pacemaker implantation after 
TAVR, even more so with deeper THV implants and next generation devices (ESV-S3 and Lotus). Sizing 
algorithms should focus more on LVOT dimensions to reduce PPI.
67Importance of left ventricular outflow tract in need for permanent pacemaker implantation
PA
RT
 I
INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is increasingly adopted for treatment of symptomatic 
severe aortic stenosis (AS) (1-5). Compared to surgical aortic valve replacement (SAVR) TAVR is associ-
ated with a higher need for permanent pacemaker implantation (PPI) with frequencies varying from 2 to 
51% (4,6,7). PPI leads to prolonged in-hospital stay, more repeat hospitalizations and less improvement in 
quality of life (7). The atrioventricular bundle of His is located in the left ventricular outflow tract (LVOT) 
close to the native aortic valve. This proximity exposes the AV conduction system to all
kinds of TAVR associated trauma from wires, balloons and transcatheter heart valves (8,9). LVOT cal-
cium content and its size relative to the implanted 
transcatheter heart valve (THV) combined with the 
degree of THV protrusion into the LVOT may affect 
the underlying conduction system and consequently 
the need for PPI. This interaction of LVOT and THV is 
complex and may be THV design dependent. Newer 
THV designs (Figure 1) were developed to facilitate 
the TAVR procedure in general and reduce the fre-
quency of paravalvular aortic regurgitation, yet need 
for PPI may be higher (10,11). The aim of this study is 
therefore to determine to what extent the LVOT phe-
notype is associated with need for PPI and whether 
this correlation varies between first-generation and second/next generation valves.
METHODS
Patients
This study included all patients who under-
went TAVR in our center from November 2005 
to January 2015 (N = 504) and had multimo-
dality imaging planning with transthoracic 
echocardiography and multi-slice computed 
tomography (MSCT) assessment of the aortic 
valve and peripheral arterial tree (Figure 2). A 
multi-disciplinary heart team consisting of at 
least 1 cardio-thoracic surgeon and 1 interven-
tional cardiologist judged all patients at high 
risk for mortality with SAVR. TAVR procedure 
was performed under general anesthesia using 
standard techniques as described (12). Relevant clinical and procedural data were prospectively collected 
and entered in a dedicated database. All patients provided written informed consent for the procedure 
and data analysis for research purposes per Institutional Review Board approval.
Figure 1. Next generation valves: left Edwards-SA-
PIEN 3 and right Boston Sadra Lotus. Both have one 
cuff/skirt (arrows) designed to avoid paravalvular 
regurgitation, increasing thewidth of the frame at 
the inflow level.
Figure 2. Study population: flow diagram.
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The initial TAVR experience was with Medtronic CoreValve (Medtronic, Minneapolis, MN, USA) (MCS). In 
2012 the Edwards Sapien XT (ESV-XT) (Edwards Lifesciences, Irvine, CA, USA) was added to our prac-
tice. In September 2013 the Lotus THV (Boston Scientific, Natick, Massachusetts) was introduced and 
followed by the Edwards Sapien S3 (Edwards Lifesciences, Irvine, CA, USA) (ESV-S3) in January 2014. The 
MCS and ESV-XT were considered first generation devices, conversely, Lotus and ESV-S3 second genera-
tion. Of note, given the ample literature on the association of pre-existing right bundle branch block with 
need for pacemaker implantation and the lower incidence of PPI with balloon-expandable ESV, patients 
with RBBB at baseline were preferably treated with either ESV-XT or ESV-S3 (6,13-16). THV size selection 
was based on MSCT derived annular dimensions.
Multi-slice computed tomography imaging
MSCT was performed with Dual Source scanners (including Somatom Definition FLASH and Force, 
Siemens Healthcare, Forchheim, Germany). For the assessment of the calcium load a non-contrast scan 
was performed in an ECG-gated, prospective, sequential (step and shoot) mode, with a tube voltage of 
120 kV and slice thickness of 3mm at 1.5 mm interval. The LVOT was defined as stretching from the aortic 
annulus to 6 mm. on axial images. 
For assessment of the LVOT a contrast enhanced ECG-triggered CT acquisition of the heart was per-
formed. Kilovoltage and mAs settings were adapted to the individual patient. A dedicated software 
program (3mensio Structural Heart, PIE Medical Imaging BV, Maastricht, the Netherlands) was used for 
all MSCT analyses. The LVOT was defined as the area from the virtual annulus up to 6 mm into the left 
ventricle. The minimum LVOT dimension was identified and measured by performing a manual trace of 
the perimeter on double oblique reconstructions perpendicular to the LVOT axis. All the measurements 
were performed in end-systolic phase. Calcium load at the LVOT was semiquantitatively graded as fol-
lows: grade 0 — no calcifications (none); grade 1 — small, non-protruding calcifications (mildly calcified); 
grade 2 — protruding (N1 mm) (moderately calcified) or extensive (>50% of cusp sector) calcification 
(severely calcified). We made a distinction between non/mildly calcified and moderately/severely calci-
fied LVOT (17). Device sizing relative to the LVOT was computed as follows:  ((Normal Perimeter Device 
(Inflow) - LVOT perimeter) / LVOT perimeter) x 100.
Measurement of depth of implantation
To assess the depth of THV implantation (DVI), quantitative angiographic analysis was performed using 
CAAS 5.9 (Pie Medical, Maastricht, the Netherlands). DVI was defined as the mean of the distance from 
the THV inflow to the nadir of the non-coronary and left coronary cusp measured in an optimal projec-
tion where the three cusps were aligned.
Statistical analysis
Normality of the distributions was assessed using Shapiro–Wilk test. Continuous variables with normal 
distribution are presented as mean ± standard deviation and differences compared using the Student’s 
69Importance of left ventricular outflow tract in need for permanent pacemaker implantation
PA
RT
 I
T test or ANOVA, as appropriate. Median and interquartile range was used for non-normally distributed 
continuous variables and differences were compared by using the Mann–Whitney U test or Kruskal–Wal-
lis test, as appropriate. Categorical variables are presented as frequencies and differences were compared 
using the Pearson chi-square test.
We performed a further analysis of depth of implantation and LVOT sizing distinguishing first and sec-
ond-generation devices. Additionally, we studied the relation of these 2 variables in the overall population 
and per device by relating tertiles of both variables. Sensitivity curves were used in order to find a cut-off 
value for depth of implantation
and LVOT sizing for the entire population and separately for first and second-generation devices. 
To identify predictors of PPI, univariable and multivariable logistic regression was performed. Clinical 
and procedural relevant variables were considered for univariate analysis. Clinically relevant variables 
with a p-value ≤0.20 in univariate analysis entered the multivariate stage. The co-variates age and gender 
were included in the model
since they are well-known confounders. A maximum of 7 variables were allowed to enter the multivari-
able analysis given the absolute event rate of 68 in keeping with the frequency of the dependent variable y 
(n/10).We report crude and adjusted odds ratios together with their 95% confidence interval.
All statistical tests were two-sided, and a p-value < 0.05 was considered statistical significant. The statisti-
cal analyses were performed using SPSS software version 21.0 (SPSS INC., Chicago, IL).
RESULTS
Patient population and baseline characteristics 
A total of 504 patients underwent TAVR in our center from November 2005 to January 2015. Clinical 
follow up and good quality MSCT were available in 334 patients; 32 patients were excluded because of a 
Total Population (n = 302) New PPI (n = 68) No PPI (n=234) P-value
Age (years) 81.0 [75.0–84.0] 82.5 [77.3–86.8] 80.0 [74.0–84.0] 0.005
Gender. male (%) 154 (51.0) 38 (55.9) 116 (49.6) 0.36
Body mass index 26.2 [23.4–29.3] 25.8 [23.1–28.4] 26.3 [23.5–30.0] 0.23
Diabetes mellitus (%) 87 (28.8) 17 (25.0) 70 (29.9) 0.43
Hypertension (%) 217 (71.9) 52 (76.5) 165 (60.5) 0.34
Atrial fibrillation (%) 78 (26.1) 21 (31.3) 57 (24.6) 0.27
Prior stroke (%) 68 (22.5) 16 (23.5) 52 (22.2) 0.82
Prior MI (%) 61 (20.2) 10 (14.7) 51 (21.8) 0.20
Prior CABG (%) 67 (22.2) 14 (20.6) 53 (22.6) 0.72
Peripheral vascular
disease (%)
81 (26.8) 23 (33.8) 58 (24.8) 0.14
NYHA class ≥ III (%) 226 (77.7) 51 (75.0) 175 (78.5) 0.55
Euroscore 13.0 [9.0–21.0] 13.6 [9.2–22.2] 13.0 [9.0–20.1] 0.25
Table 1. Baseline characteristics. Abbreviations: MI= myocardial infarction; NYHA = New York heart association.
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permanent pacemaker at baseline resulting in an overall study sample of 302 patients (Figure 2). Base-
line characteristics are summarized in Tables 1 and 2 and procedural details in Table 3.  Median age was 
81 (IQR 75–84) years, 51.0% were male. Median Euroscore was 13 (IQR 9–21). Two hundred and three 
(67.2%) patients received MCS, 38 (12.6%) ESVXT, 26 (8.6%) ESV-S3 and 35 (11.6%) Lotus. The incidence 
of PPI implantation within 30 days post TAVR was 22.5% (68 events): MCS 22.7%, ESV-XT 10.5%, ESV-S3 
26.9% and Lotus 31.4% (p=0.17). Overall, the frequency of PPI after first generation valves was 20.7% vs. 
29.5% after second-generation valves (p = 0.14). The most common indication for PPI was third degree 
atrioventricular block (61.8%). Patients requiring PPI had more first-degree AVB (27.9 vs. 18.4%, p = 0.086) 
and right bundle branch block (RBBB) (19.1 vs. 6.4% p = 0.001) at baseline (Table 2).
Total population 
(n = 302)
New PPI 
(n = 68)
No PPI 
(n = 234) P-value
Electrocardiographic data
First degree AVB (PR N  200 ms) (%) 62 (20.5) 19 (27.9) 43 (18.4) 0.086
QRS duration (ms) 105.0 [94.0–122.0] 107.0 [96.3–135.5] 103.5 [94.0–119.3] 0.088
RBBB (%) 28 (9.3) 13 (19.1) 15 (6.4) 0.001
LBBB (%) 32 (10.6) 5 (7.4) 27 (11.5) 0.32
Echocardiographic data
LVEF (%) 50.9 ± 13.1 53.3 ± 13.6 50.2 ± 13.0 0.19
Peak aortic gradient pre (mmHg) 67.0 [54.0–85.0] 71.0 [51.8–85.0] 67.0 [55.0–85.0] 0.98
Mean aortic gradient pre (mmHg) 40.0 [31.0–52.0] 42.0 [30.0–53.5] 40.0 [31.5–52.0] 0.75
AVA pre (cm2) 0.70 [0.6–0.8] 0.70 [0.6–0.8] 0.7 [0.6–0.8] 0.88
AR ≥ grade II (%) 140 (47.6) 30 (46.9) 110 (47.8) 0.89
MR ≥ grade II (%) 164 (55.6) 37 (56.1) 127 (55.5) 0.93
MSCT data
Annulus perimeter (mm) 78.0 [73.0–83.0] 79.0 [74.0–83.0] 77.0 [73.0–83.0] 0.26
LVOT perimeter (mm) 76.0 [70.0–82.0] 76.0 [71.2–82.8] 76.3 [70.0–81.3] 0.53
Aortic Root Agatston score 2867 [1900–4196] 2864 [1941–4612] 2904 [1883–4083] 0.52
LVOT calcium burden ≥ moderate 41 (14.2) 8 (12.3) 33 (14.7) 0.62
Table 2. Baseline electrocardiographic. echocardiographic and MSCT data. Abbreviations: AVB = atrioventricular 
block; RBBB = right bundle branch block; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; 
AVA = aortic valve area; AR = aortic regurgitation; MR = mitral regurgitation; LVOT = left ventricular out-tract.
Total Population
(n = 302)
New PPI 
(n = 68)
No PPI 
(n = 234) P-value
Second-generation valves (%)* 61 (20.2) 18 (26.5) 43 (18.4) 0.14
Sizing annulus (%) 11.9 [4.7–16.8] 12.5 [4.7–16.8] 11.9 [4.7–16.8] 0.50
Sizing LVOT (%) 13.6 ± 11.3 15.1 ± 12.3 13.1 ± 11.0 0.20
Balloon pre-dilation (%) 250 (83.1) 54 (79.4) 196 (84.1) 0.36
Balloon post-dilation (%) 53 (17.6) 13 (19.1) 40 (17.2) 0.71
Depth of implantation (mm) 7.4 ± 3.4 8.8 ± 3.4 7.0 ± 3.3 <0.001
Table 3. Procedural characteristics. Abbreviations: LVOT = left ventricular out-tract. * Second generation valves 
includes ESV-S3 & Lotus valve.
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LVOT characteristics
The LVOT perimeter was significantly smaller compared 
to the aortic annulus perimeter (76 mm (IQR 70–82) vs. 
78 (IQR 73–83) p = 0.001). LVOT phenotype and calcium 
burden were not different between patients with or with-
out need for PPI. Patients who required PPI had a deeper 
THV implantation into the LVOT (8.8 ± 3.4 vs. 7.0 ± 3.3 
mm, p < 0.001). LVOT sizing was similar in patients with 
and without PPI (15.1 ± 12.3 vs. 13.1 ± 11.0%, p = 0.20). 
LVOT sizing for MCS, ESVXT, ESV-3 and Lotus were 16.08 
± 11.3; 9.2 ± 8.0; 6.8 ± 8.6 and 4.7±7.5% (p < 0.001). Figures 
3 and 4 display the PPI rate per tertile of implantation 
depth and LVOT sizing 
overall and for each device 
separately.
Figure 3. Pacemaker implantation rate in sub-
groups combining LVOT sizing and DVI tertiles for 
all devices.
Figure 4. Pacemaker implantation rate in subgroups combining LVOT sizing 
and DVI tertiles per device.
Univariate odds ratio 
(95% CI) P-value
Multivariate odds 
ratio (95% CI) P-value
Age 1.054 (1.012–1.099) 0.012 1.044 (0.998–1.092) 0.06
Gender. male (%) 1.289 (0.749–2.218) 0.36 1.404 (0.764–2.579) 0.28
First degree AVB 1.722 (0.922–3.216) 0.09 1.211 (0.594–2.467) 0.60
QRS duration 1.007 (0.997–1.017) 0.18
RBBB 3.451 (1.552–7.675) 0.002 2.938 (1.243–6.945) 0.014
Second Generation valves 1.599 (0.850–3.009) 0.15 2.136 (1.006–4.532) 0.048
Depth of implantation 1.179 (1.081–1.285) <0.001 1.196 (1.091–1.310) <0.001
Sizing LVOT 1.016 (0.992–1.040) 0.20  1.034 (1.005–1.065) 0.022
Table 4. Univariate and multivariate logistic regression predicting new PPI. Abbreviations: AVB = atrioventricular 
block; RBBB = right bundle branch block; LVOT = left ventricular outflow tract.
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PPI predictors
By multivariate analysis RBBB at baseline (OR 2.9 (95% CI 1.2–6.9, p = 0.014), next generation valves (OR 
2.136 (95% CI 1.006–4.532), p = 0.048), depth of implantation (OR 1.196 per 1 mm increment, (95% CI 
1.091–1.310), p < 0.001) and LVOT sizing (OR per 1% increment 1.034 (95% CI 1.005–1.065), p = 0.022) 
predicted PPI (Table 4). Patients with RBBB at baseline were preferably treated with a balloon-expand-
able design. Multivariate analysis excluding patients with RBBB confirmed the association between next 
generation valves and depth of implantation with PPI, and a trend for LVOT sizing (Supplemental Table 
2). Sensitivity analysis for each THV shows 80% sensitivity for the association LVOT sizing and PPI (Figure 
5) at 10% oversizing with MCS, 9% with ESV-XT, 3%with ESV-S3 and 2%with Lotus valve. As for depth of 
implantation, 80% sensitivity was obtained with a depth of 6.3 mm for both MCS and ESV-XT, 7.0 mm for 
the ESV-S3 and 6.7 mm for the Lotus valve (Figure 6).
DISCUSSION
The key findings of our observational study can be summarized as follows. 1) LVOT oversizing but not 
LVOT calcium burden is associated with PPI. 2) Depth of implantation strengthens the association of 
sizing with PPI. 3) The degree of LVOT oversizing triggering PPI is less for next generation THVs.
Need for PPI after TAVR reportedly varies between 2 and 51% and is consistently higher with the self-ex-
panding MCS as compared to the balloon expandable Edwards THV (6). In the randomized CHOICE trial 
the 30-day PPI rate was 17% for the ESV-XT vs. 37.6% for the MCS (p = 0.001) (18). In the PRAGMATIC 
initiative the difference was 6% for ESV-XT vs. 22.5% for MCS, p < 0.001) (19). A recent meta-analysis also 
confirmed the higher need for PPI with MCS (28% vs. 6%) (6). The higher need for PPI with MCS may be 
related to the self-expanding design that may be prone to deeper implants and delayed tissue injury. In 
our study 4 different THVs were used, yet we did not detect significantly different PPI rates among these 
THV designs. This may be explained by selection bias and our policy to treat patients with RBBB at base-
line preferably with balloon-expandable devices given the compelling association of RBBB with PPI and 
the higher need for PPI with MCS in previous studies (6). Interestingly the composite of next generation 
Figure. 5. Sensitivity curve per device for the 
relation LVOT sizing and PPI.
Figure. 6. Sensitivity curve per device for the relation PPI 
and depth of implantation.
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THVs (ESV-S3 and Lotus) was associated with more PPI (2.136 (95% CI 1.006–4.532) p = 0.048).
Traditional risk factors for PPI post TAVR are RBBB and depth of THV implantation. This reality reflects 
the anatomic vicinity of the atrioventricular conduction system and the native aortic valve. Indeed, the 
AV node and its extension the bundle of His is adjacent to the membranous interventricular septum and 
particularly the left bundle is close to the base of the interleaflet triangle between the right and non-cor-
onary leaflets. It is conceivable that a device deployed in the LVOT and thus pressing on this conduction 
system may induce trauma to the left bundle and even more so if the interface is larger in association 
with a deeper implant eventually resulting in high degree AV block a fortiori when pre-existing RBBB 
exists (8,20). In our analysis 1st degree AV block trended to be associated and RBBB highly correlated with 
need for PPI. These findings underscore a recent meta-analysis including 11,210 patients that demon-
strated strong correlations between 1st degree AV block (OR 1.52) and RBBB (OR 2.89) with need for PPI 
(6). Interestingly, we also detected a close to significant correlation between age and need for PPI. This 
may feed the hypothesis that the conduction system in younger patients could be less vulnerable to TAVR 
induced trauma. Depth of implantation has previously been associated with need for PPI (21,22). In our 
study mean depth of implantation was similar for all THVs and was associated with more PPI. As for the 
LVOT phenotype and need for PPI, calcium was no factor whereas relative LVOT oversizing was, especial-
ly when adjusted for depth of THV implantation. Currently, most sizing algorithms specifically focus on 
annular dimensions for THV size selection. Yet the anatomical dimensions significantly taper down mov-
ing into the LVOT as was shown in our study. Baan et al. demonstrated that a smaller left ventricular out-
flow tract diameter by 2D echocardiography was a predictor for PPI with MCS (23). A PARTNER sub-study 
revealed that the ESV prosthesis to LVOT ratio assessed by 2D echocardiography, correlated with PPI (7). 
Typically first generation THVs require 10 to 20% oversizing relative to the aortic annulus. The degree of 
LVOT oversizing that predicts PPI seems considerably less and even smaller for second-generation THVs 
vs. first generation THVs. Interestingly, in our study the impact of LVOT oversizing seemed greater with 
deeper implants. Deeper implants would result in a larger interface between the THV and the underlying 
conduction system and therefore a higher likelihood of traumatic compression. Furthermore, additional 
sealing skirts with ESV-S3 and Lotus may minimize paravalvular regurgitation at the expense of more 
compression on surrounding tissue (Figure 1) (24). Our data suggest that patients with RBBB at baseline 
are at risk for PPI after TAVR regardless of the selected THV design. Yet, efforts to reduce depth of THV 
implantation and refined sizing algorithms with specific attention to the LVOT dimensions to avoid 
excessive sizing at the LVOT level may reduce PPI rates particularly with second-generation THVs. Indeed 
more attention to the LVOT may not only reduce the risk for aortic root rupture but also need for PPI (25). 
Limitations
This is a single center observational study using 4 different THV designs with unequal patient distribu-
tion. Also patients with RBBB at baseline were preferably treated with balloon expandable THVs, which 
may have resulted in higher PPI rate. The number of patients per THV was too small to demonstrate sig-
nificant inter-device differences, yet our observations in terms of LVOT oversizing and depth of implanta-
tion are clinically relevant and require confirmation in adequately powered studies.
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CONCLUSIONS
LVOT sizing is associated with need for permanent pacemaker implantation after TAVR, even more so 
with deeper THV implants and second generation devices (ESV-S3 and Lotus). Sizing algorithms should 
focus more on LVOT dimensions to reduce PPI.
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SUPPLEMENTAL MATERIAL
Total       
Population 
(n = 302)
MCS 
(n= 202)
ESV-XT 
(n=38)
ESV-S3 
(n=26)
Lotus
 (n=35) P-value
Age (years.) 81.0          [75.0 – 84.0]
81.0         
[76.0-85.0]
75.5         
[72.0-81.3]
83.5         
[79.0-85.8]
81.0         
[75.0-85.0] 0.002
Gender. male (%) 154 (51.0) 105 (51.7) 20 (52.6) 15 (57.7) 14 (40.0) 0.52
Body mass index 26.2          [23.4 – 29.3]
26.0         
[23.4-28.5]
26.2         
[21.9-30.7]
27.7         
[25.0-31.8]
26.3         
[22.9-30.0] 0.21
Diabetes Mellitus (%) 87 (28.8) 56 (27.6) 10 (26.3) 9 (34.6) 12 (34.3) 0.75
Hypertension (%) 217 (71.9) 135 (66.5) 30 (78.9) 22 (84.6) 30 (85.7) 0.026
Atrial fibrillation (%) 78 (26.1) 51 (25.2) 7 (18.4) 7 (26.9) 13 (39.4) 0.23
Prior Stroke (%) 68 (22.5) 48 (23.6) 6 (15.8) 4 (15.4) 10 (28.6) 0.45
Prior MI (%) 61 (20.2) 37 (18.2) 12 (31.6) 5 (19.2) 7 (20.0) 0.31
Prior CABG (%) 67 (22.2) 48 (23.6) 6 (15.8) 6 (23.1) 7 (20.0) 0.74
Peripheral vascular 
disease (%) 81 (26.8) 46 (22.7) 15 (39.5) 9 (34.6) 11 (31.4) 0.11
NYHA class ≥ III (%) 226 (77.7) 154 (77.8) 27 (73.0) 22 (84.6) 23 (76.7) 0.75
Euroscore 13.0             [9.0 -21.0]
13.4           
[9.4-21.3]
9.8             
[6.9-19.3]
14.0           
[7.5-22.2]
12.1           
[9.2-20.2] 0.12
First degree AVB  (%) 62 (20.5) 46 (22.7) 6 (15.8) 3 (11.5) 7 (20.0) 0.50
QRS duration (ms) 105.0         [94.0 -122.0]
106.0        
[95.8-120.0]
100.5         
[89.0-143.5]
105.0        
[98.5-119.0]
101.0       
[94.0-122.0] 0.83
RBBB (%) 28 (9.3) 12 (5.9) 7 (18.4) 6 (23.1) 3 (8.6) 0.006
LBBB (%) 32 (10.6) 26 (12.8) 3 (7.9) 0 (0.0) 3 (8.6) 0.21
LVEF (%) 50.9 ± 13.1 49.7 ± 13.3 48.5 ± 12.3 53.1 ± 14.2 56.7 ± 10.1 0.079
Peak aortic gradient 
pre (mmHg)
67.0           
[54.0 -85.0]
71.0         
[54.0-85.8]
71.5         
[51.8-85.0]
64.0         
[58.8-82.3]
65.5         
[52.8-79.3] 0.70
Mean aortic gradient 
pre (mmHg)
40.0           
[31.0 -52.0]
41.0          
[31.3-52.0]
41.0           
[30.0-56.1]
39.5             
[31.0-52.5]
37.5         
[30.0-46.5] 0.75
AVA pre (cm2) 0.70 [0.6 -0.8] 0.7 [0.5 -0.8] 0.8 [0.7-0.9] 0.7 [0.6-0.9] 0.7 [0.6-0.9] 0.082
AR ≥ grade II (%) 140 (47.6) 86 (42.8) 26 (68.4) 11 (47.8) 17 (53.1) 0.030
MR ≥ grade II (%) 164 (55.6) 97 (48.0) 24 (64.9) 18 (75.0) 25 (78.1) 0.001
Annulus perimeter 
(mm)
78.0           
[73.0 -83.0]
78.0          
[73.0-83.8]
77.0         
[72.8-82.0]
79.0         
[74.8-83.8]
76.0           
[72.0-82.5] 0.55
LVOT perimeter 
(mm)
76.0           
[70.0 -82.0]
77.0           
[70.0 -83.0]
74.5            
[70.0-80.0]
75.3           
[71.0-82.0] 
73.9         
[71.0-79.0] 0.52
Agatston score 
Aortic Root
2867        
[1900 -4196]
2934        
[1899-4340]
2719        
[1925-4841]
3174         
[2194 -4553]
2649        
[1858-3332] 0.37
LVOT calcium 
burden ≥ moderate 41 (14.2) 31 (15.9) 5 (13.9) 2 (8.3) 3 (8.8) 0.58
Sizing annulus (%) 11.9             [4.7 – 16.8]
13.9           
[9.8-19.5]
4.7             
[1.6-8.9]
3.5                
[0.7 -6.9]
1.0             
[-0.2-3.1] <0.001
Sizing LVOT (%) 13.6 ± 11.3 16.8 ± 11.3 9.2 ± 8.0 6.9 ± 8.6 4.7 ± 7.5 <0.001
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Balloon pre-dilation 
(%) 250 (83.1) 188 (93.1) 37 (97.4) 16 (61.5) 9 (25.7) <0.001
Balloon post-dilation 
(%) 53 (17.6) 40 (19.8) 10 (26.3) 3 (11.5) 0 (0.0) 0.013
Depth of 
implantation (mm) 7.4 ± 3.4 7.3 ± 3.8 7.7 ± 2.5 7.6 ± 2.1 7.6 ± 2.0 0.90
Supplemental table 1. Baseline clinical and procedural characteristics per device. Abbreviations: AVA = aortic 
valve area; AR = aortic regurgitation; AVB = atrioventricular block; LBBB = left bundle branch block; LVEF = left 
ventricular ejection fraction; LVOT = left ventricular outflow tract; MI = myocardial infarction; MR = mitral regurgi-
tation; NYHA = New York heart association; RBBB = right bundle branch block.
Univariate
odds ratio (95% CI) P-value
Multivariate
odds ratio (95% CI) P-value
Age 1.041 [0.997 – 1.087] 0.067 1.034 [0.987 – 1.084] 0.16
Gender. Male (%) 1.189 [0.658 – 2.149] 0.57 1.327 [0.698 – 2.523] 0.39
First degree AVB 1.576 [ 0.784 – 3.169] 0.20 1.301 [0.605 – 2.799] 0.50
QRS duration 0.997 [0.985 – 1.011] 0.71
Second Generation valves 1.845 [0.925 – 3.680] 0.082 2.394 [1.083 – 5.293] 0.031
Depth of implantation 1.176 [1.070 – 1.293] 0.001 1.185 [1.075 – 1.307] 0.001
Sizing LVOT 1.013 [0.985 – 1.042] 0.371 1.029 [0.995 – 1.064] 0.096
Supplemental table 2. Univariate and multivariate logistic regression predicting new PPI. excluding patients 
with RBBB at baseline.  Abbreviations: AVB = atrioventricular block; RBBB = right bundle branch block; LVOT = left 
ventricular outflow tract.
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Catheter-based therapies may offer a less invasive alternative to conventional surgery for a wide array 
of cardiovascular diseases. These percutaneous interventions often require large-bore catheters, and 
vascular access management may be challenging. Suture-based closure devices can be used for arterioto-
my closure. Transcatheter aortic valve replacement (TAVR) involves such large-bore arteriotomy closure. 
Despite smaller device profiles and growing experience with TAVR, the reported incidence of vascular 
complications still varies between 1% and 13% (1-3). Up to 
two-thirds of major vascular complications after TAVR are 
due to failed arteriotomy closure (4). 
The percutaneous MANTA vascular closure device (VCD) 
(Essential Medical Inc., Malvern, Pennsylvania) is a novel 
collagen-based technology dedicated to the closure of large 
bore arteriotomies. The MANTA VCD contains an 8-F punc-
ture location dilator, a dedicated sheath, a closure unit, and 
a delivery system. The closure unit consists of a resorbable 
polymer (poly-lactic-co-glycolic acid) intra-arterial toggle, an 
extravascular hemostatic bovine collagen pad, a connecting 
nonresorbable polyester suture, and a stainless steel suture 
lock, illustrated in Figure 1. This closure unit is attached to 
the delivery system that contains a carrier/release tube and a device handle with a tension gauge. Both 
the puncture location dilator and the MANTA sheath have centimeter markers on the respective surfaces. 
MANTA comes in 14-F and 18-F sizes for closing punctures of 10 to 14 F and 15 to 22 F, respectively. Use 
of the MANTA VCD precludes a pre-closure technique. After common femoral artery access is obtained 
with a 6-F sheath, this sheath is exchanged for the 8-F puncture location dilator to determine the dis-
tance of the subcutaneous track from skin level to the endoluminal arterial space. The planned cardio-
vascular intervention is then executed by upscaling the access sheath. Thereafter the procedural sheath 
is exchanged for the dedicated MANTA sheath to receive the MANTA closure unit. The MANTA sheath 
closure unit assembly is withdrawn up to the predetermined deployment level. The toggle is released 
and the assembly is withdrawn from the patient. Pulling force can be monitored by the color code of the 
tension gauge. The blue tamper tube emerges and is advanced along the suture line to secure the stainless 
steel lock onto the vessel and further compact the collagen pad. The suture is cut above the tamper and 
at skin level. It takes 6 months for the MANTA components to resorb so that only the polymer suture and 
stainless steel suture lock remain at the access site.
In our initial MANTA experience in 10 consecutive patients undergoing TAVR (n = 8), balloon aortic 
valvuloplasty (n = 1), and high-risk percutaneous intervention with a 14-F circulatory support device (n 
= 1), sheath sizes varied from 14 to 22 F. MANTA access closure was successful in all patients. Hemostasis 
was obtained within 22 ± 20 s after starting MANTA deployment. A patent artery was angiographically 
confirmed in all cases. There were neither significant bleeding events nor vascular complications at the 
access site closed by MANTA. Our initial experience supports further study to determine if use of the 
MANTA VCD could reduce access-site complications with large-bore cardiovascular interventions. The 
CE-mark study (NCT02521948) to evaluate the safety and performance of the MANTA VCD has complet-
ed enrollment, and results will be presented in 2016.
Figure 1. MANTA concept. A bovine colla-
gen pad in gray seals the arteriotomy from 
the outside of the vessel and is connected 
with the endoluminal bioresorbable toggle 
through a suture that is closed by a stain-
less steel suture lock.
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ABSTRACT
Catheter-based interventions have become a less invasive alternative to conventional surgical techniques 
for a wide array of cardiovascular diseases but often create large arteriotomies. A completely percutane-
ous technique is attractive as it may reduce the overall complication rate and procedure time. Currently, 
large bore arteriotomy closure relies on suture-based techniques. Access-site complications are not 
uncommon and often seem related to closure device failure. The MANTA VCD is a novel collagen-based 
closure device that specifically targets arteriotomies between 10 and 22 Fr. This technical report discusses 
the MANTA design concept, practical instructions for use and preliminary clinical experience.
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Introduction
For a wide array of cardiovascular diseases less invasive catheter-based therapies have become available 
as an alternative to conventional surgery. Achieving large bore catheter access and vascular access man-
agement may be challenging. For large arteriotomies (>12 Fr) suture-based percutaneous closure devices 
such as Prostar XL (Abbott Vascular, Santa Clara, CA, USA) or Perclose ProGlide (Abbott Vascular) are an 
established technique, yet major vascular complications are relatively common (1). 
Balloon aortic valvuloplasty (BAV) – with sheath sizes of 10 to 13 Fr – is associated with major vascular 
complications in 7% of cases (2), and with transcatheter aortic valve implantation (TAVI) this rate goes 
up to 12% (3). The ClOsure device iN TRansfemoral aOrtic vaLve implantation (CONTROL) multicentre 
study, comparing Prostar with ProGlide, showed more major vascular complications with Prostar (4). 
Two thirds of major vascular complications after TAVI result from failed arteriotomy closure (5). 
Over time, the rate of vascular complications has gradually declined due to growing experience, improved 
access technique with fluoroscopic or ultrasound guidance and design modifications with smaller profile 
devices (6,7); yet, access-site complications and bleedings are still fairly common and associated with 
mortality (8). Precautionary crossover balloon occlusion may facilitate suture-based closure but requires 
an additional femoral or radial arterial access and may 
increase overall procedural costs (9). 
The percutaneous MANTA Vascular Closure Device 
(VCD) (Essential Medical Inc., Malvern, PA, USA) is a 
novel collagen-based technology for closure of large 
bore arteriotomies. This technical report describes the 
MANTA design concept, practical instructions for use 
and preliminary clinical experience. 
MANTA design 
The MANTA VCD has a closure unit, a delivery system 
and a dedicated sheath with introducer. There is also a separate 
8 Fr puncture location dilator (Figure 1). The puncture location 
dilator and the MANTA sheath both have a visible metric ruler 
for assessing the adequate depth. The closure unit comprises the 
following components: a resorbable polymer (poly-lactic-co-gly-
colic acid) intra-arterial toggle, an extravascular haemostatic 
bovine collagen pad, a connecting non-resorbable polyester 
suture, and a stainless steel suture lock (Figure 2). The delivery 
system has a tube containing the closure unit and a device 
handle with a tension gauge to release the closure unit from the 
tube. The MANTA system comes in a 14 Fr or 18 Fr size. The 14 
Fr MANTA VCD is indicated for closing punctures of 10 to 14 Fr, 
the 18 Fr MANTA VCD for punctures of 15 to 22 Fr. 
Figure 1. MANTA closure device. Shown are 
closure unit (A), delivery system (B), dedicated 
sheath with introducer (C), and 8 Fr puncture lo-
cation dilator (D). The sheath and location dilator 
have centimetre markers.
Figure 2. MANTA concept. 
A bovine collagen pad (in grey) seals 
the arteriotomy from the outside of the 
vessel and is connected with the endo-
luminal bioresorbable toggle through a 
suture that is closed by a stainless steel 
suture lock.
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Technique 
Ultrasound or fluoroscopy guidance may help to achieve a median anterior vessel entry. Angiography 
should confirm access quality. Pre-closure is not necessary with the MANTA system. Figure 3 and Sup-
plemental Figure 1 illustrate the procedural steps with MANTA closure. After a 0.035” guidewire and 6 Fr 
sheath are introduced into the common femoral artery, the sheath is exchanged for the 8 Fr puncture lo-
cation dilator to measure the length of the subcutaneous track from the skin to the endovascular lumen. 
Pulsatile blood emerges when the dilator tip is in the arterial vessel. The operator pulls back the dilator 
until the blood flow ceases and the depth of the vessel lumen can be read from the metric ruler. Empir-
ically 2 cm is added to assure endoluminal deployment of the toggle during the actual MANTA delivery. 
The arterial access is then up-scaled to the proper sheath size to perform the index procedure. At the 
end of the index procedure, significant subcutaneous blood collection should be excluded before using 
the MANTA VCD because significant haematoma could alter the puncture depth relative to the state at 
baseline. The procedural sheath is exchanged over a 0.035” guidewire for the dedicated MANTA sheath. 
Figure 3. MANTA closure in real practice. A) Puncture depth estimation with the 8 Fr puncture location dilator. 
Note (pulsatile) blood exiting on the side (black arrow). B) The location dilator is re-advanced and blood ceases 
(black arrow). C) The MANTA sheath is introduced over a 0.035” guidewire. D) The sheath introducer is remo-
ved. E) The MANTA closure unit is advanced over the wire into the sheath. F) The MANTA sheath closure unit 
assembly is slowly withdrawn at a 45° angle with the right hand while providing slight left hand counter push to 
the skin level to avoid skin tenting. G) The lever is rotated (orange arrow) to release the toggle. H) The assembly is 
slowly withdrawn from the patient along the angle of the initial puncture. Pulling force can be monitored by the 
colour code of the tension gauge and the tamper tube is advanced down along the suture line. I) The suture is cut 
above the tamper and at skin level.
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The sheath introducer is removed and the MANTA closure unit is advanced over the wire into the sheath 
until the MANTA delivery hub snaps the sheath hub and a clicking sound will be heard. The MANTA 
sheath closure unit assembly is then slowly withdrawn at a 45° angle with the right hand while providing 
slight left hand counter push to the skin level to avoid skin tenting. At the predetermined deployment 
level, the toggle is released by rotating the lever of the MANTA delivery handle in a clockwise direction. 
The assembly is then slowly and gently withdrawn from the patient. Pulling force can be monitored by a 
colour code. When excessive force is applied the colour code will switch from green to red, accompanied 
by an audible “click”. As the MANTA sheath clears the skin layer a blue tamper tube emerges from the de-
ployment tube. Digital left hand pressure around the puncture site is released to advance the tamper tube 
down along the suture line and secure the stainless steel lock onto the vessel to compact the collagen 
pad further. The black suture marker becomes visible to indicate full compaction of the collagen. At this 
point, the arterial wall is sandwiched between toggle and collagen. Tension on the assembly is released 
and the tamper is slid up the suture line out of the puncture tract. When haemostasis is confirmed, the 
guidewire is removed. If needed, a final tamp with tension on the handle and monitored pressure on the 
tamper (green colour at tension gauge) can be performed to ensure complete haemostasis. The suture is 
cut above the blue tamper and at skin level. 
The MANTA components will resorb in six months. In the event that the patient requires re-access within 
six months from MANTA closure, X-ray 
should be used to identify the radiopaque 
lock, and the common femoral artery should 
be punctured at least 2.5 cm from the pres-
ent MANTA device. 
MANTA closure should be used with caution 
at puncture sites: 1) in the proximity (<1 
cm) of large bifurcations, 2) with significant 
atherosclerotic disease or circumferential 
calcifications, or 3) with non-central vessel 
entry. 
Initial Rotterdam experience 
MANTA closure was applied in 10 consec-
utive patients undergoing various large 
bore catheter interventions, including TAVI 
(n=8), BAV (n=1) and high-risk percutane-
ous intervention with a 14 Fr circulatory 
support device (n=1). All patients underwent 
pre-procedural planning by MSCT and/or 
ultrasound plus ad hoc angiography to assess 
the iliofemoral arterial tree in terms of size, 
atherosclerotic disease, calcium distribution 
N=10
Age in years (mean±SD) 79±6
Male gender (n) 8
BMI in kg/m² (mean±SD) 27±4
Glomerular filtration rate in ml/min 
(mean±SD) 55±26
Stroke (n) 3
Atrial fibrillation (n) 2
Pacemaker (n) 3
Bundle branch block (n) No 4
LBBB 1
RBBB 2
Prior myocardial infarction (n) 3
Prior CABG (n) 2
Prior PCI (n) 2
Diabetes mellitus (n) 4
Hypertension (n) 7
Peripheral vascular disease (n) 3
COPD (n) 2
New York Heart Association 
Class (n)
II 4
III 3
IV 3
Table 1. Baseline characteristics. Abbreviations: BMI = body 
mass index; CABG = coronary artery bypass grafting; LBBB = 
left bundle branch block; PCI = percutaneous coronary inter-
vention; RBBB = right bundle branch block
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N=10
Procedure sheath size (n)
14 Fr 3
14 Fr – eSheath 2
16 Fr – eSheath 3
20 Fr 2
Procedure type (n)
TAVI 8
BAV 1
Percutaneous heart pump 1
Valve type, if TAVI was 
performed (n)
Edwards SAPIEN 3 29 mm 3
Edwards SAPIEN 3 26 mm 2
Boston Scientific Lotus 27 mm 2
Medtronic Evolut R 26 mm 1
MANTA sheath size (n)
14 Fr 3
18 Fr 7
Bleeding <24 hr (n)
No bleeding 9
Minor bleeding 0
Major bleeding 0
Life-threatening bleeding 1*
Bleeding >24 hr (n) No bleeding 10
Vascular complication (n) No vascular complications 9
Minor 0
Major 1*
Percutaneous closure device failure (n) 0
Unplanned closure technique (n) 0
Time to haemostasis in seconds (mean±SD) 22±20
Patent artery after deployment of MANTA VCD (n) 10
Manual pressure needed to achieve haemostasis (n) 0
Table 2. Procedure characteristics. *One patient experienced a li-
fe-threatening bleeding from the contralateral inferior epigastric artery. 
Abbreviations: BAV = balloon aortic valvuloplasty; TAVI = transcatheter 
aortic valve implantation
and tortuosity. Baseline patient 
characteristics are displayed in 
Table 1. Mean age was 79±6 years, 
and eight of the 10 patients were 
male. Procedural characteristics are 
shown in Table 2. Sheath size closed 
with the MANTA device varied from 
outer diameter 14 Fr to 22 Fr, in-
cluding the self-expanding eSheath 
technology (Edwards Lifesciences, 
Irvine, CA, USA) in five patients. The 
14 Fr and 18 Fr MANTA were used 
in three and seven patients respec-
tively. MANTA access closure was 
successful in all patients. Time from 
toggle release (i.e., start of device 
deployment) to haemostasis was 
22±20 seconds. Angiography con-
firmed a patent artery in all cases. 
There were no relevant bleeding or 
vascular complications after MAN-
TA closure. One patient experienced 
a major vascular complication due 
to laceration of the inferior epi-
gastric artery in the contralateral 
access site that was not related to 
the MANTA VCD.
Conclusion 
Early clinical experience is promising but needs confirmation in larger clinical trials. Results from the CE-
mark study (NCT 02521948) to evaluate the safety and performance of MANTA VCD are awaited in 2016. 
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Supplemental figure 1. Typical MANTA closure.
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ABSTRACT
Objectives
The authors sought to study the safety and efficacy of the MANTA Vascular Closure Device (VCD), a novel 
collagen-based technology dedicated to closure of large-bore arteriotomies.
Background
Novel transfemoral therapeutic interventions requiring large-bore catheters have become valid minimally 
invasive options but have inherent access management challenges. To date, no dedicated vascular closure 
devices exist for large arteriotomies.
Methods 
A prospective, single-arm clinical investigation enrolling patients who underwent elective percutaneous 
interventions with large-bore catheters and planned percutaneous arteriotomy closure in 3 European 
institutions.
Results
A total of 50 patients with a mean age of 79.5 ± 8.3 years underwent high-risk percutaneous coronary 
intervention, balloon aortic valvuloplasty, or transcatheter aortic valve replacement with large-bore cath-
eters sized 12-F to 19-F. MANTA closure was performed by 9 different operators. The 14-F MANTA VCD 
was deployed in one-third of the overall cohort (16 of 50, 32%), and the 18-F MANTA VCD in the remain-
der. The MANTA VCD was deployed successfully in all patients. The mean time to hemostasis was 2 min, 
23 s. One patient had a major vascular and major bleeding complication with prolonged femoral bleeding 
that was successfully treated with a covered stent and eventual surgical repair. There were no other access 
site–related complications.
Conclusions
This first multicenter experience demonstrates rapid and reliable hemostasis and low complication rates 
with the use of the plug-based MANTA VCD for large-bore arteriotomy closure.
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INTRODUCTION
The advent of endovascular aneurysm repair, transcatheter aortic valve replacement (TAVR), and me-
chanical circulatory support has offered new, minimally invasive therapeutic options that are rapidly be-
coming standard of care. These percutaneous transfemoral interventions require large-bore catheters and 
have created challenges for femoral arterial access management. Current approaches include surgical 
cut-down with arterial puncture under direct vision, and suture-based “pre-closure.” Surgical cut-down is 
associated with longer procedural time, increased patient discomfort, deeper anesthesia, risk of wound 
complications including infection, and slower ambulation. The pre-closure technique overcomes many of 
the disadvantages of surgical cut-down but can be technically demanding, time consuming, and associat-
ed with a significant failure rate. Recent randomized TAVR trials have reported major vascular complica-
tions in 6% to 8% (1,2). Furthermore, a study on the 2 suture-based closure techniques for management of 
TAVR access reported a 20% vascular complication rate despite being used by experienced operators (3). 
Currently, the majority of access site complications result from failed arteriotomy closure (4). 
The percutaneous MANTA Vascular Closure Device (VCD) (Essential Medical Inc., Malvern, Pennsylvania) 
is a novel collagen-based technology dedicated to closure of large-bore arteriotomies (5). The MANTA 
VCD underwent prospective multicenter evaluation for Conformité Européenne (CE) mark approval in 
the first detailed report of outcomes achieved with a dedicated large-bore vascular closure device. 
METHODS
This prospective, multicenter, non-blinded, single-arm clinical investigation enrolled 50 patients in 3 
European institutions. Eligible patients underwent elective percutaneous interventions with large-bore 
catheters sizes 12-F to 19-F (sheath outer diameter (OD) profile of 16-F to 24.5-F) and planned percutane-
ous arteriotomy closure. All patients were discussed in a multidisciplinary heart team including inter-
ventional cardiologists and cardiac/vascular surgeons. Key exclusion criteria were: 1) arterial puncture 
outside of the common femoral artery; 2) common femoral artery size inappropriate for the selected 
sheath size; 3) complicated femoral access, including excessive hematoma surrounding the puncture site, 
arteriovenous fistula, and posterior wall puncture; 4) renal insufficiency defined by a serum creatinine 
>2.5 mg/dl; and 5) inability to ambulate at baseline. Patients provided written informed consent before 
enrolment. Operators were first-time users of the MANTA VCD, and their training included a detailed 
device description and bench-top training on a dry plastic model. The study design was approved by 
each institutional review board and was conducted in accordance with the Declaration of Helsinki, Good 
Clinical Practice principles, and the International Organization for Standardization of medical devices for 
human subjects (ISO 14155:2011). The study was registered as NCT02521948 (Clinical Study to Evaluate 
the Safety and Performance of MANTA Vascular Closure Device). 
Device description
A detailed description of the MANTA VCD and its mode of operations has been previously described in 
detail (5). In brief, the MANTA VCD consists of an implantable closure unit and a delivery system. The 
delivery system comprises a device handle, a carrier/release tube, a custom introducer and device sheath, 
96 Chapter 8
PA
RT
 II
and an 8-F puncture location dilator (Figure 1). The loca-
tion dilator and device sheath have centimeter markers. 
The closure unit consists of an intra-arterial bioresorbable 
polymer (poly-lactic-co-glycolic acid) toggle, an extra-vas-
cular hemostatic bovine collagen pad, a connecting non-
resorbable polyester suture, and a stainless steel suture 
lock. Hemostasis is achieved primarily by the mechanical 
means of the toggle-arteriotomy-collagen sandwich, 
which is supplemented by the coagulation-inducing prop-
erties of the collagen. With the exception of the perivas-
cular stainless steel lock (1.6 ± 2.9 mm) and the polyester 
suture that ties the collagen, toggle, and lock together, all 
MANTA composites are resorbed within 6 months. In the 
event the patient requires re-access within 6 months from 
MANTA closure, fluoroscopy should be used to identify 
the radio-opaque lock, and the common femoral artery 
should be punctured at least 2.5 cm away from the present 
MANTA device.
Procedure planning and execution
Computed tomography (CT) angiography of the iliofemoral arterial tree was recommended for all pa-
tients and was typically available for all TAVR patients. Ultrasound assessment of the common femoral 
arteries before the procedure, pre-discharge, and at 30 days and 60 days after the procedure, as well as se-
lective angiography following arterial access with a 6-F sheath and after MANTA access closure attempt, 
were mandatory per protocol. After successful and uncomplicated access confirmation, the initial sheath 
was exchanged for the MANTA puncture location dilator to measure the distance from the arteriotomy to 
the skin level. The access was then up-scaled per planned procedural requirements. At the end of the per-
cutaneous intervention, the large-bore access sheath was exchanged for the dedicated MANTA sheath. 
The MANTA device is inserted into the dedicated sheath and positioned according to puncture distance. 
Once the toggle is released, the seal is achieved through familiar tamping procedure and confirmed with 
the included tension gage. Deployment takes 1 to 2 min. The 14-F and 18-F MANTA VCD accommodate 
10-F to 14-F (OD profile 14-F to 18-F) and 14-F to 19-F (OD profile 18-F to 24.5-F) access sheath sizes, re-
spectively. All interventions were performed under anticoagulation with heparin, aiming for an activated 
clotting time between 250 and 300 s. At the time of MANTA VCD deployment, the activated clotting time 
needed to be below 250 s with a systolic blood pressure <180 mm Hg. Heparin reversal with protamine 
was at the operator’s discretion.
Safety and effectiveness
The primary means of evaluating safety was occurrence of any access site–related vascular injury, as well 
as major and life threatening/disabling bleeding complications according to the most recent Valve Aca-
Figure 1. MANTA Vascular Closure Device. 
(Upper panel: from top to bottom) MANTA 
device with closure unit, 8-F puncture locator, 
introducer, and sheath. (Lower panel) Schema-
tic representation of arteriotomy closure with 
MANTA toggle and plug.
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demic Research Consortium (VARC) definitions (6). The primary performance endpoint was hemostasis 
success, defined as hemostasis at the puncture site within 10 min of removing the MANTA sheath with-
out need for manual or mechanical compression and without later re-bleeding. Secondary performance 
endpoints included time to hemostasis (TTH). TTH was defined as the elapsed time between MANTA 
deployment (withdrawal of sheath from artery) and the first observed and confirmed arterial hemostasis 
(no or minimal subcutaneous oozing and the absence of expanding or developing hematoma). All pa-
tients returned for a clinical and ultrasound follow-up including ankle brachial indices and a plain x-ray 
of the femoral access site. Demographic, procedural, and endpoint data were entered in electronic case 
report forms. An independent clinical research organization, Factory-CRO (Bilthoven, The Netherlands), 
was responsible for study conduction and monitoring, which included on-site monitoring visits. Clinically 
relevant endpoints, including vascular and bleeding complications, were adjudicated according to the 
latest VARC definitions (6).
Statistical analysis
Statistical analysis was conducted using SPSS version 
21.0.01 (IBM Corp., Armonk, New York). Continuous vari-
ables are presented as mean ± SD or as median (interquar-
tile range), and categorical variables are expressed as per-
centages. Repeated measurements in individual patients 
were compared using a paired Student t test. 
RESULTS
A total of 50 patients were included from 3 European 
centers between July 2015 and January 2016. Overall, 9 
different operators deployed the MANTA VCD. None of 
the operators had MANTA experience before entering the 
study. Baseline demographics are displayed in Table 1. 
Mean age was 79.5 ± 8.3 years. Women represented 54% of 
the cohort. The Society of Thoracic Surgeons predicted risk 
of mortality (STS PROM) 
was 5.8 ±4.3. Procedural 
characteristics are sum-
marized in Table 2. One 
patient underwent high 
risk percutaneous coro-
nary intervention with a 
14-F circulatory support 
system, 2 patients under-
went balloon aortic valvu-
loplasty, and 47 patients 
N=50
Age, yrs 79.5 ± 8.3
Female 27 (54)
Weight, kg 75.3 ± 15.6
STS score 5.85 ± 4.31
Prior CABG 1 (2)
Prior PCI 6 (12)
Pacemaker 2 (4)
Atrial fibrillation 1 (2)
Stroke 2 (4)
COPD 2 (4)
Hemodialysis 1 (2)
Creatinine, mmol/l 116 ± 79
Hemoglobin 12.20 ± 1.66
Table 1. Baseline patient characteristics. 
Values are mean  SD or n (%). Abbreviations: 
CABG = coronary artery bypass graft; COPD 
= chronic obstructive pulmonary disease; PCI 
= percutaneous coronary intervention; STS = 
Society of Thoracic Surgeons.
Figure 2. Frequency Distribution of Time to Hemostasis. 
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TAVR. The large-bore sheath size varied from an 
internal diameter of 12-F to 19-F, including the use 
of expandable 14-F and 16-F e-sheaths, with ODs 
ranging between 14-F and 24.5-F. The 14-F MANTA 
VCD was applied in one-third of the overall cohort 
(16 of 50, 32%), including all non-TAVR patients, 
and the 18-F MANTA VCD in the remainder. 
The MANTA VCD was deployed successfully in all 
patients. Forty-seven of the 50 patients (94%) met 
the primary performance endpoint of hemosta-
sis success. The mean TTH was 2 min, 23 s. The 
median TTH was 24 s, with 74% of the patients 
having hemostasis in <1 min (Figure 2). All-cause 
mortality at 30 days was 8% (n = 4), none of the 
deaths were related to the MANTA device or access 
site. One patient had a minor stroke. Overall, 12 pa-
tients required packed red blood cell (RBC) trans-
fusions, but none were for MANTA access site–re-
lated issues (Table 3). A total of 6 patients needed 
1 unit of packed RBC, 4 patients needed 2 RBC, 
and 2 patients needed 4 RBC. According to VARC-2 
definitions, 1 patient experienced a major vascular 
and major bleeding complication with prolonged 
femoral bleeding that was successfully treated with 
a covered stent and eventual surgical repair because of persistent oozing while needing emergency valve 
Procedure and Device Procedure Sheath Sheath OD Profile (French) n
MANTA 
Size
Balloon  aortic valvuloplasty 12-F to  14-F Cook* 16–18 2 14-F
Evolut  R  TAVR† Sheathless 14-F 18 13 14-F
Continuous  flow Circulatory support device‡ 14-F 18 1 14-F
Evolut  R  TAVR† Sheathless 18 4 18-F
Portico  TAVR§ 19-F SoloPath || 23 1 18-F
Direct  Flow  TAVR¶ 18-F Direct  Flow¶ 22 5 18-F
CoreValve  TAVR† 18-F CoreValve† 22 2 18-F
Lotus  TAVR  (23 mm)# Small Lotus# 22 5 18-F
Sapien  3 TAVR (23  and  26  mm)** 14-F e-Sheath** 23 9 18-F
Lotus  TAVR (25  and  27 mm)# Large Lotus# 24 3 18-F
Sapien  3 TAVR (29  mm)** 16-F e-Sheath** 24.5 5 18-F
Table 2. MANTA Size Selection per Procedure Type and Sheath Size. *Cook Medical, Bloomington, Indiana. 
†Medtronic, Fridley, Minnesota. ‡Thoratec, Pleasanton, California. §St. Jude Medical, Little Canada, Minnesota. 
|| Terumo Interventional Systems, Somerset, New Jersey. ¶Direct Flow Medical, Santa Rosa, California. #Boston 
Scientific, Marlborough, Massachusetts. **Edwards Lifesciences, Irvine, California. OD = outer diameter; TAVR = 
transcatheter aortic valve replacement.
Hemostasis success, %
Overall 94
14-F 100
18-F 91.2
Time to hemostasis, mm:ss 00:24 (00:02–37:10)
Safety*
All-cause death 4 (8)
Major stroke 0
Minor stroke 1 (2)
VARC bleeding
Life-threatening/disabling 0
Major 1 (2)
VARC vascular complications
Major 1 (2)
Minor 0
Hemoglobin 12.20 ± 1.66
Need for any RBC 12 (24)
RBC per patient if RBC required 1.5 (1–4)
Table 3. MANTA Effectiveness and Safety (N = 50). 
Values are n, median (interquartile range), n (%), or 
mean  SD. *Defined according to the Valve Academic 
Research Consortium (VARC). Abbreviations: mm:ss = 
min:s; RBC = packed red blood cells.
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surgery for a misplaced TAVR device. There were no VARC-2 minor vascular complications. One patient 
needed prolonged balloon inflation to control bleeding (minor bleeding according to VARC-2), and 1 
patient needed balloon inflation to treat a pseudoaneurysm. Five patients presented with subcutaneous 
hematomas without further medical intervention. 
Angiography showed widely patent femoral vessels in all subjects (Figure 3). In 3 patients, there was 
angiographic evidence of extravasation. As described in the preceding text, 2 of these were resolved with 
femoral balloon inflation, and 1 was repaired surgically as the patient proceeded to emergent surgical 
valve replacement. Duplex studies immediately post-deployment and at discharge confirmed patency 
in all vessels. Ultrasound evidence showed stability of the absorbable, intravascular MANTA anchor and 
extravascular collagen layer up to 60 days. Ankle brachial indices remained stable over the study period: 
1.09 ± 0.19 at baseline, 1.01 ± 0.10 at discharge, and 1.02 ± 0.17 at later follow-up (p = 0.111). There were no 
late vascular complications related to the MANTA device.   
                                                                                                                                                                                                                    
DISCUSSION
The prospective multicenter MANTA CE mark study demonstrates rapid and reliable vascular hemostasis 
after 12-F to 19-F (OD 16-F to 24.5-F) transfemoral arteriotomies with this second-generation, dedicated, 
large-bore vascular closure device. MANTA VCD was applied in various completely percutaneous inter-
ventions including TAVR, balloon aortic valvuloplasty, and mechanical circulatory support.
Vascular and bleeding complications in the MANTA CE mark study were low despite the operators’ 
inexperience with the novel closure device. Overall, vascular complications according to VARC-2 were 
encountered in 1 patient (2%), including 1 major and 0 minor complications. The CONTROL (Closure 
Device in Transfemoral Aortic Valve Implantation) multicenter study included 944 patients undergoing 
Figure 3. MANTA angiographic and ultrasound appearance. (Left upper panel) Angiogram shows the position 
of the “Manta-plug” in the femoral artery, visible by the metal cm marker appearing as a black spot (black arrow). 
(Bottom left panel) Macro photograph of the plug. The poly-lactate toggle, the collagen, and the nitinol lock are 
respectively indicated by t, c, and l. Longitudinal ultrasound images of the femoral artery were acquired before 
the procedure, post-procedure, and at 2 months follow-up. The poly-lactate toggle (t) is visible in the lumen 
against the vessel wall as a long double-layered bright structure. The collagen (c) appears as a darker area.
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TAVR and suture-based arteriotomy closure with either Prostar XL or Perclose Proglide (Abbott Vascular, 
Redwood City, California) in a propensity matched analysis. VARC major and minor vascular complica-
tions were noted in 7.4% and 14.8% with Prostar and 1.9% and 18% with Proglide, respectively (3). Impor-
tantly, operators participating in the CONTROL study were experienced with the respective suture-based 
closure devices, whereas the MANTA study represented the initial learning curve of the participating 
operators.
A study on 380 consecutive patients undergoing balloon aortic valvuloplasty with a sheath size ranging 
from 9-F to 13-F reported serious vascular complications, including arterial perforation, pseudoaneu-
rysm formation, arteriovenous fistula, and leg ischemia in 5.5% to 6.7% depending on the closure device 
used (7). A single-center study including 274 patients undergoing transfemoral TAVR with either sur-
gical cut-down and repair, or suture-based percutaneous closure showed similar acute closure success 
and access site–related events but more femoral stenosis and dissection with the percutaneous closure 
(7.1% vs. 0.7%; p = 0.007) and more wound infections and need for surgical debridement with the surgi-
cal approach (0.7% vs. 6.7%; p = 0.007) (8). The completely percutaneous approach reduced procedural 
time and patient morbidity. Comparison of clinical endpoints like vascular complications across differ-
ent studies may be difficult because of nonuniformity in endpoint definitions and reporting bias in the 
absence of independent clinical event adjudication. The VARC is an initiative by research organizations, 
academics and regulatory instances to provide consensus definitions on important clinical endpoints (6). 
These VARC endpoints are currently well adopted and allow more reliable data comparison. In random-
ized TAVR versus surgical aortic valve replacement trials with controlled and independently adjudicated 
outcome data, vascular complications were consistently more frequent with TAVR (5.9% vs. 1.7%; p = 
0.003, in the U.S. CoreValve High-Risk study and 11.3% vs. 3.8%; p < 0.001, in the PARTNER (Placement of 
Aortic Transcatheter Valve) Cohort A), whereas disabling, life-threatening, or major bleedings occurred 
more often with surgical aortic valve replacement (35% vs. 13.6%; p < 0.001, in the U.S. CoreValve High-
Risk study, and 26.7% vs. 15.7% in PARTNER Cohort A) (9,10). Over time, the rate of vascular complica-
tions has gradually declined due to growing experience, improved access technique with fluoroscopic 
or ultrasound guidance, and design modifications with smaller profile devices (11,12). Also, additional 
maneuvers such as the cross-over balloon technique may create a low pressure milieu for optimal closure 
device functioning at the time of sheath removal and facilitate the percutaneous management of vascular 
complications (13,14). A relatively small single-center study on 137 patients reported a low rate of major 
and minor vascular complications of 1% and 8%, respectively (12). However, contemporary rigorous trials 
with independent clinical event adjudication still report major vascular complications after TAVR in >5% 
of patients, and two-thirds of these major complications are due to failed arteriotomy closure (1,2,4). 
Therefore, in the current era, and despite growing operators’ experience, vascular complications are still 
a limitation of TAVR and other large bore interventions. These vascular complications, bleedings, and 
the need for transfusions are associated with worse clinical outcomes and thus warrant further improve-
ments in access site management (15).
Plug-based closure is well established for 5-F to 8-F arteriotomies and among the most widely used glob-
ally (16). It reduces TTH, promotes early patient ambulation, and improves patient satisfaction compared 
with manual compression (17,18). So far, no head-to-head comparisons between plug-based and su-
ture-based closure devices exist. One meta-analysis on percutaneous vascular closure devices suggested 
that only plug-based closure reduced major vascular complications compared with manual compression 
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(odds ratio: 0.51; 95% confidence interval 0.45 to 0.58), with a neutral effect for suture-based closure (odds 
ratio: 1.0, 95% confidence interval: 0.13 to 7.48) (19). Clearly, no convincing data have proven the superior-
ity of one closure technique over the other. Of note, for MANTA closure, a prophylactic cross-over balloon 
technique does not seem beneficial because it is felt that a pressurized vessel is best for spreading the 
collagen pad over the arteriotomy defect, and collagen in contact with blood and tissue factor is required 
to develop a stabilizing layer. MANTA closure failure can theoretically occur when the endovascular 
toggle does not connect with the arteriotomy from the inside (e.g., because it was caught by plaque), the 
plug does not connect with the vessel wall at the arteriotomy from the outside (e.g., because a growing 
subcutaneous hematoma has extended the subcutaneous track, and the depth has been underestimat-
ed), or too much pulling force has been applied, and the toggle is pulled outside of the vessel. Bail-out 
strategies in case of MANTA closure failure include prolonged endovascular balloon inflation and manual 
compression, covered stent placement, or vascular surgery. 
Study limitations
A limitation of the MANTA CE mark study is its relatively small sample size and its nonrandomized na-
ture. Selection bias may have affected the reported clinical results. Yet the involvement of an independent 
clinical research organization with rigorous data monitoring and the favorable results should spur further 
research in larger studies, preferably including randomized trials comparing MANTA VCD with current 
suture-based closure techniques. 
CONCLUSIONS
The MANTA VCD is a novel, collagen plug-based, large-bore closure device. It targets large-bore pro-
cedures requiring devices up to 19-F (true OD profiles up to 24.5-F). This initial multicenter experience 
demonstrated rapid and reliable hemostasis and low complication rates. Broader community-based 
experience and randomized trials comparing the MANTA device to alternative techniques are warranted.
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Part III 
Neurological events
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I
BACKGROUND AND INDICATIONS
As the technique of transcatheter aortic valve implantation (TAVI) is maturing and its application 
broadening, reduction of TAVI related complications is crucial. TAVI has proven to be superior to medical 
therapy in inoperable patients with aortic stenosis (AS) and at least as effective as surgical aortic valve 
replacement (SAVR) in AS patients at high risk for perioperative complications and mortality (1,2). The 
first randomized trials seemed to suggest that clinically overt neurological events complicated TAVI in 
comparison to medical therapy or the more invasive SAVR (1,2). Recently the randomized CoreValve US 
Pivotal trial refuted this premature notion. In a carefully designed trial setting encompassing neurolo-
gists who assessed patients before and after aortic valve replacement, there was no difference in clinical 
neurological events between TAVI and SAVR (3). Nevertheless, TAVI implies: 1) the use of large-bore 
catheters, 2) passage through an aged and diseased aortic arch and ascending aorta, 3) crossing of a 
calcified and degenerated aortic valve, 4) positioning and deployment of a transcatheter valve within the 
diseased native aortic valve, and 5) passage and maneuvering of guidewires within the left ventricle. Brain 
magnetic resonance imaging (MRI), transcranial Doppler and histopathology studies have revealed that 
cerebral embolization is inherent to TAVI (4-8). Although most TAVI cases seem uneventful from a clini-
cal neurological perspective, silent brain ischaemia and defects occur in up to 80% of patients (9). These 
silent brain lesions and micro infarcts may not be so harmless after all, as an association with premature 
neurocognitive impairment seems established (10-12). This global brain dysfunction (i.e., slight cognitive 
decline, memory and mood disturbances, reduction of psychomotor speed, and personality changes) 
might be easily missed during routine neurological examination (13). Especially in patients with a longer 
life expectancy, these events may thus become clinically and socially relevant. Cerebral embolic protec-
tion devices (EPDs) may reduce intraprocedural cerebral embolization which may be associated with 
silent brain ischaemia and subsequent infarct.
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TOOLS AND TECHNIQUES
Currently, three different EPDs with two fundamentally different designs have obtained a CE mark for use 
in TAVI. 
Triguard
The TriGuard embolic deflection device (Keystone Heart Ltd., Caesarea, Israel (previously known as SMT 
Research & Development)) is a single-use, biocompatible mesh made of fine nitinol wires with pores of 
130 µm and an antithrombotic coating (Applause™ Heparin Coating; SurModics, Inc., Eden Prairie, MN, 
USA) (Figure 1) (14,15). The TriGuard mesh forms a barrier and subsequently deflects emboli down-
stream. It contains two stabilisers for optimal positioning and stability. It covers the ostia of the brachio-
cephalic trunk, the left common carotid artery and the left subclavian artery. An atraumatic stabiliser in 
the brachiocephalic trunk supports the position throughout the procedure.
Technique
The device is delivered through a transfemoral access using a 9 Fr Mullins introducer sheath (Medtron-
ic, Minneapolis, MN, USA). The sheath is advanced beyond the aortic arch take-offs. While holding the 
TriGuard in place, the sheath is pulled back to expand the device in the aortic arch. The atraumatic 
stabiliser extends into the brachiocephalic trunk to anchor the TriGuard. Optimally, the mesh protects 
all major arterial contributories to the brain by deflecting debris and maintaining blood flow. Device 
positioning on average takes 11 minutes (15). Of note, in the “Prospective, Randomized Evaluation 
of the TriGuard™ HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation” 
(DEFLECT-III) trial, mean total fluoroscopy time was 10 minutes longer (28.4 vs. 18.8 min, p<0.001) 
in TriGuard subjects compared with controls (16). After transcatheter heart valve implantation, the 
TriGuard is pulled back into the Mullins sheath and retrieved from the body. 
Device limitations
The TriGuard is currently the only commercially available EPD that potentially covers all extracranial 
Figure 1. The TriGuard embolic deflection device. The TriGuard embolic deflection 
device has a nitinol frame which contains a nitinol mesh with 250 (and in the latest 
design 130) um pores and antithrombotic coating. It contains two stabilisers for 
optimal positioning and stability. It covers the ostia of the brachiocephalic trunk, the 
left common carotid artery and the left subclavian artery. An atraumatic stabiliser in 
the brachiocephalic trunk supports the position throughout the procedure.
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cerebral vessels. The overall profile mandates 9 Fr femoral access, which may increase the risk of vascular 
complications. Device stability may vary during THV navigation through the aorta. The “Prospective, 
Single Arm Feasibility Study to Evaluate the Safety and Performance of the SMT Embolic Deflection De-
vice in Patients Undergoing Transcatheter Aortic Valve Replacement” (DEFLECT-I) and the DEFLECT-III 
trials revealed device instability in 36% and 11%, respectively (15,16). Furthermore, in the DEFLECT-II 
trial, the TriGuard interfered with balloon and THV systems in 36% of cases (17). Excessive atherosclerot-
ic disease in the aortic arch, particularly at the outer curve, may pose a relative contraindication for use. 
Embrella embolic deflector
The Embrella Embolic Deflector system (Edwards Lifesciences, Irvine, CA, USA) consists of a porous 
polyurethane membrane within a nitinol frame (Figure 2) (18). The pore size is 100 µm and the mem-
brane contains a hydrophilic coating with antithrombotic properties. The Embrella forms a barrier and 
subsequently deflects emboli downstream (18-20). Of note, in the majority of cases the ostium of the left 
subclavian artery will not be covered; therefore, the posterior part of the brain which is vascularised by 
the left vertebral artery may not be protected from potential emboli (Figure 2).
Technique
Access is gained via a right radial (or brachial) artery approach. A 0.035” or 0.038” guidewire is advanced 
under fluoroscopic guidance and positioned in the brachiocephalic artery ostium. A 6 Fr (90 cm) Flexor® 
Tuohy-Borst Sidearm Introducer sheath (Shuttle®-SL; Cook Medical, Bloomington, IN, USA) is advanced 
over the wire into the aorta. The Embrella is inserted into the sheath with an Embrella loading tool and 
advanced up to the ostium of the brachiocephalic trunk. The assembly is then pushed outside of the 
sheath and the device petals fold open in the aortic arch. The system is then fully deployed and should 
be pulled back to be apposed to the greater curvature of the aortic arch to cover the ostia of the brachio-
cephalic trunk and the left common carotid artery. Three radiopaque markers on the petals facilitate 
device positioning. A contrast injection through the introducer sheath side port or a pigtail catheter can 
confirm proper device positioning within the aorta. The device is then locked in place by tightening the 
Tuohy-Borst adapter on the introducer sheath and fixating the “Embrellasystem Shaft Torquer” proximal 
to the Tuohy-Borst adapter. An adhesive dressing is placed on the skin at the insertion site. A pressure 
sensor is attached to the side port of the introducer sheath to monitor systemic arterial pressure while 
the Embrella is in place. The Embrella in situ requires full anticoagulation with ACT levels >300 seconds. 
In the PROTAVI-C study, the median time for Embrella deployment was 2 min (IQR 1 to 3 min). After 
Figure 2. The Embrella Embolic Deflector system. The Embrella Embolic Deflector 
system has an oval-shaped nitinol frame with a polyurethane membrane with 100 
um pores. The frame has two opposing petals which cover the ostia of the brachio-
cephalic trunk and the left common carotid artery.
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transcatheter heart valve implantation, the Embrella is retrieved by pulling the device into the introducer 
sheath. During this maneuver it is paramount to immobilise the sheath at the level of the ostium of the 
brachiocephalic trunk.
Device limitations
The Embrella covers three of four entry routes to the Willis polygon, leaving the left vertebral artery un-
protected (21). The Embrella does not seem to interfere with the transcatheter valve system during TAVI, 
yet the introduction and deployment of the device itself seem to result in more high-intensity transient 
signals (HITS) by transcranial Doppler and ischaemic cerebral lesions by MRI (19,20). Excessive athero-
sclerotic disease in the aortic arch – particularly at the outer curve – and brachiocephalic trunk may pose 
a relative contraindication for use.
Sentinel
The Sentinel™ dual filter system (Claret Medical Inc., Santa Rosa, CA, USA) is delivered through a 6 Fr 
sheath, which is inserted transradially or transbrachially (Figure 3) (22). The Sentinel is a 100 cm co-axial, 
steerable sheath housing two cone-shaped filters made of 140 µm pore size biocompatible polyurethane 
film. The proximal filter is deployed into the brachiocephalic trunk and accommodates vessel sizing of 9 
to 15 mm in diameter. The dedicated handle is designed to articulate the distal segment of the catheter 
to navigate through the aortic arch and direct the tip of the system into the left common carotid artery to 
deploy the distal filter, which is smaller and fits within 6.5 to 10 mm vessels.
Technique
The anatomical landing zones - the brachiocephalic trunk and the left common carotid artery – need 
to be assessed by contrast aortography or MSCT planning (Figure 4) to determine proper vessel size 
Figure 3. The Sentinel dual filter device. The Sentinel dual filter device consists of 
a steerable and rotatable catheter that contains two polyurethane mesh filters with 
140 µm pores mounted on a nitinol frame. One filter is deployed in the brachiocepha-
lic trunk and the other in the left common carotid artery.
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for adequate apposition and 
protection. The central lumen 
of the delivery system is loaded 
with a 0.014” coronary guide-
wire which precedes the tip of 
the delivery system to facilitate 
navigation through the arterial 
tree of the upper extremity. The 
tip of the assembly is advanced 
into the ascending aorta so that 
the sheathed radiopaque frame of 
the proximal filter is positioned 
proximally within 30 mm of the 
ostium of the brachiocephalic trunk. With the sliding mechanism on the handle the proximal filter is 
deployed in the designated landing zone. The rotating knob on the handle can curve the distal portion of 
the catheter. The distal tip is pulled and oriented towards the left common carotid artery. The 0.014” wire 
is advanced into the left common carotid artery followed by the distal filter. Proper positioning can be 
confirmed using contrast injection. At the end of the TAVI procedure, the previous steps are reversed. The 
distal filter is pulled into the distal segment of the delivery system first, the curve is straightened and the 
proximal filter is re-sheathed.
Device limitations
The Sentinel leaves the left vertebral artery unprotected. Excessive tortuosity in the arterial trajectory 
towards the filter landing zones precluded deployment in 4 to 9% of reported cases, and device interfer-
ence with the pigtail catheter occurred in one case (2%) (22,23). The CLEAN-TAVI investigators reported a 
90% procedure success with inability to deploy any of the filters due to excessive tortuosity of the arteries 
in 2/50 patients. Excessive tortuosity, significant atherosclerotic disease and small vessel size need to be 
ruled out prior to device insertion. Device interference with transfemorally inserted catheters and the 
THV delivery system is rare. 
PERFORMANCE DATA
Clinical outcome
The thirty-day disabling stroke rate in elderly patients undergoing TAVI is <5% (24). Approximately half of 
these major neurological events occur within the first 24 hours and seem directly amenable to EPDs (25). 
Against this backdrop of relatively low incidence, surrogate endpoints are probably required to document 
the meaningful effects of the use of EPDs. Neurological outcomes for all EPDs are displayed in Table 1. 
Figure 4. Preprocedural MSCT planning with 3mensio software showing 
the most common aortic arch anatomy.
Study DEFLECT-I (n=37) (15)
DEFLECT-II 
(n=14) (17)
DEFLECT-III 
(n=46) (16)
PROTAVI-C 
(n=41) (19)
Samim et al 
(n=15) (20)
Naber et al 
(n=40) (22)
Major stroke 2 (5.4%) 0 (0%) 2 (4.3%) 2 (4.9%) 0 (0%) 2 (5.0%)
Worsening 
NIHSS score NA NA 2 (4.3%) 0 (0.0%) NA 3 (7.5%)
Table 1. 30-day neurological outcome for all embolic protection devices.
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So far, none of the available EPDs has shown significant reductions in disabling clinical strokes. In DE-
FLECT-III, paired NIHSS assessments revealed “new neurologic impairment” in 3.1% of TriGuard-protect-
ed patients vs. 15.4% of controls (p=0.16). Neurocognitive testing has been proposed to document subtle 
changes in cognitive performance. A different battery of tests has been suggested but currently there is 
no consensus on which tests would be most suitable to evaluate EPD with TAVI. The Montreal cognitive 
assessment (MoCA) is frequently applied. In the PROTAVI-C pilot study, the Embrella EPD did not affect 
MoCA test results. In both DEFLECT-III and CLEAN-TAVI, fewer protected patients appeared to have 
worsening MoCA scores compared to controls (16,23).
DW-MRI
Diffusion-weighted magnetic resonance imaging (DW-MRI) 
has a high sensitivity for new ischaemic brain lesions. All 
available EPDs have been evaluated by brain MRI studies. 
Several MRI-specific caveats need to be considered before 
comparing these results. The MRI field strength is essential 
as it renders the study even more sensitive (26). A 3-Tesla 
scanner may yield a higher lesion detection rate than a 
1.5-Tesla scanner. The acquisition of baseline MRI may be 
important to eliminate any visible pre-existing lesions and 
co-register the baseline against the follow-up MRI visible 
lesions. Size and number of lesions will change considerably 
throughout the first week after the procedure. Also, the 
impact of new clinical situations such as new-onset atrial fibrillation may induce new areas of brain isch-
aemia due to thromboembolisation. In the DEFLECT-III trial, use of the TriGuard EPD resulted in more 
patients with no lesions on brain MRI (Figure 5) (16). Also, total new lesion volume was reduced, although 
the number of lesions was similar (Figure 6, Figure 7). Use of the Sentinel showed significant reductions in 
the total number of lesions (50% reduction with p=0.002) at two days and reduced the overall total lesion 
volume compared to patients without EPD by more than 50% at two days (p=0.002) (23). Conversely, the 
PROTAVI-C pilot study demonstrated numerically more new lesions and overall larger total lesion volume 
with use of the Embrella EPD.
Figure 5. Proportion of patients in present 
studies with detected lesions on DW-MRI for 
different embolic protection devices com-
pared with controls. Abbreviations: PP: per 
protocol group (16,17,19,20).
Figure 6. Number of lesions per patient detected 
on DW-MRI in the present studies for different 
embolic protection devices compared with controls  
(14,16,17,19,20,23).
Figure 7. Total lesion volume per patient detected 
on DW-MRI in the present studies for different 
embolic protection devices compared with controls 
(16,17,19,20,23).
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Current MRI data do not allow fair comparison between EPDs and selected THVs. For this purpose, head-
to-head comparisons in the context of a randomised trial using identical MRI techniques and timing of 
follow-up MRI studies seem essential. However, MRI studies: 1) have major logistic limitations, 2) are not 
patient-friendly for elderly subjects due to concomitant noise and the relatively tight-fitting tube, 3) have 
not consistently had baseline MRI performed. Fourthly, new permanent pacemaker implantation post 
TAVI may pose a relative contraindication for MRI examination. Not surprisingly, follow-up MRI was not 
completed in 22% to 41% of patients in contemporary studies (16,19,23).
Transcranial Doppler
Transcranial Doppler (TCD) sonography can detect HITS that represent embolic activity, either solid or 
gaseous. HITS appear most commonly during THV implantation and deployment (5,27,28). Interpre-
tation of TCD remains somewhat challenging, and overall TCD results with TAVI are controversial. In 
the PROTAVI-C study, deployment of the Embrella EPD generated approximately the same number of 
HITS as the THV deployment and a greater total number of HITS throughout the entire procedure (19). 
In DEFLECT-I, use of the TriGuard EPD generated fewer HITS than THV positioning and deployment. 
Interestingly, gaseous emboli were approximately three times more common than solid emboli during all 
stages of the procedure.
Histopathology
The filter-based Sentinel is the only EPD that allows capture and retrieval of debris en route to the brain. 
Embolic material was captured in 75 to 86% of patients in whom the filter was used (7,29). Debris could 
be either thrombotic or tissue-derived. Solid dislodged tissue debris was found in 52 to 63% of patients. 
Histopathological analysis revealed material from the native aortic valve leaflets, aortic wall and left 
ventricular myocardium. 
FUTURE PERSPECTIVES
Device iterations
Each device described above may intuitively have room for improvement. Stability of embolic deflectors 
in the outer curve of the aortic arch may increase over time. Also, the likelihood of complete protection 
including left subclavian ostium coverage may be targeted. Similarly, filter protection of the left vertebral 
artery in addition to current Sentinel protection may be evaluated. Smaller device profiles may further 
reduce the risk for access-site complications, especially when using the femoral route.
Consensus
The Valve Academic Research Consortium (VARC) proposed uniform endpoint definitions which were 
widely adopted in clinical practice, registries and randomised trials. Similar consensus statements on 
trial designs, study endpoints and definitions may help interpret results of future EPD studies and allow 
relevant comparison. The participation of trained and certified neurology specialists (neurologists, nurse 
practitioners, etc.) is essential to detect reliably the sometimes subtle neurologic changes post TAVI. 
Neurocognitive assessment should rely on a standardised battery of neurocognitive tests. Optimal timing 
of post-procedural brain MRI studies as well as standardised MRI settings are mandatory to compare 
study results. Importantly, the value of brain MRI-based surrogate endpoints (number of lesions, lesion 
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volume, total lesion volume) needs validation and acceptance because the incidence of clinically appar-
ent disabling strokes is low and the appearance of new subclinical brain lesions and micro-infarcts may 
truly pose meaningful threats to neurocognitive function and psychosocial wellbeing in lower-risk and 
younger patients with symptomatic severe AS who will arguably become the next target population for 
TAVI in the near future.
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ABSTRACT
Aims
Our aim was to determine whether use of the filter-based Sentinel™ Cerebral Protection System (CPS) 
during transcatheter aortic valve implantation (TAVI) can affect the early incidence of new brain lesions, 
as assessed by diffusion-weighted magnetic resonance imaging (DW-MRI), and neurocognitive perfor-
mance.
Methods and results
From January 2013 to July 2015, 65 patients were randomised 1:1 to transfemoral TAVI with or without the 
Sentinel CPS. Patients underwent DW-MRI and extensive neurological examination, including neurocog-
nitive testing one day before and five to seven days after TAVI. Follow-up DW-MRI and neurocognitive 
testing was completed in 57% and 80%, respectively. New brain lesions were found in 78% of patients 
with follow-up MRI. Patients with the Sentinel CPS had numerically fewer new lesions and a smaller total 
lesion volume (95 mm3 (IQR 10-257) vs. 197 mm3 (95-525)). Overall, 27% of Sentinel CPS patients and 
13% of control patients had no new lesions. Ten or more new brain lesions were found only in the control 
cohort (in 20% vs. 0% in the Sentinel CPS cohort, p=0.03). Neurocognitive deterioration was present in 
4% of patients with Sentinel CPS vs. 27% of patients without (p=0.017). The filters captured debris in all 
patients with Sentinel CPS protection. 
Conclusions
Filter-based embolic protection captures debris en route to the brain in all patients undergoing TAVI. 
This study suggests that its use can lead to fewer and overall smaller new brain lesions, as assessed by 
MRI, and preservation of neurocognitive performance early after TAVI.
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) is less invasive and results in faster recovery and improve-
ment in quality of life as compared to surgical aortic valve replacement (SAVR) (1-6). In selected patients 
TAVI also reduces one-year mortality (7). Major stroke is still a vexing complication associated with aortic 
valve replacement (8). Recent studies suggest similar stroke rates with SAVR and TAVI, varying between 
2 and 10% (9). Transcranial Doppler (TCD) and brain diffusion-weighted magnetic resonance imaging 
(DW-MRI) studies revealed, respectively, cerebral high-intensity transient signals (HITS) and new isch-
aemic brain lesions in up to 90% of all patients undergoing TAVI (10-13). Approximately half of all strokes 
within 30 days after TAVI occur in the first 24 hours and are thus directly related to the procedure (14-16). 
TAVI inevitably releases debris from the aortic wall, the aortic annulus and even from cardiac structures, 
and catheter-related foreign body particles (17,18). Recently, the randomised DEFLECT III trial demon-
strated fewer DW-MRI-detected ischaemic brain lesions and less cognitive decline with the use of the 
TriGuard cerebral embolic protection device (Keystone Heart Ltd., Caesarea, Israel) (19). The Sentinel™ 
Cerebral Protection System (CPS) (Claret Medical Inc., Santa Rosa, CA, USA) provides filter protection to 
the brachiocephalic trunk and the left common carotid artery. The safety and efficacy of the device were 
demonstrated and the device obtained CE mark in January 2014 (20). Furthermore, recent pathology 
studies have confirmed capture of debris with the Sentinel CPS in 75 to 86% of all patients undergoing 
TAVI (17,21). The clinical impact of this embolised debris into the brain and consequent new ischaemic 
brain lesions by DW-MRI is controversial, but silent brain infarcts have been correlated with premature 
neurocognitive deterioration and dementia (22,23). The aim of the randomised MRI Investigation in TAVI 
with Claret (MISTRAL-C) study (Dutch trial register-ID: NTR4236) is to determine whether use of the 
Sentinel CPS during TAVI can decrease the incidence of new brain lesions as assessed by DW-MRI, and 
can prevent neurocognitive decline. 
METHODS
The MISTRAL-C was a multicentre double-blind randomised trial. All eligible patients underwent mul-
timodality imaging, including multislice computed tomography (MSCT) scan of the aortic valve and the 
arterial vasculature. Patients were deemed at high risk for SAVR and selected for transfemoral TAVI by 
Heart Team consensus. Aortic arch anatomy had to fit the sizing requirements for the Sentinel CPS: the 
brachiocephalic trunk and left common carotid artery should range between 9 and 15 mm and 6.5 and 10 
mm, respectively, without excessive tortuosity or >70% obstructive atherosclerotic disease. Key exclusion 
criteria were the presence of a permanent pacemaker or automated internal cardiac defibrillator (AICD) 
at baseline, a history of prior stroke with sequelae and dementia. Patients were randomised 1:1 to TAVI 
with or without the Sentinel CPS. Per protocol, a DW-MRI scan and extensive neurological examination 
were performed one day before and planned again five to seven days after TAVI. One dedicated experi-
enced neuroradiologist independently read all MRI studies. A trained neurology specialist performed a 
comprehensive neurological exam, including the National Institutes of Health Stroke Scale (NIHSS) and 
the modified Rankin Scale (mRS), and a neurocognitive evaluation with the Montreal Cognitive Assess-
ment (MoCA) and the Mini-Mental State Examination (MMSE) (24,25). The Center for Epidemiologic 
Studies Depression scale (CES-D) was used to rule out significant depression. The neuroradiologist and 
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neurology specialists were blinded to the randomisation arm. The most recent Valve Academic Research 
Consortium definitions were applied to report relevant clinical endpoints (26). The local institutional 
review board at each site approved the study protocol, all subjects provided written informed consent, 
and the study was conducted in accordance with the principles of the Declaration of Helsinki. The 
Erasmus Medical Center received a research grant from Claret Medical which partially covered study-re-
lated expenses. The authors are fully responsible for the study design, study execution and drafting of the 
manuscript. 
Sentinel CPS
The Sentinel CPS is a 6 Fr-compatible 100 cm coaxial, steerable sheath housing two cone-shaped filters 
made of a 140 µm pore size biocompatible polyurethane film. The device is inserted using a right radial 
or brachial arterial access. The proximal filter is first deployed into the brachiocephalic trunk. The distal 
segment of the catheter can then articulate to navigate through the aortic arch and into the left common 
carotid artery where the distal filter is deployed (Figure 1). At the end of the TAVI procedure, the previous 
steps are reversed. 
Magnetic resonance imaging
The MRI exam was performed with a 3.0 Tesla scanner with an 8-channel head coil. The MRI protocol 
consisted of three sequences: 1) transverse DW-MRI sequence with a b-value of 0,500,1000 s/mm² (SE/
EPI, TR 8,000 ms, TE 80 ms, FOV 24×24 cm, matrix 128×128, slice thickness 3.6 mm, 3 NEX); 2) sagital 
3D-FLAIR sequence (TR 6,500, TE 115, FOV 26×26 cm, matrix 224×224, slice thickness 1.2 mm, NEX 1); 
3) 2D-T2w TSE sequence (TR 5,000 ms, TE 105 ms, FOV 24×24 cm, matrix 416×384, slice thickness 3 mm, 
NEX 2). The number, location, and volume (cm) of new hyperintense lesions were recorded. New lesions 
were allocated to the cerebellum, or the left or right vascular territory of the anterior, medial or posterior 
cerebral artery. To calculate the volume of hyperintense lesions on DWI, a semi-automated segmentation 
method was developed using MeVisLab (MeVis Medical Solutions AG, Bremen, Germany) (27). The brain 
was arbitrarily divided into Sentinel CPS protected and unprotected regions. Unprotected regions are 
Figure 1. Sentinel dual filter system. A) Fluoroscopic image of the Sentinel CPS after deployment in the 
brachiocephalic trunk and left common carotid artery. B) Photograph of a retrieved filter containing 
embolic debris. C) Microscopic image showing the lamina spongiosa of the aortic valve (H&E staining, 
magnified ×20).
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vulnerable to embolisations coming from the unprotected left vertebral artery, which corresponds to the 
cerebellum and the vascular territory of both posterior cerebral arteries. 
Histopathology
Filters were retrieved and released from the delivery system, stored in a buffered formalin (4%) solution. 
Debris was dehydrated, embedded in paraffin and cut into 3 to 4 mm thick sections. Staining was done 
with haematoxylin and eosin and Movat pentachrome. Additional staining techniques were performed 
whenever applicable to identify specific tissue origin, as previously described (17). 
Statistical analysis
Power analysis was based on the primary endpoint of new cerebral lesions by DW-MRI five to seven 
days after TAVI. To reach a reduction from 80% to 40% in volume of new ischaemic lesions by DW-MRI 
(standard deviation 50%) with the Sentinel CPS and based on the continuity-corrected chi-square test, 
we estimated that 54 patients (27 in each treatment arm) would be needed with an 80% power and a 
two-sided alpha of 0.05. To balance a potential 20% drop-out in MRI follow-up, 65 patients would be need-
ed to obtain 54 patients with MRI before and after TAVI. Continuous variables were displayed as either 
mean±standard deviation or median with interquartile range, depending on distribution. Normality was 
tested by use of histograms and the Shapiro-Wilk test. Normally distributed variables were compared 
using a Student’s t-test, while non-normally distributed variables were compared using the Kruskal-Wallis 
test. Categorical variables were displayed as frequencies and percentages. A chi-square test for equality 
of proportions was used for trends. Between-group comparisons for new brain lesions and neurocogni-
tive function were restricted to patients with MRI or neurocognitive testing pre and post TAVI. Binary 
outcomes were compared using log-linear regression and were displayed as relative risks. All statistical 
analyses were performed with SPSS, Version 22 (IBM Corp., Armonk, NY, USA). 
RESULTS
From January 2013 to July 2015, 65 patients were ran-
domised 1:1 to transfemoral TAVI with or without 
cerebral protection with the Sentinel CPS (Figure 2) at 
four centres. Table 1 depicts baseline characteristics. The 
median age was 81 years (IQR 78-85) and 52% were male. 
The STS predicted risk of mortality was 4.8% (IQR 3.4-7.2), 
and appeared higher in the control cohort (STS 6.6 (IQR 
3.8-9.9) vs. 4.6 (IQR 3.4-6.4)). Frailty was common (68%). 
A prior history of neurological events was present in 19% 
of patients. The distribution of the different transcatheter 
valve designs is displayed in Figure 3. The Sentinel CPS 
was successfully deployed in all but two patients. In one patient no Sentinel CPS was inserted because 
Figure 2. Patient flow diagram including 
follow-up missing for MRI and neurocognitive 
testing.
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of protracted haemodynamic instability after induction 
of general anesthesia. One patient was a screening failure 
and presented with an anatomic anomaly (arteria lusoria) 
that precluded Sentinel CPS placement. There were no 
device-related injuries. 
Clinical endpoints at 30-day follow-up are summarised 
in Table 2. Overall, all-cause mortality at 30 days was 3%. 
Two patients – both in the unprotected cohort – suffered 
a disabling stroke and died within 30 days. Twelve patients 
(19%) needed a new permanent pacemaker after TAVI. 
Baseline characteristics Sentinel  (n=32)
No Sentinel 
(n=33)
Total       
(N=65) P-value
Age, median (IQR) 82 (79-84) 82 (77-86) 82 (78-85) 0.505
Female, n (%) 15 (47%) 16 (49%) 31 (48%) 0.897
Hypertension, n (%) 21 (66%) 23 (70%) 44 (68%) 0.726
Diabetes, n (%) 4 (13%) 9 (27%) 13 (20%) 0.137
Dyslipidaemia, n (%) 12 (38%) 17 (52%) 29 (45%) 0.256
Angina pectoris, n (%) 6 (19%) 9 (27%) 15 (23%) 0.415
Previous myocardial infarction, n (%) 2 (6%) 2 (6%) 4 (6%) 0.975
Atrial fibrillation, n (%) 8 (29%) 8 (27%) 16 (28%) 0.871
Peripheral arterial disease, n (%) 9 (28%) 11 (33%) 20 (31%) 0.649
Previous TIA/CVA, n (%) 6 (19%) 6 (18%) 12 (19%) 0.953
New York Heart Association Class, n (%)
II 5 (20%) 6 (21%) 11 (20%)
0.782III 18 (72%) 19 (66%) 37 (69%)
IV 2 (8%) 4 (14%) 6 (11%)
Left ventricular ejection fraction, % (mean±SD) 57±14 53±16 55±15 0.408
STS score, median (IQR) 4.6 (3.4-6.3) 5.8 (3.5-9.8) 4.8 (3.4-7.2) 0.029
Frail, n (%) 20 (65%) 23 (72%) 43 (68%) 0.530
Porcelain aorta, n (%) 4 (13%) 4 (13%) 8 (13%) 0.962
Table 1. Baseline characteristics. Abbreviations: CVA = cerebrovascular accident; STS PROM = Society of Thoracic 
Surgeons predicted risk of mortality; TIA = transient ischaemic attack.
Figure 3. Relative proportion of various trans-
catheter heart valve designs used in the trial.
Sentinel 
(n=32)
No Sentinel 
(n=33)
Total 
(N=65)
Relative risk 
[95% CI] P-value
Dead after 5 days 1 (3%) 0 (0%) 1 (2%) NA NA
Dead after 30 days 1 (3%) 3 (10%) 4 (7%) 0.36 [0.04-3.43] 0.371
Dead after 6 months 1 (5%) 4 (17%) 5 (11%) 0.27 [0.30-2.44] 0.245
Stroke
Non-disabling 0 (0%) 0 (0%) 0 (0%) NA NA
Disabling 0 (0%) 2 (7%) 2 (3%) NA NA
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Brain MRI
Baseline brain MRI assessment confirmed ischaemic lesions in 11% of patients. Follow-up MRI was com-
pleted in 57% of the patients a mean of 5.0±1.1 days post TAVI. Twenty-eight patients did not undergo 
Delirium 1 (3%) 5 (15%) 6 (9%) 0.21 [0.02-1.77] 0.150
New permanent pace-
maker 7 (23%) 5 (16%) 12 (19%) 1.45 [0.46-4.55] 0.529
Coronary obstruction 0 (0%) 1 (3%) 1 (2%) NA NA
Valve embolisation 0 (0%) 0 (0%) 0 (0%) NA NA
Cardiac tamponade 0 (0%) 2 (6%) 2 (3%) NA NA
Myocardial infarction 0 (0%) 2 (6%) 2 (3%) NA NA
Acute kidney injury 0 (0%) 1 (3%) 1 (2%) NA NA
Bleeding within one day
Any bleeding 10 (32%) 14 (44%) 24 (38%) 0.74 [0.33-1.66] 0.462
Minor 9 (29%) 9 (28%) 18 (29%) 1.03 [0.41-2.60] 0.946
Major 1 (3%) 0 (0%) 1 (2%) NA NA
Life-threatening 0 (0%) 5 (16%) 5 (8%) NA NA
Bleeding after one day
Any bleeding 9 (29%) 13 (41%) 22 (35%) 0.72 [0.31-1.67] 0.438
Minor 8 (26%) 12 (38%) 20 (32%) 0.69 [0.28-1.68] 0.413
Major 0 (0%) 1 (3%) 1 (2%) NA NA
Life-threatening 1 (3%) 0 (0%) 1 (2%) NA NA
Vascular complications
Any vascular complica-
tion 12 (39%) 19 (59%) 31 (49%) 0.65 [0.32-1.34] 0.246
Minor 12 (39%) 13 (41%) 25 (40%) 0.95 [0.44-2.09] 0.904
Major 0 (0%) 6 (19%) 6 (10%) NA NA
Table 2. Clinical endpoints at 30-day follow-up. Valve Academic Research Consortium-2 (VARC) definitions were 
applied.
Figure 4. Occurrence and distribution of brain lesions by MRI.
124 Chapter 10
PA
RT
 II
I
a follow-up MRI for the following reasons: implantation of a non-MRI-compatible pacemaker (n=10), 
patient refusal (n=6), unstable clinical condition/deceased (n=5), logistical challenges (n=4) and delirium 
(n=3). Overall, 78% of patients with follow-up MRI had new brain lesions. There were numerically fewer 
new lesions and a smaller total lesion volume (95 mm3 (IQR 10-257) vs. 197 mm3 (95-525)) in patients 
with Sentinel CPS protection (Figure 4, Figure 5). 
The difference was driven by fewer lesions and smaller total lesion volume (0 mm3 (IQR 0-102) vs. 76 
mm3 (IQR 40-221), p=0.057) in the protected lobes. No difference in single lesion volume was apparent 
(Figure 5). Overall, 27% of Sentinel CPS patients and 13% of control patients had no new lesions (Figure 
4). Ten or more new brain lesions were found only in the control cohort (in 20% vs. 0% in the Sentinel CPS 
cohort, p=0.03). Half of the patients with Sentinel CPS protection had no new lesions in the protected 
lobes vs. 20% of patients without protection (p=0.04). There was no difference in the occurrence of new 
lesions in the unprotected lobes. Total lesion volume was greater in patients with self-expanding TAVI vs. 
balloon-expandable TAVI (693 mm3 (IQR 459-744) vs. 266 mm3 (IQR 155-358), p=0.067). In particular, the 
lesion volume in the posterior lobes was significantly greater with self-expanding THVs (405 mm3 (IQR 
332-530) vs. 92 (IQR 40-240), p=0.037). 
Neurocognitive performance
Neurocognitive assessment was complete for all pa-
tients at baseline and for 80% at follow-up at a mean of 
5±1.0 days after TAVI. Fifteen patients did not undergo 
follow-up neurocognitive testing, due to logistical 
issues (11 cases), delirium (two cases) and clinically 
unstable condition (two cases). Changes in neurocog-
nitive performance were mainly identified through 
MMSE. MMSE score increased by 0.25±1.6 in patients 
with Sentinel CPS and decreased by 0.77±2.5 in the 
control group (p=0.086). Neurocognitive deterioration 
was present in one patient (4%) with the Sentinel CPS vs. six patients (27%) without (p=0.017) (Figure 6).
Figure 5. Brain lesion volumes at follow-up MRI. Left: overall lesion volume. Right: volume per lesion
Figure 6. Relative proportion of patients with dete-
rioration in neurocognitive performance after TAVI.
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Histopathology
Debris was found in all patients who were 
treated with the Sentinel CPS (Figure 7). 
Thrombotic material and tissue-derived 
material were present in 87% and 100% of 
patients, respectively. Tissue stemmed from 
the myocardium, aortic valve and/or ath-
erosclerotic arterial plaques. Foreign body 
polymer material stemming from catheters 
and valve delivery systems appeared in 30% 
of all patients. 
DISCUSSION
The MISTRAL-C trial is a mechanistic study that underscores the potential value of filter-based cerebral 
embolic protection with TAVI. Filters capture thrombotic and/or tissue-derived debris in all patients un-
dergoing TAVI and will result in fewer and overall smaller ischaemic brain lesions in the protected brain 
areas and consequently preserve neurocognitive performance. 
The primary endpoint of MISTRAL-C was the presence and volume of new ischaemic brain lesions as as-
sessed by sequential (pre- and post-TAVI) MRI. Unfortunately, compliance with follow-up MRI appeared 
challenging in this population of octogenarians at high operative risk. A total of 43% of patients did not 
complete the follow-up MRI study, mainly because of the need for PPI and patient refusal. This loss to MRI 
follow-up parallels the 41% and 33% in the DEFLECT III and PROTAVI trials (19,28). In MISTRAL-C, 78% 
of patients had new brain lesions at a median of five days after TAVI. This finding reconciles the previous-
ly reported 60-90% incidence of new brain lesions by MRI within one week after TAVI (29). The use of filter 
protection did reduce the total number and the total volume of lesions. These benefits clustered in the 
areas irrigated by the carotid arteries and seem to fit with the fact that the current Sentinel CPS version 
does not protect the left vertebral artery. Over a quarter of patients undergoing TAVI with Sentinel CPS 
protection had no new brain lesions, while half had no new lesions in the protected lobes. In the PROTA-
VI pilot study, all patients developed new brain lesions post TAVI and use of Embrella embolic protection 
(Edwards Lifesciences Ltd, Irvine, CA, USA) did not affect lesion characteristics (28). The randomised DE-
FLECT III trial reported freedom from ischaemic brain lesions in 21% of patients undergoing TAVI with 
TriGuard embolic protection and, furthermore, there were numerically fewer and smaller lesions (19). A 
more detailed comparison between the various MRI studies evaluating different embolic protection de-
vices is hazardous because of MRI field strength (1.5 vs. 3 Tesla), MRI analysis methodology and because 
the timing of MRI follow-up after TAVI was not uniform. DWI at a higher field strength is more sensitive, 
can detect smaller lesions, allows shorter acquisition time and has a higher signal-to-noise ratio (18). 
Baseline mapping may be important to address existing lesions properly. Also, the number and size of 
detected lesions can change considerably within the first week post procedure. A short interval following 
TAVI is logistically and clinically challenging, yet longer intervals may miss transient brain injuries and 
new lesions may appear that are not immediately procedure-related. Kahlert et al demonstrated that 80% 
Figure 7. Frequency and characterisation of captured debris in 
all patients undergoing TAVI with Sentinel CPS protection.
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of the newly acquired brain lesions by MRI at a median of 3.4 days after TAVI had resolved three months 
later and thus represent ischaemic but not infarcted areas (10). 
In MISTRAL-C, two neurological events were described, both in patients without Sentinel CPS. This 3% 
disabling stroke rate fits with contemporary published TAVI data (8,30). Paired neurocognitive testing 
comprised three screening tests and was complete in 80% of patients. Neurocognitive performance 
deteriorated more often in patients without Sentinel CPS. Only the MMSE showed significant dynamic 
changes around the TAVI procedure. In DEFLECT III, MoCA neurocognitive testing was performed, and 
paired assessments with baseline were available for 88% and 74% of patients at a mean of 5.6±2.2 days 
and 30 days, respectively (19).
Patients who underwent TAVI with TriGuard protection appeared to have less worsening in MoCA assess-
ment. Ghanem et al used the repeatable battery for the assessment of neuropsychological status (RBANS) 
in 111 patients undergoing TAVI (31). Procedural testing three days after TAVI could not be completed in 
13% of patients because of critical illness, and transient early cognitive decline was detected in 6% (6/97). 
Neurocognitive performance was similar to baseline at later time points up to two years. In the absence 
of solid guidelines, results of serial neurocognitive assessments need to be interpreted with caution. In 
fact, MMSE has not been developed for frequent serial testing, and changes of <2 points may still repre-
sent measurement error, regression to the mean, or a practice effect (24). The comparison of TAVI studies 
involving serial brain MRI and neurocognitive assessment requires caution in the absence of uniformity 
in the timing and methodology of these tests (18). Initiatives to harmonise further research in this field 
and provide guidance based on expertise and consensus are underway. 
The current-generation Sentinel CPS offers filter protection to three of the four major arterial conduits to 
the brain, leaving the left vertebral artery unprotected. In general, the left vertebral artery is more domi-
nant than the right vertebral artery and therefore has a larger vascular territory (32). Filter effects should 
therefore predominantly manifest in the vascular territory of the anterior and medial cerebral arteries. 
Indeed, half of all patients with Sentinel CPS protection did not have new lesions in the protected brain 
regions and new lesions appeared smaller. The appearance of new subclinical ischaemic brain lesions and 
micro infarcts may pose meaningful threats to neurocognitive function and psychosocial wellbeing in 
lower-risk and younger patients with symptomatic severe AS who may arguably become candidates for 
TAVI in the near future (22,23). 
Limitations 
Our study had a small sample size and was underpowered due to a higher than expected MRI drop-out 
rate. Also, despite randomisation, the STS score was significantly higher in patients treated without Sen-
tinel CPS, who also had more major vascular complications. Yet, patients with major vascular complica-
tions did not complete MRI or neurocognitive follow-up and therefore did not affect our findings in terms 
of brain lesions and neurocognitive performance. We only assessed the early postoperative timeframe. 
The longer-term significance of early neurocognitive deterioration and transient ischaemic brain lesions 
that may not result in permanent infarcts is unsettled. The MISTRAL-C results should be considered 
hypothesis-generating and justify the larger randomised SENTINEL trial (NCT02214277) evaluating the 
Sentinel CPS that is currently recruiting patients in the USA and Germany. 
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Conclusion 
Filter-based embolic protection captures debris en route to the brain in all patients undergoing TAVI. 
This study suggests that its use can lead to fewer and overall smaller new brain lesions as assessed by MRI 
and preservation of neurocognitive performance early after TAVI. These hypothesis-generating findings 
need confirmation in a larger randomised trial.
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ABSTRACT
Objectives
To evaluate the value of left vertebral artery filter protection in addition to the current filter-based embol-
ic protection technology to achieve complete cerebral protection during TAVR.
Background
The occurrence of cerebrovascular events after transcatheter aortic valve replacement (TAVR) has fueled 
concern for its potential application in younger patients with longer life expectancy. Transcatheter cere-
bral embolic protection (TCEP) devices may limit periprocedural cerebrovascular events by preventing 
macro and micro-embolization to the brain. Conventional filter-based TCEP devices cover three extracra-
nial contributories to the brain, yet leave the left vertebral artery unprotected.
Methods
Patients underwent TAVR with complete TCEP. A dual-filter system was deployed in the brachiocephalic 
trunk and left common carotid artery with an additional single filter in the left vertebral artery. After 
TAVR all filters were retrieved and sent for histopathological evaluation by an experienced pathologist. 
Results
Eleven patients received a dual-filter system and nine of them received an additional left vertebral filter. 
In the remaining two patients, the left vertebral filter could not be deployed. No periprocedural strokes 
occurred. We found debris in all filters, consisting of thrombus, tissue derived debris, and foreign body 
material. The left vertebral filter contained debris in an equal amount of patients as the Sentinel filters. 
The size of the captured particles was similar between all filters.
Conclusions
The left vertebral artery is an important entry route for embolic material to the brain during TAVR. Selec-
tive filter protection of the left vertebral artery revealed embolic debris in all patients. The clinical value of 
complete filter-based TCEP during TAVR warrants further research.
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INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is recommended in patients with symptomatic severe 
aortic valve stenosis (AS) and an elevated surgical risk (1–6), and is serving a growing proportion of 
patients (7). As with surgical aortic valve replacement TAVR comes with a 30-day major stroke rate of 
approximately 2–5% (8). TAVR requires large bore catheter navigation through the arterial vasculature 
and the implantation of a bioprosthesis within a degenerated aortic valve, which may provoke intrapro-
cedural tissue dislodgment. Indeed, transcranial Doppler, brain magnetic resonance imaging (MRI) and 
histopathology studies suggest cerebral embolization in the vast majority of TAVR procedures (9–12). 
Silent brain lesions and (micro-) infarcts may not be trivial, as they are associated with neurocognitive 
deterioration (13).
Dedicated deflecting and filter-based devices were designed to reduce cerebral embolization. The 
DEFLECT-III trial demonstrated fewer ischemic brain lesions and preserved neurocognition with the 
TriGuard deflector (14). The Sentinel transcatheter cerebral embolic protection (TCEP) device (Claret 
medical, Santa Rosa, CA) provides filters to the brachiocephalic trunk and the left common carotid artery 
and thus omits the left vertebral artery. Recent studies demonstrated debris capture in almost all patients 
undergoing TAVR with Sentinel TCEP (15,16). Three randomized trials compared brain-MRIs several days 
after TAVR in patients who did receive TCEP to those who did not (16–18). None of those studies reached 
the primary endpoint and the efficacy of embolic protection is currently still under debate. In the CLaret 
Embolic Protection ANd TAVI—Trial (CLEAN-TAVI) a 57% reduction in lesion volume to the entire brain 
was assigned to the use of embolic protection, and a 65% reduction in protected areas only (i.e., not 
vascularized by the left vertebral artery) (17). Interestingly, in the randomized MRI Investigation in TAVI 
with Claret (MISTRAL-C) trial, the difference between reduction of lesion volume of protected regions 
compared to the entire brain was greater (100% vs. 48%) (18). Similarly, the cerebral protection in tran-
scatheter aortic valve replacement (SENTINEL) trial showed a 42% reduction of lesion volume in protect-
ed territories whereas this effect was only 5% when the entire brain was considered (16). These findings 
suggest that debris could still embolize to the brain through the unprotected left vertebral artery. Indeed, 
current generation Sentinel TCEP leaves the left vertebral artery unprotected which is known to account 
for up to 20% of total brain perfusion (19). This hypothesis is strengthened by a study, which demonstrat-
ed that a significant number of cerebral infarcts after TAVR occur in regions that are partly vascularized 
by the vertebral arteries, namely the posterior lobes (33%) and the cerebellum/brainstem (27%) (20).
The Wirion (Allium Medical, Inc., Caesarea, Israel) is a single filter unit that can be delivered, locked and 
deployed on any commercial 0.01400 guidewire, and deployed in vessels ranging from 3.5 to 6.0 mm in 
diameter. The aim of this study was to evaluate whether selective Wirion deployment in the left vertebral 
artery would capture additional thrombotic or tissue derived debris during TAVR and as such could com-
plement Sentinel TCEP protection.
MATERIALS AND METHODS
This prospective single-arm observational study enrolled 11 patients with severe AS from June 2014 to 
January 2015 in the Erasmus Medical Center in Rotterdam. All patients were deemed at high operative 
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risk and suitable for transfemoral TAVR by heart team consensus. All patients provided written informed 
consent for the procedure and data analysis for research purposes per Institutional Review Board approv-
al.
TAVR procedures evolved under general anesthesia. All patients were preloaded with aspirin and clopi-
dogrel and received intravenous heparin during the procedure aiming for an activated clotting time >250 
s. A contrast injection in the aortic arch was performed to visualize the dimensions and position of the 
carotid and vertebral arteries in order to assess eligibility for both TCEP devices. The TCEP devices were 
inserted prior to any catheter manipulation in the aortic arch. All commercially available transcatheter 
heart valve designs were allowed. During the inclusion period of the study, our automated software for 
3-dimensional CT reconstruction (3mensio, Pie Medical Imaging, Maastricht, The Netherlands), did not 
possess the functionality to assess small vessels such as the carotid arteries and left vertebral artery, yet. 
In 2016 a software update enabled assessment of these small vessels as well. We performed a post-hoc CT 
analysis to assess the aortic arch anatomy and vascular diameters and calcification.
Embolic protection technique
Figure 1 illustrates the position of the Sentinel TCEP 
and Wirion filter during TAVR. The Sentinel TCEP 
consists of two cone-shaped nitinol filters with a 
polyurethane film and 140 mm pores mounted on a 
steerable delivery catheter. The filters are integrated 
in a 100 cm steerable delivery system with a custom-
ized handle to articulate its distal portion. The target 
vessel size for the proximal filter (brachiocephalic 
trunk) ranges from 9 to 15 mm and for the distal filter 
(left common carotid artery) from 6.5 to 10 mm. The 
assembly is inserted through a right radial access. 
The proximal filter is deployed in the brachiocephalic 
trunk, the distal filter in the left common carotid 
artery. A detailed description of the deployment tech-
nique was described previously (21).
The Wirion contains a nitinol frame and a 120 mm 
pore size membrane. A dedicated delivery system 
with a rapid exchange (Rx) port 38 cm from its tip 
houses the filter unit. A dedicated activating handle 
can lock the filter unit onto any 0.014” guidewire. The 
target vessel size ranges from 3.5 to 6.0 mm.
Through a left radial approach a 0.014” guidewire is maneuvered into the left vertebral artery. The Wiri-
on-delivery catheter is inserted onto the guidewire and advanced into the left vertebral artery under flu-
oroscopic guidance. The filter unit is then locked onto the wire by rotating the handle clockwise. Retract-
ing the delivery catheter expands and deploys the filter. The Wirion is removed by advancing a dedicated 
Figure 1. Reconstruction of the aortic arch illus-
trating the position of the filters during TAVR. One 
dotted line (Diamond A&B) represents the Sentinel 
TCEP with the proximal filter positioned in the 
brachiocephalic trunk (Diamond A) and the distal 
filter in the left common carotid artery (Diamond B). 
The other dotted line represents the Wirion device 
with the filter positioned in the left vertebral artery 
(Diamond C).
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retrieval catheter over the filter unit and pulling the assembly back.
At the end of the TAVR procedure, Sentinel and Wirion filters were detached from their respective de-
livery system and stored in a buffered formalin (4%) solution. An experienced pathologist (MS) analysed 
all filters. Captured debris was dehydrated, embedded in paraffin and cut into sections of 3- to 4-mm 
thickness. Tissue sections were stained with hematoxylin-eosin and Movat pentachrome. Material small-
er than 0.25 mm was processed using the Cellient-system and stained with both Giemsa and hematoxy-
lin-eosin. Additional staining techniques were performed whenever applicable to identify specific tissue 
origin, as previously described (11).
Data management
Patient specific and procedure related data was prospectively collected and stored in a dedicated data-
base. All patients were followed for 30 days. Relevant clinical endpoints at 30 days were categorized using 
the most recent Valve Academic Research Consortium (VARC) document (22).
Statistical analysis
All statistical analyses were performed with SPSS version 21.0.1 (IBM Corp, Armonk, NY). Data are pre-
sented as mean (6SD) or median 
(interquartile range) if continuous 
or as number if dichotomous. Con-
tinuous variables were compared 
using the Mann-Whitney-U test 
and a Chi-square test was used for 
trends in dichotomous variables. A 
two-sided value of p<0.05 was con-
sidered statistically significant.
RESULTS
Patient characteristics
Eleven patients were included in 
this study. Baseline characteristics 
are shown in Table 1. Median age 
was 81 and 7 patients were female. 
Most patients were symptomatic, 
10 of 11 patients were New York 
Heart Association (NYHA)-class 2–4. 
Comorbidities were common, mean 
Log-EuroSCORE and STS-score were 
15.7 ± 8.4 and 5.1 ± 1.7, respectively. 
N=11
Age; median, IQR 81, 78–83
Female; n 7
Body mass index in kg/m2; mean ± SD 26 ± 4
Diabetes; n 2
Hypertension; n 7
New York Heart Association (NYHA)—class; n
I 1
II 3
III 6
IV 1
Log EuroSCORE; mean ± SD 15.7 ± 8.4
Society of thoracic surgeons (STS)-score; mean ± SD 5.1 ± 1.7
Peripheral arterial disease; n 3
Chronic obstructive pulmonary disease; n 4
Previous stroke; n 2
Previous myocardial infarction; n 3
Previous coronary artery bypass grafting; n 4
Previous percutaneous coronary intervention; n 4
Previous surgical aortic valve replacement; n 1
Carotid stenosis; n 4
Porcelain aorta; n 3
Table 1. Baseline characteristics.
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Two patients previously underwent 
a cerebral stroke and four patients 
had a known carotid stenosis. Three 
patients had a porcelain aorta.
Procedural characteristics
Eight patients underwent TAVR 
with the Lotus valve (Boston 
Scientific, Marlborough, MA), 
two patients with a Sapien 3 valve 
(Edwards Lifesciences, Irvine, CA), 
and one patient with a CoreValve 
(Medtronic, Minneapolis, MN). Me-
dian fluoroscopy time was 27.4 min 
(IQR 23.3–35.5). Median anesthesia 
time (i.e., time on catheterization 
laboratory) was 212 minutes (IQR 
190–214). Median contrast load was 
110cc (IQR 80–150).
Sentinel TCEP was successfully 
deployed in all patients. In two of 
eleven patients the implantation of 
the Wirion-filter was unsuccessful due to the following reasons: In one patient we were unable to advance 
a guidewire into the left vertebral artery due to anatomical difficulties and in one patient we caused a 
dissection of the left vertebral artery. The latter was treated with a stent. We excluded these patients from 
our histopathological analysis.
Clinical endpoints
Clinical outcomes are displayed in Table 2. None of the eleven patients died during the first month of 
follow-up. There were no events of coronary obstruction, valve embolization or cardiac tamponade. 
Conversion to surgery did not occur. One patient experienced a life-threatening gastro-intestinal bleeding 
within 24 hr after the procedure. This same patient developed an ischemic stroke on the 8 days after the 
procedure. One major vascular complication resulted from the introduction of the Wirion-device into the 
left vertebral artery, which was previously mentioned. Six patients experienced a minor vascular compli-
cation related to the femoral access site. In five cases there was a hematoma at the femoral puncture site 
and one patient had a dissection of the femoral artery, which was treated with a covered stent.
N=11
Thirty day mortality, n 0
Thirty day stroke, n                                                                         1*
New Permanent pacemaker, n 2
Conversion to surgery, n 0
Coronary obstruction, n 0
Valve embolization, n 0
Cardiac tamponade, n 0
Peri-procedural myocardial infarction, n 0
Bleeding within 24 hr, n
Minor bleeding 2
Major bleeding 0
Life-threatening bleeding 1
Bleeding after 24 hr, n
Minor bleeding 5
Major bleeding 0
Life-threatening bleeding 0
Vascular complication, n
Minor vascular complication 6
Major vascular complication 2
Access site related vascular complication, n 6
Table 2. VARC-II endpoints. *Patient had an ischemic stroke 8 days after 
the TAVI procedure.
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Histopathological analysis
In total, 31 filters were retrieved: 11 originating from the brachiocephalic trunk (Sentinel first filter), 11 
from the left common carotid artery (Sentinel second filter), and 9 from the left vertebral artery (Wir-
ion filter). The histopathological analysis revealed that all filters contained debris. An overview of the 
retrieved contents is shown in Figure 2. Fibrin/trombus was the most frequently seen element, which was 
found in the Sentinel TCEP filters in all patients and in seven of nine Wirion filters. When fibrin/trombus 
was not taken into account, Sentinel and Wirion filters all contained tissue material. Endothelium was 
the most commonly found tissue (Sentinel 9/11 patients vs. Wirion 7/9 patients). Apart from endogenous 
tissue, foreign body material was also detected in the majority of patients (Sentinel 6/11 patients vs. 
Wirion 6/9 patients). This foreign body material consisted of blue gel or colored fibers, likely derived from 
catheters or the TAVR delivery system. No differences were observed between the Sentinel and Wirion 
filter for any type of debris.
Tissue size
Concerning the size of the 
debris, the largest particles 
consisted of amorphous calcium 
in both the Sentinel and Wirion 
filters with a median diameter of 
0.60 and 0.33 mm, respectively 
(Figure 3). There were no differ-
ences in the median diameter 
for each tissue type between the 
Sentinel and Wirion filters.
Figure 2. Graph illustrating distribution of embolic debris in Sentinel and Wirion filters. 
*Presence of tissue fragments excluding thrombus tissue.
Figure 3. Boxplots displaying median size (minimum -Q1-median-Q3-maxi-
mum) per tissue type for debris from Sentinel and Wirion filters.
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CT analysis
Results from the post-hoc CT 
analysis are displayed in Table 3. 
Aortic arch anatomy was normal 
in 8 of the 11 patients, two patients 
had a bovine arch and one patient 
had an anomalous origin of the left 
vertebral artery. All dimensions of 
the brachiocephalic trunk, left com-
mon carotid artery and left vertebral 
artery were within the range of the 
manufacturers’ instructions for use. 
Three patients had at least moderate 
calcification of the brachiocephalic 
trunk and left common carotid. 
Also, three patients had at least 
moderate calcification of the left 
vertebral artery, of which two had 
no calcifications in the brachioce-
phalic trunk of left common carotid 
artery, whatsoever.
As mentioned above, in two of the 
eleven patients the implantation of 
the Wirion filter was unsuccessful. 
The first was the patient with the 
anomalous origin of the vertebral 
artery. The second was the patient 
with the severely calcified vertebral 
artery in which a dissection was caused by the guidewire.
DISCUSSION
This study reveals that both the amount and size of debris that passes through the left vertebral filter 
during TAVR is comparable to the amounts that passes through the brachiocephalic trunk and left com-
mon carotid artery. Currently available filter-based TCEP only includes the brachiocephalic trunk and left 
common carotid artery (21). Our study indicates that protection of three out of four extracranial arterial 
contributors offers incomplete brain protection.
A study by Arnold et al. demonstrated lesion frequency on MRI after transapical TAVR without embolic 
protection (20). The authors concluded that 17 of the 25 patients (68%) had new embolic lesions, of which 
six had more than five lesions. This is in line with previous studies that reported brain MRI findings after 
TAVR (9,10,23,24). Interestingly, 27% of the lesions was localized in the cerebellum and brainstem (27%) 
                                                                                                            N=11
Aortic arch anatomy
Normal                 8
Bovine                           2
Left vertebral arises from arch                     1
Brachiocephalic trunk average diameter in mm; 
median, IQR 12.7 (11.0–13.4)
Left common carotid artery average diameter in 
mm; median, IQR 7.1 (6.7–8.0)
Left vertebral artery average diameter in mm; 
median, IQR 4.0 (3.5–4.4) 
Brachiocephalic trunk calcification
None               7
Mild                  1
Moderate                     3
Severe                              0
Left common carotid artery calcification
None 7
Mild 1
Moderate 3
Severe 0
Left vertebral artery calcification
None 5
Mild 3
Moderate 2
Severe 1
Table 3. Computed tomography findings.
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of which the vertebral arteries is a large vascular contributor. A study by Kahlert et al. reported 29% of 
new lesions in the vertebro-basillary region after transfemoral TAVR (9). Both studies did not differenti-
ate between the left and right vertebral artery. A study by Ghanem et al. reported that ≈12% of cerebral 
lesions is located in the region that is particularly vascularized by the left vertebral artery (10), and a 
study by Astarci et al. reported a number as large as ≈17% in this region (24). Of note, these are probably 
underestimations since the vascular territories of the posterior cerebral arteries and vertebral arteries 
largely overlap. In conclusion, these four studies are in line with previous findings that indicated the left 
vertebral artery accounts for up to 20% of blood flow to the brain (19).
Previously, we reported the embolic load that was captured with the Sentinel TCEP (11). This study 
showed that 75% of patients had some amount of debris in the filters. In both the MISTRAL-C and SEN-
TINEL trials debris was captured in ≈100% of patients (16,18). This study showed debris in all filters too. 
Both self-expanding and balloon expandable valve designs have been studied in earlier studies (16,18). In 
this study, eight patients were treated with the mechanically expanded Lotus valve, two with the balloon 
expandable Sapien 3 and 1 with the self-expanding CoreValve.
In our study fibrin/trombus, endothelial tissue and foreign body material were frequent. The debris size 
in the Sentinel TCEP filters of 0.05–1.6 mm and in the Wirion filters of 0.05–1.6 mm is similar to what we 
reported earlier (11). Interestingly, myocardial tissue was captured in more than half of the patients and 
compares with the 33% reported in the MISTRAL-C and 16% in SENTINEL trials. It indicates that TAVR 
induces myocardial tissue damage due to traumatic contact with the introduced catheters or delivery 
system.
The additional use of the Wirion filter had minimal implications on the TAVR procedure itself. The total 
fluoroscopy time of 27.4 min was comparable with usual TAVR standards (25), as was the anesthesia time 
or 212 min (26). Use of contrast was modest with 110 ml per procedure, and in keeping with other studies 
(27). The Wirion filter is easy to advance over a genuine coronary 0.014” guidewire and its deployment is 
intuitive. However the take-off and trajectory of the left vertebral artery may be challenging and might 
preclude safe negotiation. In two patients we were unsuccessful to deploy a Wirion filter selectively into 
the left vertebral artery and even generated a vascular complication that required stenting. Sub-selective 
filter deployment in the subclavian artery distal to the origo of the left vertebral artery may be a safer 
landing zone. In addition, pre-procedural CT analysis of the carotid and vertebral arteries with dedicated 
software (that became available to us in 2016) might be helpful to select those patients who are eligible 
for embolic protection filters. In this small pilot study, the post-hoc CT analysis was able to show that 
the two patients in which the deployment of the left vertebral filter was unsuccessful had an unfavorable 
anatomy beforehand. In our experience, pre-procedural planning using multiplanar CT reconstructions 
has become a prerequisite for both the TAVR procedure itself as the use of embolic protection.
In our relatively small study population of eleven patients, none experienced a periprocedural stroke. One 
patient underwent a stroke on the eight day after TAVR after two episodes of cardiopulmonary resuscita-
tion for total atrioventricular block.
Since periprocedural stroke occurs seldom after TAVR previous studies have been underpowered to re-
veal a benefit of embolic protection on this endpoint. Therefore, studies focused on softer endpoints such 
as lesion volume by brain-MRI. Three randomized trials investigated the benefit of TCEP by brain-MRI 
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several days after TAVR. First, the CLEAN-TAVI study randomized 100 patients to either TAVR with or 
without TCEP and 88 patients underwent a brain-MRI at 7 days (17). The lesion volume in the entire brain 
was reduced by 57% (205 mm3 vs. 472 mm3, p=0.009) with use of TCEP, and 65% (101 mm3 vs. 292 mm3, 
p=0.002) in the protected areas. Second, the MISTRAL-C study randomized 65 patients of which 37 un-
derwent brain-MRI at 5 days (18). Total lesion volume in the entire brain was reduced by 48% (95 mm3 vs. 
197 mm3, p=0.171) and by 100% (0 mm3 vs. 76 mm3, p=0.057) in the protected lobes. Third, the SENTINEL 
study randomized 240 patients of which 185 underwent brain-MRI between day 2 and 7 (16). Total lesion 
volume in the entire brain was reduced by 5% (294 mm3 vs. 310 mm3, p=0.81), and by 42% (103 mm3 vs. 
178 mm3, p=0.33) in the protected territories. Although these studies were likely underpowered to show 
a significant reduction in lesion volume all studies point toward a greater reduction in the protected 
regions compared to the entire brain. This strengthens the hypothesis that protection of the left common 
carotid and brachiocephalic trunk might be suboptimal.
It will be hard to demonstrate a clinical benefit of complete over incomplete filter protection, therefore 
future studies should focus on surrogate endpoints such as lesions on brain-MRI or neurocognitive per-
formance, as proposed by a recent academic research consortium consensus document (28).
Limitations
This prospective single arm study was intended to reveal whether protection of the left vertebral artery 
could be beneficial in TAVR. The study was small, and should therefore be considered hypothesis gener-
ating. Post-procedural brain imaging was not performed and we acknowledge that this should be a target 
for future studies to investigate the benefit of left vertebral artery protection during TAVR.
CONCLUSION
This study, involving first in human complete filter-based TCEP during TAVR confirms that the left 
vertebral artery is relevant entry route for embolic material toward the brain. No periprocedural strokes 
occurred during 30-day follow up. More evidence is needed to support beneficial effects of TCEP over 
existing strategies.
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Transcatheter MitraClip (Abbott Vascular, Santa Clara, California) implantation has emerged as the sin-
gle catheter-based technique for mitral valve repair with global adoption. Worldwide, an estimated 25,000 
patients have been treated with the MitraClip so far. Typically, the incidence of major stroke after surgical 
mitral valve repair or replacement is similar to what is seen after surgical aortic valve replacement, and 
varies between 1% and 5% (1–3). In the only randomized trial comparing MitraClip with mitral valve 
repair/ replacement, major stroke rate at 30 days was 1% after MitraClip and 2% after mitral valve surgery 
(4). The EVEREST (Endovascular Valve Edge-to-Edge Repair Study) 2 predominantly enrolled patients 
with degenerative mitral valve disease (4). In the larger European MitraClip registries, patients had more 
functional mitral regurgitation (MR). The clinically major stroke rate after clipping appeared to be negligi-
ble and <1%: 0.7% in 560 patients in the ACCESS EU (ACCESS-Europe A Two-Phase Observational Study 
of the MitraClip System in Europe) trial, and 0% in 1,064 patients in the German TRAMI (Transcatheter 
Mitral Valve Interventions) Registry (5,6). 
Important lessons were learned after a decade of controversy about stroke rates in patients undergoing 
surgical or catheter-based aortic valve replacement. The randomized PARTNER (Placement of Aortic 
Transcatheter Valve) I trial seemed to suggest that the less-invasive transcatheter aortic valve replace-
ment (TAVR)was associated with a higher neurological event rate compared with surgical aortic valve 
replacement; yet, the randomized U.S. CoreValve high-risk study refuted these findings (7,8). Interestingly, 
the involvement of competent authorities like the U.S. Food and Drug Administration, efforts by the Valve 
Academic Research Consortium to determine uniformity in endpoint definitions and trial design, and 
the advent of embolic protection devices have scrutinized research on neurological events in the field (9). 
Neurology experts are now involved in most important TAVR trials and assess all enrolled patients under-
going valve replacement before and after the procedure. This scrutiny has revealed more (subtle) neuro-
logical changes in significantly more patients. Indeed, new neurological events were detected in 15% of 
patients in the control arm of the randomized DEFLECT III (A Prospective, Randomized Evaluation of the 
TriGuard HDH Embolic Deflection Device During TAVI) trial and in 17% of patients undergoing surgical 
aortic valve replacement in the DeNOVO (Determining Neurologic Outcomes from Valve Operations) 
prospective cohort study (10,11). Diffusion-weighted magnetic resonance imaging (MRI) studies and 
histopathology studies have revealed signs of cerebral embolization in over 80% of patients undergoing 
TAVR (12–14).
Deflecting and filter-based embolic protection devices (EPDs) are being intensely studied in the field 
of TAVR, and not surprisingly, interest for EPD also emerges in the MitraClip space (15). In this issue of 
JACC: Cardiovascular Interventions, Frerker et al. (16) study the use of filter-based embolic protection in 
patients undergoing MitraClip implantation.
The Sentinel EPD (Claret Medical Inc., Santa Rosa, California) provides filter protection for 3 of 4 arterial 
contributories to the brain. The filters can be retrieved and microscopically analyzed. Fourteen patients 
with severe MR were included in the analysis. Most patients had functional MR and concomitant perma-
nent atrial fibrillation. Debris was detected in all patients. Acute thrombus and foreign body material was 
most common. The presence of acute thrombus is remarkable, especially since optimal per-procedural 
anticoagulation with heparin was achieved (mean activated clotting time 289 ± 48 s). This raises the ques-
tion about the etiology of this acute clot formation: device manipulations in the left side of the heart but 
also the use of the filters themselves may be pro-thrombogenic. Furthermore, procedure times exceeding 
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90 min may result in transient suboptimal anticoagulation and, thus, promote acute thrombus formation. 
In fact, MitraClip procedure/device time has previously been associated with more new brain lesions 
by MRI (17). Conversely, the presence of organizing thrombus in the filters may be associated with the 
high prevalence of atrial fibrillation that hypothetically may have accounted for the organized thrombus 
surrounding the mitral valve apparatus. The authors describe the foreign body material as nonpolarizable 
basophilic material consistent with hydrogel, most probably from the hydrophilic coating of the transsep-
tal sheath, guide delivery catheter, or the clip delivery system and thus inherent to the procedure. In more 
than one-half of the patients, mitral valve and atrial tissue was found. The authors do not discuss the 
effect of the number of attempts to grasp both mitral leaflets to eventually close and deploy the MitraClip. 
One can only wonder whether more attempts could dislodge more tissue. Furthermore, would there be 
a difference between functional and degenerative MR, with the latter displaying an excess of tissue? The 
finding that the use of more clips seemed to generate larger debris is intriguing.
In comparison to what typically is captured after TAVR, debris seemed smaller with MitraClip: 295 mm 
(interquartile range: 104 to 509 mm) versus 1 mm (interquartile range: 0.6 to 1.5 mm) (14). Smaller par-
ticle size may reflect the preponderance of functional MR in this study with structurally normal mitral 
valve leaflets. Similarly, this may explain why no calcium particles were captured. This contrasts with the 
yield after TAVR, with tissue debris in two-thirds of all patients including amorphous calcium. 
The current data are complementary to the recent brain MRI study by Blazek et al. (17), in which a medi-
an of 3 new brain lesions were found in 85% of patients after MitraClip.
Given the (very) low clinical stroke rates after MitraClip, purists may claim that EPDs are useless in this 
setting. Others may argue that even subclinical brain infarcts may not be harmless and may increase 
the risk for dementia and neurocognitive deterioration in the long run (18). Future research efforts may 
focus on: 1) the difference in cerebral embolization between functional and degenerative MR; 2) the effect 
of EPD on new brain lesions by MRI; 3) cerebral embolization burden with transcatheter mitral valve 
implantation, which intuitively seems more traumatic than MitraClip and may thus dislodge more tissue 
debris; and maybe most importantly, 4) the effect of new brain lesions after structural heart interventions 
on immediate and late neurocognitive performance.
In aggregate, cerebral embolization seems ubiquitous with structural left-sided heart interventions. The 
study by Frerker et al. (16) provides complementary histopathological evidence to prior brain imaging 
data. Only the future can tell whether filter-based cerebral embolic protection is merely an interesting 
research tool or an essential clinical accessory for superior procedural (brain) safety.
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A 62-year-old woman underwent transcatheter aortic valve implantation (TAVI) for severe low-flow 
low-gradient stenosis of a bicuspid aortic valve (Supplemental Figure 1). She was declined for open heart 
surgery because of severe left ventricular dysfunction. The TAVI procedure was performed under local 
anesthesia and full anticoagulation with heparin and preloading with aspirin and clopidogrel. Following 
balloon aortic valvuloplasty, a 29 mm Core-Valve Evolut R bioprosthesis (Medtronic, Minneapolis, MN, 
USA) was attempted. Its deployment was associated with immediate haemodynamic compromise com-
plicating the valve positioning and resulting in a deep implant with residual significant paravalvular aor-
tic regurgitation (AR). A second Evolut R was implanted more cranially with complete resolution of the 
AR (Supplemental Figure 2). The patient was discharged home with daily aspirin and clopidogrel after an 
uneventful hospital stay. A planned multi-phasic CT (MSCT) scan after 30 days revealed a large thrombus 
(13  6 mm) at the interface of the two bioprostheses (Panel B: cross-sectional; Panel C: longitudinal). The 
patient was put on oral anticoagulation therapy with coumadins (acenocoumarol). MSCT scan 4 months 
later confirmed almost complete resolution of the stentframe thrombus. The bioprosthetic leaflets ap-
peared slim and mobile and there were no signs of residual stenosis at 1 month after TAVI (Figure 1: Panel 
A) and after 4 months of subsequent oral anticoagulation therapy (Figure 1: Panel D) (Figure 1: Panel E: 
cross-sectional; Figure 1: Panel F: longitudinal). This case illustrates a novel phenomenon of unequivocal 
thrombus formation at the stent frame level without affecting the leaflets that almost completely resolved 
after 4 months of anticoagulation therapy. Its true incidence is unknown and requires further research. 
TAVI operators and treating physicians need to be aware of this entity especially in a situation of tran-
scatheter valve-in-transcatheter-valve implantation’ in combination with low-flow and low-gradient AS.
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SUPPLEMENTAL MATERIAL
Supplemental figure 1. TTE confirmed a classical low-flow low-gradient aortic stenosis (A) of a bicuspid valve 
(B). Bicuspidy was also confirmed on MSCT (C).
Supplemental figure 2. Procedural angiograms before release of the first valve – depth 9 mm (A), after release of 
first valve – depth 20 mm (B) and after TAV-in-TAV (C).
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A73-year old man presented with acute cardiac decompensation due to severe degenerative mitral regur-
gitation (Figures 1A and 1B). The patient previously underwent surgical aortic valve replacement with 
a mechanical valve. The patient was declared inoperable by heart team consensus based on excessive 
comorbidities. After staged left main bifurcation rotablation and stenting (Figures 1C and 1D), the patient 
was accepted for transapical transcatheter mitral valve implantation (TMVI) with the CardiAQ transcath-
eter heart valve (Edwards Lifesciences, Irvine, California) (Figure 2A) under compassionate use. Pre-pro-
cedural imaging work-up confirmed eligibility for the procedure in terms of overall anatomy and sizing. 
Relative orientation of the aortic mechanical valve and its distance to the mitral annular plane were 
deemed reassuring (Figures 1E and 1F). The procedure was supported by fluoroscopic and transesopha-
geal echocardiography guidance. Through a left lateral minithoracotomy, the CardiAQ valve was smoothly 
navigated over a stiff guidewire into the mitral annulus and gradually deployed, with no residual mitral 
regurgitation on transesophageal echocardiography (Figure 2D). Final release was quickly followed by 
hemodynamic compromise due to massive aortic regurgitation (Figure 2E) caused by 1 immobile leaflet 
of the aortic mechanical valve (Figure 2F). Despite extracorporeal cardiopulmonary support and multi-
ple bail-out transcatheter maneuvers, the patient succumbed to intractable cardiogenic shock. Autopsy 
revealed anatomically correct placement and sealing of the CardiAQ valve (Figure 2G). Despite excessive 
preprocedural planning, 2 anchors of the CardiAQ valve eventually interfered with the aortic mechanical 
valve (Figures 2H and 2I). As previously described, the inherent radial force needed to anchor the stented 
valve might squeeze the left ventricular outflow tract (1,2). This case demonstrates that the left ventric-
ular outflow tract is an essential yet dynamic anatomic structure for TMVI, especially in the case of an 
aortic mechanical valve. Proper understanding of the mitral valvular anatomy is crucial for the clinical 
implementation and further refinement of TMVI. We believe that the presence of an aortic mechanical 
valve currently is a formal contraindication for TMVI.
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Figure 1. Pre-procedural work-up. (A) Baseline transesophageal echocardiography (TEE) showing flail of the 
mitral valve posterior leaflet. (B) Baseline TEE showing significant mitral regurgitation. (C) Fluoroscopic image of 
left main stem stenosis. (D) Fluoroscopic image of left coronary artery after main stem rotablation and stenting. 
(E) Pre-procedural multislice computed tomography (CT) image showing measured distance from mitral annulus 
to aortic mechanical valve. (F) Pre-procedural 3-dimensional reconstruction of multislice CT showing anatomic 
dimensions.
158 Chapter 14
IN
TE
R
LU
D
E
REFERENCES
1. Van Mieghem NM, Piazza N, Anderson RH et 
al. Anatomy of the mitral valvular complex and 
its implications for transcatheter interven-
tions for mitral regurgitation. J Am Coll Cardiol 
2010;56:617-26.
2. Anyanwu AC, Adams DH. Transcatheter mitral 
valve replacement: the next revolution? J Am 
Coll Cardiol 2014;64:1820-4.
Figure 2. Procedure and autopsy. (A) The CardiAQ transcatheter heart valve (THV). (B) Fluoroscopic image du-
ring implantation of the THV. (C) Fluoroscopic image of CardiAQ THV directly after release. (D) Transesophageal 
echocardiography (TEE) showing absence of mitral regurgitation. (E) TEE showing massive aortic regurgitation. 
(F) Fluoroscopic image of interference between the aortic mechanical valve and the CardiAQ THV. (G) Autopsy 
photograph showing correct placement of CardiAQ THV, seen from the left atrium. (H) Autopsy photograph with 
visible anchor from the CardiAQ THV, seen from the ascending aorta. (I) Autopsy photograph showing 2 anchors 
of the CardiAQ THV interfere with the aortic mechanical valve, seen from the left ventricle. 
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Part IV 
Procedural planning
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ABSTRACT
Aims 
Paravalvular aortic leakage (PVL) after transcatheter aortic valve implantation (TAVI) is a complication 
with potentially severe consequences. The relation between native aortic root calcium burden, stent 
frame eccentricity and PVL was not studied before.
Methods and results
Two-hundred-and-twenty-three consecutive patients with severe aortic stenosis who underwent TAVI 
with a Medtronic CoreValve System VC and who had available pre-discharge transthoracic echocardi-
ography were studied. Echocardiographic stent inflow frame eccentricity was defined as major–minor 
diameter in a short-axis view >2 mm. PVL was scored according to the updated Valve Academic Research 
Consortium (VARC-2) recommendations. In a subgroup of 162 (73%) patients, the calcium Agatston score 
was available. Stent frame eccentricity was seen in 77 (35%) of patients. The correlation between the Ag-
atston score and stent frame eccentricity was significant (q = 0.241, P = 0.003). Paravalvular leakage was 
absent in 91 cases (41%), mild in 67 (30%), moderate in 51 (23%), and severe in 14 (6%) cases. The correla-
tion between stent frame eccentricity and PVL severity was significant (q = 0.525, P < 0.0001). There was a 
relation between particular eccentric stent frame shapes and the site of PVL.
Conclusion 
Calcification of the aortic annulus is associated with a subsequent eccentric shape of the CoreValve pros-
thesis. This eccentric shape results in more PVL, with the localization of PVL related to the shape of stent 
frame eccentricity.
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INTRODUCTION
Paravalvular aortic leakage (PVL) after transcatheter aortic valve implantation (TAVI) is a complication 
with potentially severe consequences (1,2). In particular in a self-expandable system such as the Cor-
eValve System©, calcified valves may pose resistance to prosthesis deployment, resulting in an ellip-
soid-shaped valve stent and a higher incidence of PVL. Indeed, quantification of calcification by the Agat-
ston score was predictive for PVL in patients who underwent a CoreValve implantation (3-5). However, in 
CoreValve specific studies the relationships between the Agatston score and stent frame eccentricity and 
stent frame eccentricity vs. PVL severity and localization were not studied. Only for the balloon-expand-
able Edwards SAPIENTM prosthesis, data on the correlation between stent frame eccentricity and PVL 
were reported by one single centre (6,7). Unfortunately, discrepant findings were reported by the authors. 
No relation was seen when eccentricity was assessed by transoesophageal echocardiography(7) whereas 
a positive relation was seen when eccentricity was defined by computed tomography (CT) (6). This study 
sought to assess in a large single-centre consecutive CoreValve series the relation between the Agatston 
score and native annulus shape vs. stent frame eccentricity, and stent frame eccentricity and subsequent 
PVL as defined by Valve Academic Research Consortium (VARC-2) criteria (8). 
METHODS
Included in the study were 223 consecutive patients with severe aortic stenosis (AS) who underwent TAVI 
with a Medtronic CoreValve System VC from June 2006 to November 2012 and had pre-discharge trans-
thoracic echocardiography. 53% of the patients were male, with a median age of 81 (78–85) years. The 
median logistic euroSCORE was 13 (10–21). The mean 
aortic pressure gradient was 42 ±17mmHg, and the 
mean valve area was 0.7± 0.2 cm2. The TAVI implantation 
procedure in the Thoraxcenter is described in full detail 
elsewhere (9,10). 
Echocardiographic study 
At the time of hospital discharge, on average 6± 3 
days after TAVI, the patients were evaluated using an 
iE33 ultrasound system (Philips Medical System, Best, 
TheNetherlands) equipped with a S5-1 transthoracic 
transducer. The extent of PVL was assessed according to 
VARC-2 criteria (8). PVL was measured as a continuous 
value as well as a categorical value: less than 10% of the 
circumference was defined as mild, between 10% and 
30% as moderate, and more than 30% as severe PVL. The 
localization of PVL was assessed by dividing the stent 
circumference into twelve equal sectors according to a 
clock model. As seen in Figure 1, the native commissure 
Figure 1. PVL localization was assessed by di-
viding the stent circumference into twelve equal 
sectors according to a clock model. The native 
commissure between the right and left cusps is 
located in segments 1 to 3, the one between left 
and non-coronary cusps in segments 5 to 7, and 
the one between the right and the non-coronary 
cusps is located in segments 9 to 11. LCC, left 
commissural cusp; NCC, non commissural cusp; 
RCC, right commissural cusp.
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between the right and left cusps (RLC) is located in 
segments 1 to 3, the one between left and non-coro-
nary cusps (LNC) in segments 5 to 7, and the commis-
sure between the right and the non-coronary cusps 
(RNC) is located in segments 9 to 11. 
The minimum and maximum diameters of the stent 
were also recorded in the parasternal short axis view 
in a mid-to-late diastolic frame, at the same stent 
level where PVL was measured; stent inflow frame 
eccentricity was defined as a difference between the 
maximum and the minimum diameter larger than 
2mm. The non-eccentric stents were further labelled as 
truly circular, with identical minimum and maximum 
diameters, and near circular, with a difference between 
the diameters up to 2mm. The stents found to be 
eccentric were further divided in different categories 
following the orientation of the longest diameter in the 
short-axis view. As seen in Figure 2, the wide (W) shape 
was defined as horizontally orientated with the longest 
diameter between 67.5 and 112.5 degrees, the zero 
degree being on the upper part of the circumference; 
the height (H) shape as a vertically orientated longest 
diameter (between –22.5 and +22.5); the right (R) oblique shape with an upper right–lower left position 
(the longest diameter between 22.5 and 67.5 degrees); and the left (L) oblique shape with an upper left–
lower right position (between 112.5 and 157.5 degrees). Finally, the echocardiographic eccentricity index 
was defined as 100 x (1–(minimum stent frame diameter/maximum stent frame diameter)). 
CT study 
CT data were available in a subgroup of 162 (73%) patients. The assessment of the aortic annulus was 
performed using dual source CT (Somatom Definition, Siemens Medical Solutions, Forchheim, Germany). 
The pitch was adjusted to fit the heart rate. After a non-contrast scan, performed to obtain the Agatston 
calcification score, 50–60mL of VisipaqueVR 320 mg l/mL, (GE Health Care, Eindhoven, The Netherlands) 
was injected in an antecubital vein at a flow rate of 5.0mL/s followed by a second contrast bolus of 30–40 
at 3.0mL/s. The scan ranged from the top of the aortic arch to the diaphragm. 3D reconstructions in 
end-systole were then derived using a single-segmental reconstruction algorithm with slice thickness 
1.5mm and increment 0.4mm. The radiation doses ranged from 8 to 20 mSv depending on body habitus 
and table speed, the vast majority received radiation doses between 8 to 12 mSv. The shape of the native 
annulus was assessed by the eccentricity index, defined as 100 x (1–(minimum aortic annulus diameter/
maximum aortic annulus diameter) (11). 
Figure 2. Example of the different stent frame 
shapes. A=Circular, C=Wide (‘W’), D= Height (‘H’), 
E= Right oblique (‘R’), F= Left oblique (‘L’). In B, the 
definition of shapes is explained according to the 
orientation of the major axis of the stent frame.
165Calcium burden, stent frame eccentricity and paravalvular leakage after TAVI
PA
RT
 IV
Statistical analysis
All data were analysed using SPSS (IBM, version 20). Continuous variables were checked for normality 
of distribution via the Kolmogorov–Smirnov test and were expressed as mean (± standard deviation) or 
median (interquartile range). Categorical data is presented as frequency (percentage). Correlations were 
evaluated using the Spearman’s coefficient (q). Statistical differences between groups were assessed using 
the Mann–Whitney and Kruskal–Wallis tests for nonparametric data. 
RESULTS
Stent eccentricity
The distribution of the various stent in-
flow frame shapes at predischarge echo-
cardiography is reported in Table 1. Most 
of the stents were circular or near-circu-
lar (difference between minor and major 
axis of stent frame ≤2mm) (146; 65%). 
Among the non-circular ones, the W 
shape accounted for 24 cases (11%), the 
H shape for 11 (5%), the R shape for 25 
(11%), and the L shape for 17 (8%).
Relation between Agatston score and stent frame eccentricity
The mean Agatston score was 3345± 1870. As seen in Table 2, the values according to the shapes were 
for circular stents: 2919± 1505 with 3241± 1774 in true circular stents and 2776 ± 1357 in near circular 
ones. The values for eccentric stents were 4159 ± 2116; W shape: 4139 ± 2320, H shape: 4757± 2639, R 
shape: 4299± 2076, and L shape: 3500± 1870. The correlation between the Agatston score and the amount 
of eccentricity, calculated as the post-TAVI echocardiographic stent eccentricity index, was significant 
(q=0.241, P=0.003).
Shape             
category 
Patients Agatston score   VARC-2 score      
Pre-TAVI CT  
eccentricity 
index                  
Post-TAVI echo 
eccentricity 
index        
Circular 106 (65%) 2919 ± 1505 4% (±7%) 21% (± 6%) 4% (±2%)
True circular 33 (20%) 3241 ± 1774 1% (±5%) 20% (± 7%) 0% (by definition)
Near circular 73 (45%) 2776 ± 1357 5% (±8%) 21% (± 6%) 6% (±2%)
Non-circular 56 (35%) 4159 ± 2116* 16% (±16%)* 21% (± 6%) 17% (±6%)*
Wide 20 (12%) 4139 ± 2320* 14% (±14%)* 19% (± 7%) 17% (±5%)*
Height 9 (6%) 4757 ± 2639* 15% (±17%)* 19% (± 7%) 15% (±6%)*
Right 16 (10%) 4299 ± 2076* 23% (±19%)* 22% (± 5%) 18% (±6%)*
Left 11 (7%) 3500 ± 1.870* 11% (±9%)* 20% (± 7%) 15% (±6%)*
Table 2. Distribution of the CoreValve stent frame shape, Agatston score, and VARC-2 score in the 162 patients 
with both pre-TAVI CT scan and pre-discharge echocardiography. *P < 0.05 compared to the Circular group.
Shape category Patients    VARC-2 score    
P-value vs. 
circular 
shape
Circular 146 (65%) 4% (±7%)
Truly circular 43 1% (±5%)
Near-circular 103 5% (±8%)
Eccentric 77 (35%) 16% (±16%) <0.001
Wide 24 (11%) 14% (±14%) <0.001
Height 11 (5%) 15% (±17%) 0.05
Right 25 (11%) 23% (±19%) <0.001
Left 17 (8%) 11% (±9%) <0.01
Table 1. Distribution of the echocardiographic CoreValve stent frame 
shape and VARC-2 scores in all 223 patients. Data are displayed as 
number (percentage) and mean values (±SD).
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Relation between native aortic annulus eccentricity and subsequent stent frame eccentricity
As seen in Table 2, the CT-derived eccentricity index of the native aortic annulus was not different 
between the circular, near-circular, and eccentric shaped stent frames as seen at pre-discharge echocar-
diography, nor was there a difference between the different shape types. Also, the correlation between the 
CT-derived eccentricity index of the native aortic annulus and the echocardiographic eccentricity index 
of the implanted stent was extremely poor (q=–0.016, P= 0.845).
Paravalvular leakage
The median PVL extent along the stent circumference 
as suggested by VARC-2 score was 3% (0–11%). Para-
valvular leakage was absent in 91 cases (41%),mild in 
67 (30%), moderate in 51 (23%), and severe in 14 (6%) 
cases. The correlation between stent frame eccentricity 
and PVL severity (VARC-2 score) was significant (q = 
0.525, P <0.0001). As seen in Table 1, PVL was more often 
seen in non-circular stents than circular stents; the 
median VARC-2 value for circular was 0% (0–4%), while 
it was 12% (6–18%) for eccentric shapes (P <0.001). No 
significant differences in PVL extent were seen between 
particular stent frame shapes.
Relationship between stent eccentricity and loca-
tion of paravalvular leakage
Distribution of sectors positive for PVL for each stent 
shape is reported in Figure 3. The number of patients 
with evidence of PVL in the area of the defined native 
commissures is displayed in Table 3, according to the 
commissure localization previously defined in Figure 1. 
Compared to (near) circular stent frames PVL occurred 
more often at the RLC in W, R, and L-shaped stent 
frames (63%, 68%, and 65% vs. 26%, respectively; all P < 
0.05), at the LNC in W and R-shaped stent frames (50% 
and 64% vs. 16%; all P < 0.05), and at the RNC in the 
R-shaped stent frame only (28% vs. 7%; P< 0.05). Figure 4 
shows the PVL localization in two patients with W and 
R-shaped stent frames, respectively.
Figure 3. PVL distribution (percentage of 
patients with PVL seen in that specific hour) ac-
cording to the clock model for the different stent 
frame shapes.
Figure 4. PVL localization in two patients with-
Wand R shape, respectively. The W-shaped stent 
frame shows typically PVL in the upper and lower 
parts of the clock model and the R-shaped stent 
frame most typically shows PVL at the native 
commissure between the left and non-coronary 
cusps.
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Relationship between the CT-derived angle of the aortic annulus plane and stent eccentricity or 
paravalvular leakage 
No significant correlations were found between the CT-derived angle of the aortic annulus and stent 
frame eccentricity. Also, no significant correlations were found with PVL severity or PVL location.
DISCUSSION
The main findings of this study are (1) approximately one third of CoreValve stent frames show a clear 
asymmetric shape at predischarge echocardiography, (2) the pre-TAVI Agatston score correlates–in 
contrast to the eccentricity index of the native aortic annulus–to the extent of frame eccentricity, (3) PVL 
severity correlates to the eccentricity of the stent frame, and (4) the site of PVL was dependent on the 
shape of the stent frame.
The relationship between the amount of calcification of the native aortic annulus measured as the aortic 
root Agatston score and the degree of PVL after TAVI has been described before in multiple studies (3,12-
18) although in most of them PVL was not scored according to the current VARC-2 recommendations (8). 
In one study, the relation between the localization of calcium in the aortic annulus and the localization of 
PVL was also highlighted (13). However, the association between calcium score, stent frame eccentricity 
and subsequent PVL is not described in detail before.
For balloon-expandable devices it has been shown that consistent radial forces during the placement are 
developed, leading to a change in the structure of the aortic annulus which becomes less elliptic after 
the TAVI procedure (6,19,20). The CoreValve system instead only relies on the passive expansion of the 
nitinol structure to adhere to the aortic walls, and could be less effective in remodeling a calcified native 
valve, although it should be recognized that pre-dilatation in severely calcified aortic valves is often done. 
To our knowledge, no study has been published yet about the evaluation of the stent frame shape after 
the placement of a CoreValve prosthesis and the relation with PVL. One third of CoreValve stent frames 
showed an asymmetric shape at pre-discharge transthoracic echocardiography. Importantly, there was no 
relation between the native annulus shape and the eccentricity of the stent frame, so even in the self-ex-
pandable CoreValve device the native shapes seems to adapt to the prosthesis, rather than vice versa. On 
the other hand, the Agatston score correlated to the extent of stent frame eccentricity, so it is the calcium 
that defines the shape of the CoreValve prosthesis expansion. The eccentricity of the stent frame was 
strongly associated to the extent of PVL. According to the eccentricity, we defined several categories (pro-
found irregularities other than these were only rarely seen). In order of prevalence these were the R-shape, 
W-shape, L-shape, and H-shape. Interestingly, the localization of the PVL was influenced by the shape 
Shape category
Circular W H R L
Right-left commissure (1–3 h) 38/146 (26%)   15/24 (63%)* 5/11 (45%) 17/25 (68%)* 11/17 (65%)*
Left-non commissure (5–7 h) 24/146 (16%) 12/24 (50%)* 5/11 (45%) 16/25 (64%)* 8/17 (47%)
Right-non commissure (9–11 h) 10/146 (7%) 3/24 (13%) 1/11 (9%) 7/25 (28%)* 3/17 (18%)
Any commisure 62/146 (42%) 21/24 (88%)* 9/11 (82%)* 25/25 (100%)* 15/17 (88%)*
Table 3. Site of aortic leakage in the different stent frame shapes in all 223 patients. *P < 0.05 compared to the 
Circular group. Aortic leakage included all severity categories.
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of the stent frame. Leakage at the RLC was more often seen in W, R, and L-shaped stent frames, leakage 
at the commissure between the LNC was more often involved in W, R-shaped stent frames, and leakage 
at the RNC was more often seen only in R-shaped stent frames. This is not surprising, as the particular 
configuration of the L-shaped stent frames is likely to be not well adherent to the aortic wall in the right 
upper quadrant, where the RLC is located. In contrast, the R-shaped stent frame is most likely to show 
PVL at the other commissures. Of note, the R-shaped stent frames also showed, as compared to circular 
stents, more PVL in the RLC but the increase was only 2.5-fold compared to 4-fold increases in PVL at the 
other two commissures. Finally, the W-shaped stent frame is most likely to be not well adherent to the 
wall at the LNC commissure sectors in the inferior sectors.
Clinical implications
The randomized CHOICE trial demonstrated more PVL with the self-expanding CoreValve than with the 
balloon expandable SAPIEN XT prosthesis (21). In addition, devices with a sealing fabric may perform 
better in patients with more annular calcification. The mechanically expanded Lotus valve has repeatedly 
demonstrated extremely favourable moderate PVL rates. Therefore, balloon-expandable transcatheter 
heart valves with more radial power may be preferred over mechanically expanded valves in cases of 
heavy annular calcification. However, a definite recommendation should be based on direct comparison 
between different devices in a randomized fashion with a pre-specified analysis for calcium burden.
Limitations of the present study
The data about the stent frame eccentricity and shape could be affected by the limitations of two-dimen-
sional echocardiography since this technique is easily influenced by an incorrect scan plane or by subop-
timal image quality. In this respect, it should be acknowledged that three-dimensional echocardiography 
and in particular transoesophageal echocardiography would be a superior technique (7). However, this 
was at the time not considered feasible in patients as a routine screening technique for PVL. In particular, 
a scanning plan not perfectly perpendicular to a circular stent could give the illusion of a H-shaped stent 
frame, while it is unlikely to result in a false W, R, or L-shaped stent frame. This may also be the expla-
nation why the H shaped stent frames (that actually more often looked a little bit fuzzy) had the lowest 
prevalence of PVL and were not related to specific PVL localizations. Remarkably, however, the H-shape 
stent frame only accounted for the least number of cases in the present study. Conversely, it is possible to 
inadvertently ‘correct’ a real W-shaped stent frame to circular by choosing an oblique scan plan during 
image acquisition. The two-dimensional transthoracic echocardiographic defined stent shape should in 
the future be validated against a superior standard such as three-dimensional transoesophageal echocar-
diography or post-TAVI CT images. It would also be interesting to correlate stent frame eccentricity to 
other outcome parameters.
The direct effects of post-dilatation on PVL could not be assessed because in this study only the pre-dis-
charge echocardiograms were assessed. Final stent eccentricity in patients with and without postdilata-
tion was similar (data no reported).
Unfortunately, the CT software used in this study was not able to study the relation between the precise 
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site of calcium and subsequent stent frame shape (and thus PVL) (13).
CONCLUSIONS
Calcification of the aortic annulus is associated with a subsequent eccentric shape of the CoreValve pros-
thesis. This eccentric shape results in more PVL, with the localization of PVL related to the shape of stent 
frame eccentricity.
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ABSTRACT
Objectives
The aim of this post hoc analysis from the RESPOND (Repositionable Lotus Valve System–Post-Market 
Evaluation of Real World Clinical Outcomes) post-market study was to assess the final implantation 
depth on the contrast aortogram after Lotus valve (Boston Scientific, Marlborough, Massachusetts) 
transcatheter aortic valve replacement (TAVR) and to correlate with permanent pacemaker implantation 
(PPI) and paravalvular leak (PVL).
Background
Contrast aortography allows for the assessment of implantation depth and PVL during and after TAVR. 
Previous reports suggested an association between final device position and rates of PPI and PVL.
Methods
The RESPOND study was a prospective, open-label, single-arm study in 41 centers evaluating outcomes 
after Lotus TAVR in routine clinical practice. Aortograms were collected at the Erasmus Medical Center 
and analyzed by researchers who were blinded to clinical outcomes. The primary analysis correlated 
implantation depth with PPI and PVL and required aortograms in a coaxial projection. The relation 
between implantation depth and need for PPI was assessed by multivariate logistic regression, adjusting 
for pre-defined confounders. A secondary analysis compared PVL analysis by contrast aortography with 
transthoracic echocardiography (TTE) performed by the independent core laboratory.
Results
A total of 724 angiographic studies were included in this analysis. Mean Lotus implantation depth was 
6.67 ± 2.19 mm. The overall PPI rate was 35%. PPI rate was lower with shallow implants (<6.5 mm: 21%vs. 
$6.5 mm: 41%; p < 0.001). After adjustment for confounders, implantation depth independently predicted 
need for PPI (odds ratio per 1-mm increment in depth: 1.200; 95% confidence interval 1.091 to 1.319; p = 
0.002). More than trivial PVL was present in 23% by contrast aortography and in 8% by TTE. Implantation 
depth was not correlated with PVL by contrast aortography or TTE (p = 0.342 and p = 0.149, respectively). 
PVL grading by contrast aortography and TTE was concordant in 77%.
Conclusions
In this post hoc analysis of the RESPOND study PPI was highly correlated with implantation depth, 
whereas PVL was not. Higher Lotus implantation may reduce need for PPI.
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INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is recommended for symptomatic severe aortic stenosis 
in patients at elevated surgical risk (1–7). Multiple transcatheter heart valve (THV) designs are commer-
cially available (8). The Lotus valve (Boston Scientific, Marlborough, Massachusetts) is a mechanically 
expanding system and includes an adaptive seal. These features make it completely repositionable and 
retrievable for precise placement as well as minimizing paravalvular leak (PVL) (9,10). The RESPOND (Re-
positionable Lotus Valve System–Post-Market Evaluation of Real World Clinical Outcomes) study was a 
prospective post-market study including 1,014 patients from 41 centers and confirmed Lotus valve safety 
and efficacy with an 2.6% all-cause mortality and 2.2% disabling stroke rate at 30 days with more than 
mild PVL in 0.3% and permanent pacemaker implantation (PPI) undertaken in 30% of patients (11). TAVR 
in its current form no longer requires general anesthesia and relies mostly on fluoroscopic guidance. 
Operators use contrast aortography to determine the implantation depth, device position relative to the 
coronary ostia, and final PVL assessment. The aim of this post hoc analysis from the RESPOND study was 
to assess the final implantation depth on the contrast aortogram after Lotus TAVR and to correlate with 
need for PPI and PVL. 
METHODS
Study population and design
The design and outcomes of the RESPOND post-market study (NCT02031302) have been reported 
elsewhere (11). In brief, 1,014 patients with elevated operative risk were treated with Lotus TAVR and pro-
spectively enrolled. An independent core laboratory (Cardialysis, Rotterdam, the Netherlands) analyzed 
the transthoracic echocardiography (TTE).
Clinical events were reported through electronic clinical research forms using the latest Valve Academic 
Research Consortium-2 criteria (12); all events were monitored by a contract research organization, and 
an external independent medical reviewer adjudicated death and stroke. The final contrast aortograms 
after implantation of the Lotus valve were collected and transferred to the Erasmus Medical Center for 
centralized uniform and blinded analysis. All patients provided written informed consent for participa-
tion in the RESPOND study. The primary objective of this study was to correlate depth of Lotus implan-
tation with need for PPI and occurrence of more-than-trivial PVL by contrast aortography. A secondary 
analysis looked at the concordance of PVL grading between contrast aortography and pre-discharge TTE 
as assessed by the independent core laboratory.
Data quality
The current analysis used the as-treated population from the RESPOND study (n = 996) and excluded 132 
patients with a pacemaker before TAVR. Of the 864 patients without a pacemaker a final contrast aorto-
gram was not acquired in 140 patients, thus 724 cases were available for the final analysis.
For the PVL analysis contrast aortograms were submitted to the following quality check: 1) presence of 
sufficient contrast volume; 2) pigtail located >2 cm above the aortic annulus; and 3) no wire across the 
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Lotus valve. Of the 724 cases, 36 (5%) 
did not meet these criteria and were 
thus removed from the PVL analysis 
(Figure 1).
Previous reports suggested an error in 
measuring the implantation depth if 
the aortogram had been obtained in a 
noncoaxial projection (13). To address 
this matter, all participating centers 
were requested to perform a baseline 
and final aortogram in the same coaxial 
C-arm projection with the 3 coronary 
cusps aligned. Ultimately, 506 of 724 
(70%) aortograms were acquired using 
a coaxial projection. Only aortograms 
in coaxial projection were used for the 
primary implantation depth analysis.
Data analysis
Dedicated trained clinical research-
ers, who were blinded to clinical and 
echocardiographic results, analyzed all aortograms. Measurements were performed with Cardiovascular 
Angiographic Analysis System version 5.11.2 (Pie Medical Imaging, Maastricht, the Netherlands). Core 
measurements consisted of the final implantation depth at the noncoronary and left coronary cusps. 
The final implantation depth was considered as the average of the depth at the noncoronary cusp and 
left coronary cusp. Interobserver variability was evaluated using intraclass correlation coefficients in 10 
randomly chosen subjects. Depth differential of the Lotus valve was measured as the difference in implan-
tation depth at the noncoronary cusp and left coronary cusp. The degree of PVL was evaluated using the 
Sellers criteria (14) as follows: grade 1 (mild PVL), a limited amount of contrast enters the left ventricle 
during diastole resolving with each beat without reaching the apex of the left ventricle; grade 2 (moderate 
PVL), the contrast enters and fills the entire left ventricle up to the apex but the opacification remains 
less than in the ascending aorta; grade 3 (moderately severe PVL), complete left ventricular opacification 
with similar contrast density compared with the ascending aorta; and grade 4 (severe PVL), opacification 
of the entire left ventricle at a higher density than the ascending aorta. All TTE data were obtained from 
the independent core laboratory. PVL grading by TTE was according to Valve Academic Research Consor-
tium-2 criteria (12). 
Statistical analysis
Continuous data are presented as mean ± SD and categorical variables as counts and percentages. 
Categorical data were compared with the chi-square test for trend and Z-test for proportions. Due to 
Figure 1. Flowchart of data collection. * aortograms that were 
acquired in a coaxial projection were used for the primary analysis. 
Abbreviations: PPI = permanent pacemaker implantation; PVL = 
paravalvular leak; RESPOND = Repositionable Lotus Valve System 
– Post-Market Evaluation of Real World Clinical Outcomes; TTE = 
transthoracic echocardiography.
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missing site-reported left ventricular outflow tract (LVOT) dimensions by computed tomography and the 
derived oversizing relative to the LVOT (38% missing), multiple imputation was performed for comple-
tion of this single variable, assuming this variable was missing at random (15). Five imputation steps 
were performed, using the following predictor variables: age, sex, weight, height, history of heart failure, 
history of coronary artery disease, atrial fibrillation, EuroSCORE (European System for Cardiac Operative 
Risk Evaluation), pre-existent conduction disturbances, annulus diameter (area derived), pre-dilatation, 
repositioning, valve prosthesis size, implantation depth, and need for PPI. Logistic regression was applied 
to evaluate the association between implantation depth and PPI using a predefined multivariate model 
with inclusion of the following clinically suspected confounders: age, sex, body mass index, coronary 
artery disease, pre-existent conduction disturbances (i.e., first-degree atrioventricular block, right bundle 
branch block RBBB, left bundle branch block, left anterior fascicular block), repositioning, pre-dilatation, 
high enrolling centers (>50 patients enrolled), oversizing relative to the LVOT, and depth differential of 
the prosthesis. The p values from multivariate analysis were adjusted for multiple comparisons using the 
Bonferroni correction. When p values exceeded 1.0 after Bonferroni correction the p value was truncated 
at 1.0. Data analysis was performed in SPSS version 21 (SPSS Inc., Chicago, Illinois). A 2-sided p value of 
<0.05 was considered statistically significant.
RESULTS
A total of 724 patients within the RESPOND study 
were eligible for this post hoc analysis (Figure 1). 
Baseline demographics are listed in Table 1. Mean 
age was 81 ± 7 years and 46% were men. Mean 
Society of Thoracic Surgeons Predicted Risk of 
Mortality Score was 6.1±
7.0%. Coronary artery disease was present in 
54% of patients. A total of 36% had a history of 
congestive heart failure. Pre-existent conduction 
disturbances were present as follows: first-de-
gree atrioventricular block in 13%, left bundle 
branch block in 9%, RBBB in 6%, and left anterior 
fascicular block in 4%. Procedural characteristics 
are listed in Table 2. The 3 available Lotus valve 
sizes were equally distributed among patients: 23 
mm in 28% of patients, 25 mm in 40%, and 27 mm 
in 32%. Balloon pre-dilatation was performed in 
more than one-half of the patients (54%). Reposi-
tioning was attempted in one-third (32%).
Age, yrs 81 ± 7
Male 335 (46.0)
Body mass index, kg/m2 27 ± 8
Diabetes 201 (28.0)
Atrial fibrillation 217 (30.0)
Chronic obstructive pulmonary disease 109 (15.0)
Myocardial infarction 107 (15.0)
Coronary artery disease 391 (54.0)
Coronary artery bypass grafting 83 (11.0)
Percutaneous coronary intervention 213 (30)
Cerebrovascular accident 63 (9.0)
STS-PROM, % 6.1 ± 7
Porcelain aorta or hostile chest 42 (6.0)
Aortic valve area, cm2 0.74 ± 0.36
Mean aortic gradient, mm Hg 44 ± 18
First-degree atrioventricular block 93 (13.0)
Left bundle branch block 67 (9.0)
Right bundle branch block 44 (6.0)
Left anterior fascicular block 29 (4.0)
Left posterior fascicular block 3 (0.4)
Table 1. Baseline Characteristics (N = 724). Values are 
mean  SD and n (%). Abbreviations: STS-PROM = Society 
of Thoracic Surgeons Predicted Risk of Mortality.
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Clinical outcomes
All-cause death at 30 days occurred in 12 (1.7%) pa-
tients, which were all due to cardiovascular causes. 
At 30 days, clinical stroke had occurred in 20 (2.8%) 
patients, of which 14 (1.9%) were disabling strokes. 
PPI AND PVL. PPI was required in 254 (35%) pa-
tients. The primary causes for PPI were high-degree 
atrioventricular block (67%) and bradycardia (9%). 
In 23% of patients PPI was performed for other 
reasons (e.g., bifascicular block, second-degree 
atrioventricular block Mobitz I type). By contrast 
aortography, more than trivial PVL was present in 
164 (23%) patients: no PVL in 554 (77.2%) patients, 
mild PVL in 149 (20.8%) patients, moderate PVL 
in 14 (1.9%) patients, and moderate-to-severe PVL 
in 1 (0.1%) patient. By TTE, more than trivial PVL 
was present in 54 (7.9%) patients: none or trace in 
628 (92.1%) patients, mild in 53 (7.8%) patients, and 
moderate in 1 (0.1%) patient.
Implantation depth
The interobserver variability for measuring the im-
plantation depth was small (intraclass correlation 
coefficient 0.964; 95% confidence interval (CI) 0.858 
to 0.991). Final mean implantation depth below the 
aortic annulus (i.e., average of depth at the non-
coronary and left coronary cusp) was 6.67 ± 2.19 
mm. Implantation depth had a normal distribution 
(Figure 2).
Relation between implantation depth and PPI
PPI rates per implantation depth quartiles are list-
ed in Table 3. There was a clear trend toward higher 
PPI rates with deeper implants (p < 0.001).
Valve size
23 mm 202 (28)
25 mm 289 (40)
27 mm 233 (32)
Pre-dilatation 387 (54)
Post-dilatation 9 (1)
Repositioning 231 (32)
Oversizing relative to the LVOT, %
Overall 7 ± 8
23 mm 7 ± 8
25 mm 8 ± 7
27 mm 7 ± 8
Depth differential, mm* -1.24 ± 3.05
Depth differential
None (<2 mm) 358 (49)
Prosthesis at NCC >2 mm lower 281 (39)
Prosthesis at LCC >2 mm lower 85 (12)
Table 2. Procedural characteristics (N=724). Values are 
n (%) or mean  SD. *Depth differential depicts the diffe-
rence between implantation depth at the noncoronary 
cusp and left coronary cusp. Abbreviations: LVOT = left 
ventricular outflow tract.
Figure 2. Histogram of implantation depth distributi-
on over the entire cohort. The implantation depth (i.e., 
average of depth at the noncoronary and left coronary 
cusp) was normally distributed with a mean at 6.67  
2.19 mm below the annulus.
Implantation Depth Quartile
P-value  for Trend<5.0 mm 
 (n = 104) 
 5.0–6.5 mm 
(n = 138)        
 6.5–8.0 mm
 (n = 127)                       
≥8.0 mm 
(n = 135)   
26 (25) 26 (19) * 46 (36) † 61 (45) † <0.001
Table 3. PPI rates per implantation depth quartiles (coaxial projections only). Values are n (%). *No significant 
ifference compared to previous quartile at a 5% confidence level. †Significant difference compared to previous 
quartile at a 5% confidence level. Abbreviations: PPI = permanent pacemaker implantation.
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Deeper implantation depth was associated 
with PPI by univariate analysis (odds ratio 
(OR) per 1-mm increment: 1.206; 95% CI 
1.102 to 1.319; p < 0.001) in the primary 
analysis (Figure 3). When patients with 
non-coaxial projections were also included 
the implantation depth was still associated 
with an increased risk of PPI (OR: 1.172; 
95% CI 1.091 to 1.258; p < 0.001) (Supple-
mental Figure 1).
After adjustment for predefined potential 
confounders, deeper implantation re-
mained an independent predictor for PPI 
requirement (OR per 1-mm increment: 
1.200; 95% CI 1.091 to 1.319; adjusted p = 
0.002) (Figure 4). Additionally, reposition-
ing also independently predicted PPI (OR: 
1.927; 95% CI 1.261 to 2.945; adjusted p 
= 0.028). When patients with noncoaxial 
projections were also included both im-
plantation depth (OR: 1.157; 95% CI 1.074 to  
1.247; p = 0.004) and pre-ex-
istent RBBB (OR: 3.283; 95% 
CI 1.654 to 6.518; p = 0.014) 
independently predicted PPI 
(Supplemental Figure 2).
Mean oversizing was 7 ± 8% 
and did not differ between 
valve sizes (Table 2). Over-
sizing relative to the LVOT 
had no impact on PPI (p for 
trend = 0.195) (Supplemental 
Table 1).
Relation between implanta-
tion depth and PVL
There was no correlation 
between implantation depth 
and presence of more than 
trivial PVL by TTE (p for trend = 0.149) or contrast aortography (p for trend = 0.342) (Figure 5).
Figure 3. Relation Between Implantation Depth and PPI by 
Univariate Logistic Regression (Limited to Patients in Which 
Contrast Aortography Was Performed in a Coaxial Projection). 
The gray dashed lines indicate the median and interquartile 
range of implantation depth in the overall cohort. Abbrevia-
tions: CI = confidence interval; PPI = permanent pacemaker 
implantation; OR = odds ratio.
Figure 4. Forest plot of logistic regression analysis for the primary endpoint, 
PPI (limited to patients in chich contrast aortography was performed in a 
coaxial projection). Only repositioning and implantation depth were significant 
predictors for permanent pacemaker implantation (PPI) in this model. The p 
values were adjusted for multiple comparisons using the Bonferroni correcti-
on. *Odds ratios illustrate the increase in odds per 1-point increase on a con-
tinuous scale. †Depth differential depicts the difference between implantation 
depth at the noncoronary cusp and left coronary cusp. Abbreviations: AV1B = 
first-degree atrioventricular block; LAFB = left anterior fascicular block; LBBB 
= left bundle branch block; LVOT = left ventricular outflow tract; RBBB = right 
bundle branch block.
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Concordance of PVL grading between imaging strategies
PVL grading by contrast aortography and TTE 
were concordant in 77% of patients (Figure 6). 
A total of 19% of patients had more-than-trivial 
PVL by contrast aortography but not by TTE at 
discharge. Conversely, 4% of patients had more 
than trivial PVL by TTE at discharge and not by 
contrast aortography. In all patients with moder-
ate PVL by contrast aortography (n = 14) the PVL 
was either mild (n = 7) or none/trace (n = 7) by 
TTE. One patient had moderate-to-severe PVL by 
contrast aortography and died during the index 
procedure without echocardiographic analysis. 
Moderate PVL by TTE was present in 1 patient. 
Interestingly, this patient had no visible PVL by 
aortography.
DISCUSSION
This post hoc analysis from the RESPOND study reports advanced insights from contrast aortography af-
ter Lotus TAVR. First, meticulous contrast aortography technique following Lotus TAVR is a prerequisite 
for adequate evaluation of PVL and Lotus depth of implantation. Second, deeper Lotus implants lead to 
more frequent PPI. Third, contrast aortography allows for a proper PVL assessment and seems more sen-
sitive than TTE. Interestingly, all patients with more than mild PVL by contrast aortography (Sellers grade 
≥2) had either no or trivial or mild PVL by TTE. Contrast aortography thus offers important insights for 
Lotus TAVR guidance, including prediction of PPI and acceptable PVL evaluation in conscious patients.
Figure 5. PVL (more than trivial) per implantation depth quartile (limited 
to patients in which contrast aortography was performed in a coaxial pro-
jection). Implantation depth was not related to PVL on TTE or aortogram.
Figure 6. Concordance of more-than-trivial PVL bet-
ween contrast aortography and TTE. In the vast majo-
rity of patients (77%) PVL as detected on aortography 
was also present on TTE. In a considerable proportion 
of patients (19%) PVL was detected on aortography, 
but not on TTE. The reverse occurred seldom (4%).
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TAVR is increasingly executed under local anesthesia with or without conscious sedation with favour-
able results (16,17). The obvious advantages of local anesthesia include patient comfort, hemodynamic 
stability, rapid detection of complications (stroke, vascular complications), faster recovery, and shorter 
intensive care and hospital stay (18). Transesophageal echocardiographic guidance is challenging with 
TAVR under local anesthesia. Therefore, valve positioning and evaluation of PVL predominantly relies on 
fluoroscopic guidance and contrast aortography.
Pre-procedural planning by 3-dimensional multi-slice computed tomography scanning and new TAVR 
designs improved transcatheter valve sizing and positioning (8) with excellent clinical outcome and low 
PVL rates (11,19,20). Two randomized trials have established TAVR feasibility in patients at intermediate 
operative risk (5,6), and challenging anatomies (21). However, high PPI rates remain a matter of concern 
with new generation devices: ≈13% with the SAPIEN 3 (Edwards Lifesciences, Irvine, California) (20), 
≈17% with the Evolut R (Medtronic, Minneapolis, Minnesota) (19), and 30% with the Lotus (10,11).
Conduction disorders following TAVR may occur because of the close proximity of the atrioventricular 
node, bundle of His, and left bundle branch to the native aortic annulus (22,23). It seems plausible that 
deeper implants of a THV result in more interaction with the conduction system that could lead to more 
PPI.
Several studies reported a correlation between CoreValve (Medtronic) implantation depth and PPI 
(24–26). Also with balloon-expandable THVs there seems to be a relation between implantation depth 
and persistent conduction disturbances or PPI (27–29). Currently, aiming for higher implants is recom-
mended in order to reduce the need for PPI.
A subanalysis from the randomized REPRISE-II (Repositionable Percutaneous Replacement of Stenotic 
Aortic Valve Through Implantation of Lotus Valve System II) study demonstrated only a weak (nonsignif-
icant) correlation between implantation depth and need for PPI with the repositionable Lotus valve (30). 
The fact that the present post hoc analysis from the RESPOND study did demonstrate a strong correlation 
is most plausibly due to the methodological setup of the study. It represents the largest study to date with 
systematic measurements of implantation depth and outnumbers the REPRISE-II study or any other 
study with different devices for that matter. Furthermore, by dichotomizing the implantation depth (i.e., 
≤5 mm vs. >5 mm), the REPRISE-II study consequently lost statistical power to demonstrate the correla-
tion with PPI (30). The present study reveals a linear relation between Lotus implantation depth and PPI 
requirement after correction for multiple confounders. The mean implantation depth of 6.67 mm leaves 
room for improvement by device alterations on the one hand and operator awareness on the other hand. 
Depth Guard (Boston Scientific, Marlborough, Massachusetts) is a recent alteration that may improve ac-
curacy in Lotus positioning enabling higher implants (Figure 7). Ongoing studies will determine whether 
PPI rates will fall with Depth Guard. 
In this study, repositioning predicted PPI as well. Lotus radial strength and interactions at multiple differ-
ent locations within the LVOT during repositioning may promote conduction disorders.
With the self-expanding CoreValve, PVL was associated with too high or too low implants (31–34). In 
the REPRISE-II trial, high Lotus implants were associated with mild or moderate PVL (35). In contrast, 
our study suggests high Lotus implants are not associated with PVL. The adaptive seal of the outer skirt 
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seems to cover periprosthetic spaces and adequately prevents PVL. Also the latest balloon expandable 
and self-expanding THV have a sealing fabric to help reduce PVL (8).
Periprocedural PVL assessment is essential for TAVR success. Current trends of performing TAVR under 
local anesthesia and mild or no sedation make transesophageal echocardiography less suitable for PVL 
assessment. Many centers now rely more on contrast aortography, TTE, and hemodynamic assessment. 
The present study showed an overall 77% concordance between the per-procedural semi-quantitative 
Sellers grading by contrast aortography and core laboratory–evaluated pre-discharge TTE. Interestingly, 
contrast aortography seemed more sensitive to detect PVL because in 19% PVL was detected by aortog-
raphy but not by pre-discharge TTE, though it is possible that this difference might be at least partially 
explained by improvement in PVL between the time of the aortogram and echocardiography. This signal 
for a higher sensitivity for PVL detection by immediate aortography as compared with pre-discharge TTE 
was also observed in the randomized CHOICE (Comparison of Transcatheter Heart Valves in High Risk 
Patients With Severe Aortic Stenosis) trial (36). Both modalities, contrast aortography and TTE, have 
their inherent pitfalls in the detection of PVL (37). First, contrast aortography is performed during the 
procedure, whereas TTE is performed several days thereafter. In many centers TAVR still occurs under 
general anesthesia, which by itself affects hemodynamics. Also, PVL might dissolve over days due to con-
tinued frame expansion and settling of the sealing skirt.
Second, PVL grading by TTE may suffer from artifacts such as acoustic shadowing of the stented frame 
and merging jets from multiple directions. With contrast aortography, power injection too close to the 
bioprosthesis may induce PVL or overlapping anatomical entities such as the spine or the descending 
thoracic aorta may influence the interpretation of the aortogram (38,39). New software tools, such as 
video-densitometric aortography, may further improve the reliability and reproducibility of contrast 
aortography (39,40).
Figure 7. Lotus Depth Guard technology. (A) The current-generation Lotus valve (Boston Scientific, Marlborough, 
Massachusetts) results in deep left ventricular outflow tract (LVOT) interaction due to the foreshortening from 
both ends that occurs during locking of the valve. (B) The next-generation Lotus valve with Depth Guard techno-
logy involves foreshortening of the stent frame from the top down during unsheathing. This results in a less deep 
protrusion of the distal edge of the stent frame into the LVOT. Consequently, LVOT protrusion with Depth Guard is 
predictable and less pronounced resulting in less interaction with the LVOT. Courtesy of Boston Scientific Inc.
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Study limitations
This subanalysis of the RESPOND post-market study represents the largest cohort to evaluate contrast 
aortography after TAVR. However, the following limitations should be acknowledged. Although data 
collection and validation was rigorous and the population size was large, the observational design of this 
post hoc analysis must be acknowledged. Therefore, our findings may require confirmation by further 
study.
Acquisition of a post-implantation aortogram is part of the default workflow of a Lotus TAVR. Never-
theless, in 1 of 6 patients this aortogram was not available for final analysis due to logistical reasons. 
Aortograms were executed by the local TAVR teams according to local standards. Aortogram quality and 
coaxiality affect device implantation depth analysis. Despite study recommendations 30% of the aor-
tograms were obtained in a noncoaxial projection and 2% were of insufficient quality for accurate PVL 
grading. Also, the decision to proceed with PPI was per treating physician’s discretion.
Even with more shallow implants PPI rate was relatively high after Lotus implantation and suggests im-
proving the implantation depth would only partly solve the pacemaker issue with this device. 
Finally, we compared procedural contrast aortography with pre-discharge TTE. PVL may have changed 
within this time window and this may have impacted the comparison between the 2 modalities. Contrast 
aortography suffers from inherent limitations such as challenging determination of PVL mechanism and 
location. Also, it requires potentially harmful administration of intravascular contrast, especially in case 
of repeated aortograms. Nevertheless, apart from aortic regurgitation assessment aortography is essential 
in contemporary TAVR practice to determine coronary patency and device position.
CONCLUSIONS
In this post hoc analysis of the RESPOND study PPI was highly correlated with Lotus implantation depth, 
whereas PVL was not. Higher Lotus implantation may reduce need for PPI.
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SUPPLEMENTAL MATERIAL
Supplemental figure 1. Relation between implantation depth and PPI by univariate logistic re-
gression in the overall cohort. The grey dashed lines indicate the median and interquartile range 
of implantation depth in the overall cohort.
Supplemental figure 2. Forest plot of logistic regression analysis for the primary endpoint PPI 
in the overall cohort. Only pre-existent RBBB and implantation depth were significant predictors 
for PPI in this model. P-values were adjusted for multiple corrections using the Bonferroni cor-
rection. *Odds ratios illustrate the increase in odds per 1 point increase on a continuous scale. 
† depth differentiation depicts the difference between implantation depth at the noncoronary 
cusp and left coronary cusp. Abbreviations: AV1B: First degree atrioventricular block, LAFB: left 
anterior fascicular block, LBBB: left bundle branch block,LVOT: left ventricular outflow tract, 
RBBB: Right bundle branch block. 
Oversizing % quartiles
P-value for trend
< 3% (n=85) 3-7% (n=86) 7-11% (n=85) ≥ 11% (n=87)
23 (26%) 31 (36%) 34 (40%) 24  (28%) 0.195
Supplemental table 1. PPI rates per oversizing % quartiles (coaxial projections only). There was no trend towards 
higher PPI rates with more oversizing.
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ABSTRACT
Background
Left ventricular (LV) systolic dysfunction and moderate aortic stenosis (AS) are more frequent with ad-
vancing age and often coexist. Afterload reduction is the mainstay of pharmacological treatment of heart 
failure (HF). Aortic valve replacement (AVR) is only formally indicated for symptomatic severe AS.
Objectives
This study sought to determine the clinical outcome of patients with concomitant moderate AS and LV 
systolic dysfunction.
Methods
Echocardiographic and clinical data of patients with moderate AS and LV systolic dysfunction between 
2010 and 2015 from 4 large academic institutions were retrospectively analyzed. Moderate AS was defined 
as aortic valve area between 1.0 and 1.5 cm2 and LV systolic dysfunction defined as LV ejection fraction 
<50%. The primary endpoint was a composite of all-cause death, AVR, and HF hospitalization. 
Results
A total of 305 patients (mean age 73 ± 11 years; 75% male) were included. The majority were symptomatic 
at the time of index echocardiogram (New York Heart Association (NYHA) functional class II: 42%; NYHA 
functional class III: 28%; and NYHA functional class IV: 4%). Ischemic heart disease was present in 72% 
of patients. At 4-year follow-up, the primary composite endpoint occurred in 61%. The main predictors 
for the primary endpoint were male sex (p = 0.022), NYHA functional class III or IV (p < 0.001), and peak 
aortic jet velocity (p < 0.001). The rate of the composite of all-cause death or HF hospitalization was 48%, 
rate of all-cause death was 36%, and rate of HF hospitalization was 27%. AVR occurred in 24% of patients. 
Conclusions
Patients with concomitant moderate AS and LV systolic dysfunction are at high risk for clinical events. 
Further studies are needed to determine if earlier AVR in these patients might improve clinical outcome.
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INTRODUCTION
Heart failure (HF) affects up to 15% of the elderly population older than age 70 years (1,2). These patients 
still face a grim prognosis, with 1- and 5-year mortality rates of approximately 20% and 50%, respectively 
(3,4). After hospital admission for HF, the 1-year rehospitalization or mortality rate is as high as 20% to 
80% (5). Pharmacological management of HF includes beta-blockers and modulation of the renin-angio-
tensin-aldosterone system to reduce afterload (1,2). Degenerative aortic stenosis (AS) is a common valve 
disease affecting 2% to 4% of patients older than age 65 years (6,7); therefore, it often coexists with left 
ventricular (LV) systolic dysfunction. AS gradually progresses, with an annual reduction in aortic valve 
area (AVA) of ≈0.1 cm2 (8,9), and may contribute to LV systolic dysfunction through afterload mismatch 
(10). Mortality with severe AS approximates 50% after 2 years of follow-up after symptoms occur or LV 
systolic dysfunction is present (11). Aortic valve replacement (AVR) is currently indicated for patients 
with symptomatic, severe AS (12,13), but not for moderate AS. Life expectancy in patients with moderate 
AS (8,14–18) may be reduced, especially in combination with coronary artery disease and LV systolic dys-
function (14). The aim of the present study was to evaluate the clinical outcome of patients with moderate 
AS and LV systolic dysfunction in terms of death, AVR, and hospital admissions for HF.
METHODS
The echocardiography databases from 4 academic centers in the United States, Canada, and the Neth-
erlands, between January 2010 and December 2015, were screened for patientswithmoderate AS and 
LV systolic dysfunction. Moderate AS was defined as AVA >1.0 and <1.5 cm2 and peak aortic jet velocity 
(Vmax) >2 and <4 m/s at rest or after dobutamine stress echocardiography (DSE). LV systolic dysfunction 
was defined by a left ventricular ejection fraction (LVEF) <50%. The AVA was calculated using the conti-
nuity equation, and LVEF was determined by the biplane Simpson’s method (19,20). Patients with AVA 
<1 cm2 suspected of having pseudo-severe AS were only eligible for this study when DSE revealed an AVA 
>1 cm2. Exclusion criteria were prior major aortic surgery, prior surgical aortic valve replacement (SAVR) 
or transcatheter aortic valve replacement (TAVR), hypertrophic or noncompaction cardiomyopathy, and 
congenital heart disease (i.e., unicuspid or bicuspid aortic valve disease determined unequivocally by 
transthoracic echocardiography). Patient demographics and clinical follow-up information were collect-
ed from hospital records or requested from treating physicians and referring centers. Survival status was 
obtained from the respective National Population Registries whenever possible. In the United States, 
survival status was determined through hospital records and obituaries. The study was carried out under 
the approval of the Erasmus Medical Center Institutional Review Board.
Study endpoints
The primary endpoint of the study was a composite of all-cause death, AVR (i.e., SAVR or TAVR), and 
HF hospitalization. If the patient was admitted for HF at the time of the index echocardiogram, the first 
event thereafter was considered an endpoint. Secondary endpoints included the composite of death and 
rehospitalization as well as each individual component of the primary composite endpoint.
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Statistical analysis
Continuous data are presented as mean ± SD or confidence intervals (CIs) when applicable, or median 
and interquartile range (IQR) depending on distribution. Distribution of data was checked with histo-
grams and the Shapiro-Wilk test. Categorical variables were compared with the chi-square test for trend. 
Continuous variables at different time points were compared using the paired Student t test. Cumulative 
incidence functions of the pre-defined composite endpoint—death, AVR, and HF hospitalization—were 
determined using the Kaplan-Meier method, with date of the index echocardiogram as initial time of fol-
low-up (t = 0). Cumulative incidences were evaluated per year of follow-up to determine trends in timing 
of occurrence. Survival analyses for the primary endpoint were stratified for LVEF, New York Heart Asso-
ciation (NYHA) functional class, and HF admission. To determine the cumulative incidence function in 
patients admitted for HF, the admission date was computed as initial time of follow-up (t = 0). A log-rank 
test was applied to compare between-group differences. Univariate and multivariate Cox proportional 
hazard regression analyses were performed to identify independent predictors of the primary composite 
endpoint. Cox regression was performed in 
a 2-step hierarchical fashion to account for 
potential variation in outcome between in-
stitutions. A p value < 0.20 in the univariate 
model was used as an entry criterion for 
the multivariate model.
Individual components of the primary 
endpoint were analyzed using the cumula-
tive incidence competing risk method, ac-
counting for death and AVR as competing 
risks (21,22). Data analysis was performed 
using SPSS version 21 (IBM, Armonk, New 
York). A 2-sided, p value < 0.05 was consid-
ered statistically significant.
RESULTS
The study included 305 patients with baseline echocardiograms between January 2010 and December 
2015. Baseline characteristics are listed in Table 1. The mean age was 73 ± 11 years, and 75% were male. 
The majority had coronary artery disease, with prior revascularization by percutaneous coronary inter-
vention in 36% and coronary artery bypass grafting (CABG) in 28%. One-third (34%) had NYHA functional 
class III or IV symptoms at baseline. A total of 23 patients (7.5%) were admitted to the hospital at the time 
of the index echocardiogram. In terms of baseline therapy, nearly three-quarters were taking beta-block-
ing agents, and one-half angiotensin-converting enzyme inhibitors; fewer had angiotensin receptor 
blockers or mineralocorticoid receptor antagonists in their regimens (Table 2). Overall, 13% of patients 
received a regimen of beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor 
blockers, and mineralocorticoid receptor antagonists. Cardiac resynchronization therapy was present in 
13% of patients.
Figure 1. Study flowchart. In total, 305 patients were identified 
as having moderate aortic stenosis (AS) and left ventricular (LV) 
systolic dysfunction by pre-defined criteria. After 4 years of fol-
low-up, 61% of patients reached the primary composite endpoint 
of all-cause death, aortic valve replacement (AVR), or heart failure 
(HF) hospitalization. Availability of clinical data decreased as the 
follow-up time increased due to loss to follow-up. A follow-up 
echocardiography had been obtained in 56% of the patients.
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Index echocardiographic parameters are listed in Supplemental Table 1. The mean LVEF was 38 ± 9%; 
AVA 1.24 ± 0.16 cm2; indexed aortic valve area (AVAi) (AVA divided by body surface area (BSA)) 0.64 ± 0.12 
cm2/m2; Vmax 2.5 ± 0.4 m/s; peak transaortic gradient 26 ± 8 mm Hg; and mean transaortic gradient 14 ± 
4 mm Hg. The majority had a mean transaortic gradient <20 mm Hg (81%) or Vmax <3.0 m/s (84%). DSE 
was performed in 11% of patients to exclude severe AS and confirm moderate AS. Concerning AVAi, 56% 
of patients had an AVAi 0.6 to 0.9 cm2/m2 versus 33% with AVAi <0.6 cm2/m2. One-fifth of patients with 
N=305
Demographics
Age (years) 73 ± 11
Male gender 229 (75%)
Diabetes 116 (38%)
Hypertension 225 (74%)
Dyslipidemia 217 (71%)
Coronary artery disease 219 (72%)
Prior myocardial infarction 159 (52%)
Prior PCI 109 (36%)
Prior CABG 86 (28%)
Chronic lung disease 75 (25%)
Revascularization 155 (51%)
Creatinin level (mmol/L) 109 ± 73
eGFR in (ml/min) 61 ± 20
Ischemic cardiomyopathy 140 (48%)
Smoking 63 (22%)
Peripheral arterial disease 60 (20%)
Prior stroke 43 (14%)
NYHA-class I 79 (26%)
II 129 (42%)
III 86 (28%)
IV 12 (4%)
Index-echocardiography
LVEF (%)) 38 ± 9
AVA (cm2) 1.24 ± 0.16
Vmax (m/s) 2.5 ± 0.4
PG (mmHg) 27 ± 9
MG (mmHg) 15 ± 5
Table 1. Baseline characteristics. Values are 
mean  SD or n (%)). *Body mass index ≥30 kg/
m2. Abbreviations: AVA = aortic valve area; 
CABG = coronary artery bypass grafting; 
eGFR = estimated glomerular filtration rate; 
LVEF = left ventricular ejection fraction; 
NYHA = New York Heart Association; PCI = 
percutaneous coronary intervention; Vmax = 
peak aortic jet velocity.
Cardiac resynchronization therapy 38 (13%)
Medication use 
Beta-blocker 216 (73%)
ACE-i 143 (48%)
ARB 83 (28%)
MRA 62 (21%)
Combined Beta-blocker (ACE-i/ARB and MRA 39 (13%)
Other diuretic 194 (65%)
Digoxin 19 (9%)
Nitrate 81 (38%)
Calcium antagonist 99 (34%)
Statin 223 (75%)
Acetylsalicylic Acid 196 (66%)
OAC 129 (43%)
P2Y12 receptor inhibitor 71 (24%)
Table 2. Therapy at time of index echocardiography. Values are 
n (%)). Abbreviations: ACE-i = angiotensin-converting enzyme 
inhibitor; ARB = angiotensin receptor blocker; MRA = mineralo-
corticoid receptor antagonist.
Figure 2. Incidence of the composite primary endpoint. Cu-
mulative incidence increased to 61% at 4-year follow-up, with 
the steepest increase during the first year following the index 
echocardiogram. The findings implicated that this population 
faces a high clinical event rate.
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AVAi 0.6 to 0.9 cm2/m2 presented with a body mass index >30 kg/m2 versus 50% of patients with AVAi <0.6 
cm2/m2.
Primary endpoint
Follow-up data were available for 80% of patients be-
yond 1 year after the index echocardiogram, for 67% 
beyond 2 years, and for 36% beyond 3 years (Figure 
1). The median follow-up time was 638 days (IQR 280 
to 1,137 days). At 4-year follow-up, the event rate for 
the primary composite endpoint was 61% (95% CI 
54.38% to 67.78%) (Figure 2). The primary composite 
endpoint appeared to occur predominantly in the 
first year after the index echocardiogram compared 
with the years thereafter (Figure 3). The event rate 
was higher in patients with HF admission at time of 
the index echocardiogram compared with the over-
all cohort (log-rank p < 0.001) (Figure 4).
The univariate analysis is presented in Supplemental 
Figure 1. Male sex (hazard ratio (HR): 1.75; 95% CI 1.16 to 2.64; p = 0.008), diabetes (HR: 1.51; 95% CI 1.09 
to 2.10; p = 0.014); chronic lung disease (HR: 1.59; 95% CI 1.11 to 2.29; p = 0.012), NYHA functional class 
III or IV (HR: 2.86; 95% CI 1.70 to 4.24; p < 0.001), and Vmax (HR: 2.24 per 1 m/s increment; 95% CI 1.47 to 
3.42;   p < 0.001) emerged as main predictors for the composite primary endpoint by multivariate analysis 
(Figure 5). Patients with baseline NYHA functional class III or IV symptoms had a 4-year event rate of 84% 
(95% CI 76.92% to 89.21%), compared with 54% for NYHA functional class II (95% CI 41.65% to 64.81%; 
log-rank p < 0.001) and 45% for NYHA functional class I (95% CI 25.77% to 61.90%; log-rank p < 0.001) (Fig-
ure 6). There was no statistically significant difference in event rate for patients with an LVEF ≤35% com-
pared with patients with an LVEF >35% (4-year follow-up: 71% vs. 55%; log-rank p = 0.092) (Supplemental 
Figure 2). When we divided the study 
population in tertiles based on AVAi, we 
could not detect any difference in event 
rate (log-rank p = 0.107) (Supplemental 
Figure 3). The event rates were similar 
among the 4 individual institutions (log-
rank p = 0.515) (Supplemental Figure 4).
At 4-year follow-up, the rate of the 
composite of all-cause death or HF hos-
pitalization was 48% (95% CI 40.65% to 
56.61%) (Figure 7A), all-cause death was 
36% (95% CI 28.68% to 44.80%) (Figure 
7B), and cumulative HF hospitalization 
Figure 3. Primary composite endpoint at yearly in-
tervals. According to the cumulative incidence curve 
per year of follow-up for all-cause death, AVR, or HF 
hospitalization, the event rate is highest in the first 
year after diagnosis.
Figure 4. Composity primary endpoint stratified by HF hospita-
lization. During the first 2 years of follow-up, patients who were 
hospitalized at time of index echocardiogram appeared to be more 
prone to clinical events than those who were not hospitalized at 
that time. (For patients admitted for HF, date of admission is t = 0).
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rate was 27% (95% CI 20.32% to 35.67%) (Figure 
7C). New hospital admissions for HF occurred 
in 43% of patients who were admitted for HF at 
time of index echocardiogram (n = 23) versus 
4% in patients who were not admitted for HF 
at time of index echocardiogram (n = 282) (p < 
0.001). The rate of AVR was 24% (95% CI 18.96% 
to 31.44%) (Figure 7D), including SAVR in 63% 
and TAVR in 37%. The majority of SAVRs did not 
involve simultaneous CABG (31 of 37; 84%). The 
median time to SAVR or TAVR was 133 days (IQR 
22 to 543 days).
Echocardiography at follow-up
More than one-half of the patients (172 of 305; 56%) underwent a follow-up echocardiogram before the 
study end date. The median time between the index echocardiogram and follow-up echocardiogram was 
541 days (IQR 337 to 890 days) and 467 days (IQR 315 to 937 days) for patients who were medically treated 
and underwent AVR, respectively. During follow-up, AVA decreased on average from 1.24 ± 0.16 cm2 to 
1.14 ± 0.25 cm2 (p < 0.001) in patients who were medically treated and from 1.23 ± 0.14 cm2 to 1.00 ± 0.22 
cm2 (p = 0.004) in patients who underwent subsequent AVR. The evolution of echocardiographic parame-
ters is displayed in Supplemental Table 1.
Figure 5. Multivariate cox regression analysis. A 2-step hierarchical multivariate Cox regression 
model was conducted to evaluate predictors for the primary composite endpoint; the purpose of 
the hierarchical structure was to account for variation between institutions. Variables were selec-
ted if they met the entry criterion in univariate regression. *Reference category.
Figure 6. Composite primary endpoint stratified by 
NYHA functional class. Patients in NYHA functional class 
III or IV had a worse prognosis compared with patients in 
lower NYHA functional classes.
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DISCUSSION
This longitudinal multicenter cohort study reported the clinical outcome of consecutive patients with 
moderate AS and LV systolic dysfunction. The main findings can be summarized as follows: 1) the com-
posite primary endpoint of all-cause death, AVR, or HF hospitalization occurred in 61% of patients at 
4-year follow-up; 2) male sex, NYHA functional class III or IV, and higher transaortic Vmax on the index 
echocardiogram were independent predictors of events; 3) most events occurred during the first year 
after the diagnosis; and 4) patients admitted for HF at time of inclusion were particularly vulnerable and 
had event rates of 50% and 60% at 1 and 2 years, respectively (Figure 8).
The combination of moderate AS and LV systolic dysfunction in the general population is likely under-re-
ported and is expected to grow with an aging population. A large population-based study concluded that 
the prevalence of moderate or severe AS in patients ≥75 years of age was as high as 2.8% (23). The inverse 
relationship between LV wall stress and ejection fraction may at least partly explain LV systolic dysfunc-
Figure 7. Competing risk curves for individual endpoints. A cumulative incidence competing risk analysis 
was conducted to evaluate the cumulative incidence of the individual components of the primary endpoint: 
(A) all-cause death and HF hospitalization; (B) all-cause death; (C) HF hospitalization; and (D) AVR. The 
individual endpoints were all common, confirming that the occurrence of clinical events in patients with 
moderate AS and LV systolic dysfunction is multifactorial.
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tion (24), and one-quarter of all patients with AS have LV systolic dysfunction (25).
AS progression in our study was illustrated by an annual AVA decrease by ± 0.10 cm2 to   ± 0.24 cm2, and 
is in keeping with the ± 0.1 cm2 average annual AVA decrease reported in previous studies (8,9). The need 
for AVR at 1-year follow-up was higher than previously reported in patients with asymptomatic severe AS 
(13% vs. 5% to 9%) (8,26) or moderate AS and preserved LV function (13% vs. 4% to 8%) (15,16,18,27). Al-
though the decision to intervene could not be determined from this retrospective study (e.g., clinical HF, 
progression of AS, progressive symptoms), it might suggest accelerated clinical deterioration in patients 
with moderate AS and LV dysfunction.
The rates for all-cause death and hospitalization for HF were 25% and 26% respectively at 3-year fol-
low-up. In recent large HF trials enrolling symptomatic patients with an LVEF ≤35%, 3-year rates for 
HF admissions and all-cause death were <20% and 25%, respectively (28). The higher event rates in the 
current study might suggest that the presence of moderate AS in patients with LV systolic dysfunction 
negatively affects overall prognosis.
Similar to HF studies, symptoms but not LVEF were a strong predictor for clinical events (29,30). Patients 
in NYHA functional class III or IV had significantly more events than patients in NYHA functional class 
II or I (primary composite endpoint 84% vs. 54% and 45%, respectively; p < 0.001). Patients admitted for 
HF at the time of the index echocardiogram had a 2-fold higher 1-year event rate, including significantly 
more admissions for HF (43% vs. 4%; p < 0.001).
Figure 8. Moderate aortic stenosis and LV systolic dysfunction. Patients with left ventricular (LV) systolic dys-
function (left ventricular ejection fraction [LVEF] 20% to 50%) and concomitant moderate aortic stenosis (aortic 
valve area [AVA] 1.0 to 1.5 cm2) are at high risk for clinical events, including all-cause death and hospitalization 
for heart failure. Currently, aortic valve replacement is not indicated in these patients, although they may receive 
benefit. This premise will be studied in the randomized TAVR-UNLOAD (Transcatheter Aortic Valve Replacement 
to Unload the Left Ventricle in Patients with Advanced Heart Failure) trial.
198 Chapter 17
PA
RT
 V
The true effect of moderate AS in patients with LV systolic dysfunction remains unknown, although indi-
rect evidence suggests survival benefit with AVR. In the TOPAS (True or Pseudo Severe Aortic Stenosis) 
observational cohort study, an AVA <1.2 cm2 as opposed to AVA <1 cm2 was associated with mortality in 
medically treated patients with low-flow, low-gradient AS (31–34). A retrospective analysis from the Duke 
Echocardiographic Database reported a mortality benefit associated with AVR (with or without concom-
itant CABG) for moderate AS in patients with LV systolic dysfunction (35). Finally, moderate prosthesis/
patient mismatch after AVR, which generally corresponds to residual moderate AS, has been associated 
with increased risk of early and late mortality in patients with LV systolic dysfunction (36–38). In aggre-
gate, patients with moderate AS and LV systolic dysfunction might be more vulnerable to the increased 
LV afterload imposed by AS and, thus, benefit from AVR. The high event rate in these patients warrants 
further research and may justify the exploration of early TAVR in this population. Indeed, TAVR has be-
come an attractive, minimally invasive alternative to SAVR for patients with severe AS and intermediate 
or greater surgical risk (39–43). Early TAVR may provide additional afterload reduction and thus affect 
clinical outcome in patients with moderate AS and LV systolic dysfunction. This premise will be studied 
in the randomized TAVR UNLOAD (Transcatheter Aortic Valve Replacement to Unload the Left Ventricle 
in Patients with Advanced Heart Failure) trial (NCT02661451) (44).
Study limitations
The retrospective design of the study might introduce selection bias. Although all patients in our study 
shared the common denominator of moderate AS and LV systolic dysfunction, the population was 
heterogeneous. There were multiple underlying causes of LV systolic dysfunction, and there were diverse 
therapeutic regimens in this multinational population. Not all patients were necessarily treated with 
optimal HF therapy. This might be partly explained by the fact that one-quarter of patients were in NYHA 
functional class I and might never have had HF symptoms.
Furthermore, we elected to define moderate AS according to the parameters (AVA, mean gradient, and 
peak velocity) and cut-off values proposed in the guidelines (13). Using AVAi to determine AS severity 
might have reclassified some patients with large BSA from moderate to severe AS (if AVAi is ≥0.6 cm2/
m2). Conversely, patients with small BSA might have been reclassified from mild AS (based on AVA) to 
moderate AS (based on AVAi). However, 1 of the important limitations of AVAi is that it may overestimate 
AS severity in obese patients. In this regard, one-half of the patient population with AVAi <0.6 cm2/m2 in 
our series had a body mass index >30 kg/m2 versus 20% of patients with AVAi ≥0.6 cm2/m2. Furthermore, 
a recent study suggested using lower cut-off values for AVAi to define severe AS (45). Hence, further stud-
ies are needed to refine the method of indexation of AVA in patients with AS to achieve more accurate 
estimation of AS severity. Nevertheless, this database likely reflected real-life practice and underscored 
the complexity of AS diagnosis and HF treatment. A propensity-matched analysis versus patients with 
LV dysfunction without AS could further clarify the added burden of moderate AS in patients with LV 
dysfunction.
Finally, the decision to proceed with AVR in our study was undertaken by the treating physician and 
might reflect center-specific practices. DSE was performed in 11% of patients. It may be possible that we 
failed to include more patients with pseudo-severe (and thus moderate) AS because the treating physi-
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cian did not perform a DSE. It is also possible that DSE interpretation was incorrect and patients had true 
severe AS rather than moderate AS. Patients in whom the DSE revealed true severe AS were not included 
because low-flow, low-gradient severe AS falls beyond the scope of this retrospective study. Although this 
retrospective study reflected contemporary practice in 4 academic institutions, some patients might have 
had severe AS based on indexed AVA and might have benefitted from AVR at an earlier stage.
CONCLUSIONS
Patients with concomitant moderate AS and LV systolic dysfunction are at high risk for clinical events. 
Further studies are needed to determine if earlier AVR in these patients might improve clinical outcome.
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SUPPLEMENTAL MATERIAL
Medically treated (n=159) AVR* (n=13)
Index Follow-up P-value Index Follow-up P-value
LVEF (%) 38 ± 9 39 ± 11 0.226 39 ± 7 39 ± 12 0.894
AVA (cm2) 1.24 ± 0.16 1.14 ± 0.25 <0.001 1.23 ± 0.14 1.00 ± 0.22 0.004
Vmax (m/s) 2.5 ± 0.4 2.6 ± 0.5 0.001 2.8 ± 0.5 3.1 ± 0.6 0.074
PG (mmHg) 26 ± 8 29 ± 12 <0.001 32 ± 8 39 ± 14 0.085
MG (mmHg) 14 ± 4 16 ± 7 <0.001 18 ± 4 22 ± 8 0.127
Supplemental table 1. Evolution of echocardiographic parameters for patients with and without AVR. Variables 
are displayed as mean ± SD. Median time between index and follow-up echo was 541 days (IQR [337-890]) for 
medically treated patients and 467 (IQR [315-937]) for patients with AVR. *Follow-up echocardiograms were before 
AVR. Abbreviations: AVA = Aortic Valve Area; MG = mean gradient; LVEF = left ventricular ejection fraction; PG = 
peak gradient; Vmax = peak aortic jet velocity. 
Supplemental figure 1. Forest plot of hierarchical univariate cox-regression analysis. A two-
step hierarchical univariate cox-regression model was conducted to evaluate predictors for the 
primary composite endpoint – All-cause death, AVR or HF hospitalization. *reference category. 
Abbreviations: AVA = Aortic valve area, AVR = Aortic valve replacement, BMI = Body mass index, 
CI = Confidence interval, eGFR = Estimated glomerular filtration rate, HF = Heart failure, HR = 
Hazard ratio, LVEF = Left ventricular ejection fraction, NYHA = New York Heart Association, V 
max = Peak aortic jet velocity.
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Supplemental figure 2. Composite of all-cause death, AVR or HF hospitalization stratified by LVEF. Cumulative 
incidence curves (Kaplan-Meier) stratified by LVEF ≤35% and >35%. Prognosis was similar between both groups 
throughout follow-up.
Supplemental figure 3. Composite of all-cause death, AVR or HF hospitalization according to tertiles of indexed 
AVAi.  Cumulative incidence curves (Kaplan-Meier) stratified by tertiles of AVAi. Prognosis was similar across the 
three tertiles. Abbreviations: AVAi = Indexed aortic valve area. 
Supplemental figure 4. Composite of all-cause death, AVR or HF hospitalization stratified by institutions. Cumu-
lative incidence curves are stratified for the respective participating institutions. 
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ABSTRACT
Aims
Patients with bicuspid valves represent a challenging anatomical subgroup for transcatheter aortic valve 
implantation (TAVI). This analysis evaluated the clinical outcomes of the fully repositionable and retriev-
able Lotus Valve TAVI System in patients with bicuspid aortic valves enrolled in the RESPOND post-mar-
ket registry. 
Methods and Results
The prospective, open-label RESPOND study enrolled 1014 patients at 41 centres in Europe, New Zealand, 
and Latin America; 31 (3.1%) of whom had bicuspid aortic valves. The mean age in the bicuspid patient 
cohort was 76.4 years, 64.5% were male, and the baseline STS score was 6.0±10.2. Procedural success was 
100%, with no cases of malpositioning, valve migration, embolization, or valve-in-valve. Repositioning 
was attempted in 10 cases (32.3%). There was one death (3.2%) and one stroke (3.2%) at 30-day follow-up. 
Mean AV gradient was reduced from 48.7±17.0 mmHg at baseline to 11.8±5.1 mmHg at hospital discharge 
(P<0.0001); mean effective orifice area (EOA) was increased from 0.6±0.2 cm2 to 1.7±0.4 cm2 (P<0.0001). 
There were no cases of moderate or severe paravalvular leak (PVL) adjudicated by the core laboratory; 4 
subjects (13.8%) had mild PVL, 5 (17.2%) had trace PVL. The rate of pacemaker (PM) implantation for PM-
naïve patients was 22.2% (6/27).
Conclusions
Patients with bicuspid valves represent a challenging anatomical subgroup for TAVI. Data from the 
RESPOND registry demonstrate good clinical and echocardiographic outcomes with the repositionable 
Lotus valve in these patients through 30 days postimplantation. Patients with bicuspid valves represent a 
challenging anatomical subgroup for transcatheter aortic valve implantation (TAVI). This analysis evalu-
ated the clinical outcomes of the fully repositionable and retrievable Lotus Valve TAVI System in patients 
with bicuspid aortic valves enrolled in the RESPOND post-market registry.
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INTRODUCTION
Bicuspid valves are one of the most common congenital aortic valve anomalies, present in up to 2% of 
the population (1,2). Compared to tricuspid valves, bicuspid valves have a larger annulus perimeter, an 
asymmetrical valve orifice, and more heavily calcified leaflets/raphe (3,4). Patients with a bicuspid aortic 
valve are at increased risk for aortic stenosis, aortic dilation, aneurysm, and dissection (3,4). While TAVI 
is an established treatment option for patients with symptomatic aortic stenosis who are at high risk 
for surgical valve replacement (5,6), patients with bicuspid valves have been excluded from most TAVI 
clinical trials and bicuspid-TAVI data are limited. Demonstrating safety and efficacy in bicuspid valves is 
essential for TAVI devices, particularly if TAVI is to be extended into younger populations in whom bicus-
pid anatomy is more prevalent. 
Previous data have consistently shown worse outcomes following TAVI in bicuspid anatomy, including 
increased paravalvular leak (PVL), non-uniform/non-circular valve deployment, reduced procedural 
success, device migration/embolisation, malfunction, and annular rupture, (7-13). The Boston Scientific 
Lotus valve has several features which may be of benefit in patients with bicuspid anatomy, including a 
sealing skirt to reduce PVL, deployment via gradual mechanical expansion, and full retrievability and 
repositionability. The REPRISE II (REpostionable Percutaneous Replacement of Stenotic Aortic Valve 
Through Implantation of Lotus Valve System: Evaluation of Safety and Performance) (14), and the RE-
PRISE III (Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of 
Lotus Valve System – Randomized Clinical Evaluation) (15) trials excluded patients with bicuspid valves.
The RESPOND study evaluated TAVI with the Lotus Valve when used in routine clinical practice, in-
cluding in patients with bicuspid aortic valve anatomy. This analysis evaluates outcomes with Lotus in 
patients with bicuspid aortic valves.
METHODS
Study Design and Patient Selection
The RESPOND (Repositionable Lotus Valve System – Post Market Evaluation of Real World Clinical 
Outcomes) Study is a prospective, open label, single arm, multi-center, observational post-market registry 
from 41 centers in Europe, New Zealand, and Latin America. The study design has been previously de-
scribed (16).  Data collection occurred at baseline, index procedure, discharge and at 30 days post-proce-
dure for all enrolled subjects. 
The protocol was approved by the locally appointed institutional review boards/ethics committees, and 
the study was conducted in accordance with the International Conference on Harmonization Guidelines 
for Good Clinical Practice and the ethical principles outlined in the Declaration of Helsinki. The study was 
registered with ClinicalTrials.gov (NCT 02031302). All patients gave written informed consent.
Device and Procedural Details
The Lotus Valve System™ consists of a bioprosthetic aortic valve premounted on a preshaped delivery 
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catheter.  Novel features of the Lotus Valve System include an Adaptive Seal™ designed to mitigate PVL, 
controlled mechanical expansion, and the ability to fully recapture or reposition the valve prior to release. 
Detailed descriptions of the Lotus Valve System have been previously published (17-19). 
Outcomes Measures
The primary endpoint for RESPOND was all-cause mortality at 30 days and 1 year in the intent to treat 
population. Secondary endpoints included in-hospital mortality, the composite of allcause mortality and 
disabling stroke at 30 days and 1 year, and grade of paravalvular aortic valve regurgitation at discharge 
and 1 year. Major clinical events (i.e. all-cause mortality and stroke events) were adjudicated by an Inde-
pendent Medical Reviewer (IMR). Baseline and follow-up echocardiography studies were evaluated by an 
independent core laboratory (Cardialysis Core Laboratory, Rotterdam, Netherlands).
For this sub-analysis, the preliminary identification of bicuspid anatomy was site-reported. The echo core 
laboratory then provided an initial characterization of bicuspid anatomy using Sievers’ valve classifica-
tion scheme to define each valve as Type 0, Type 1, or Type 2 (20) (Figure 1). Each identified bicuspid valve 
was further validated via systematic review of CT angiograms. No specific guidance for the selection of 
valve size in bicuspid valves was provided and the final decision was at the discretion of the operator. 
This is the first registry to date to employ the use of an independent clinical event committee as well as to 
assess both CT and echo data for bicuspid valve validation and characterization.
Patient Characteristic
Bicuspid Cohort Non-bicuspid Cohort
P-value
N=31 N=965
Age. years 76.4 ± 7.9 (31) 80.9 ± 6.4 (965) <0.001
Gender. male 64.5 (20/31) 48.7 (470/965) 0.083
BMI (kg/m2) 28.1 ± 4.91 (30) 26.6 ± 4.82 (956) 0.093
STS score 6.0 ± 10.15 (28) 5.9 ± 6.74 (821) 0.948
EuroSCORE 20II 6.1 ± 7.52 (29) 8.0 ± 8.38 (821) 0.233
Diabetes mellitus. medically treated 16.1 (5/31) 22.5 (217/965) 0.403
History of COPD 9.7 (3/31) 15.7 (151/963) 0.458
NYHA Class III or IV 66.7 (20/30) 69.6 (623/895) 0.731
History of hypertension 71.0 (22/31) 79.4 (760/957) 0.254
Coronary artery disease. history 25.8 (8/31) 57.1 (550/964) 0.001
Prior PCI 12.9 (4/31) 30.4 (292/962) 0.037
Prior CABG 3.2 (1/31) 12.6 (122/965) 0.163
Prior implanted pacemaker 12.9 (4/31) 13.4 (129/965) 0.163
Atrial fibrillation. history 19.4 (6/31) 24.1 (232/964) 0.545
Porcelain aorta 6.5 (2/31) 4.3 (41/960) 0.394
Hostile chest/unfavourable chest wall anatomy 0.0 (0/31) 1.0 (10/964) 1.000
Cerebrovascular accident. history 16.1 (5/31) 9.3 (89/962) 0.205
Transient ischaemic attack. history 0.0 (0/31) 7.6 (73/958) 0.161
Table 1. Baseline Patient Characteristics. Values are mean ± SD (N) or % (n/N).
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RESULTS
Study Participants and Baseline Characteristics
The RESPOND post-market registry enrolled 1014 patients between May 2014 & February 2016; 31 of the 
996 patients implanted with a Lotus Valve were identified as having bicuspid anatomy. Most baseline 
characteristics for bicuspid and tricuspid patients from RESPOND were similar. Significant baseline 
differences existed for average age (76.4±7.9 years bicuspid vs 80.9±6.4 years tricuspid; P<0.001), history 
of coronary artery disease (CAD) (25.8% bicuspid vs 57.1% tricuspid; P<0.001), and percutaneous coro-
nary intervention (PCI) (12.9% bicuspid vs 30.4% tricuspid; P<0.05) (Table 1). The majority of the bicuspid 
patients (71.0% [22/31]) had Sievers Type 1 valve anatomy (20 L-R, 2 R-N). 16.1% (5/31) had Type 0 valves, 
3.2% (1/31; 1 R-N) had Type 2 valves, and 9.7% (3/31) were unable to be classified due to scan quality.
Core lab adjudicated baseline echocardiog-
raphy was significantly different between the 
two groups. The mean effective aortic orifice 
area (EOA) was 0.6±0.2cm2 for bicuspid and 
0.7±0.2cm2 for tricuspid (P=0.008) and the 
mean AV gradient was 48.7±17.0mmHg for 
bicuspid and 37.6±15.3mmHg for tricuspid 
(P<0.001). There were no significant differ-
ences in aortic regurgitation at baseline 
(Severe AR: 3.7% for bicuspid, 2.2% for tricuspid; Moderate AR: 18.5% for bicuspid, 14.2% for tricuspid; 
None-Mild AR: 77.8% for bicuspid, 83.6% for tricuspid; P=NS for all). Site-reported aortic valve calcifica-
tion was similar for patients with bicuspid valves and patients with tricuspid aortic valves (Severe: 38.7% 
Figure 2. Lotus valve sizing. Distribution of valve sizes within 
the bicuspid and tricuspid patient populations was similar.
Figure 3. Mean Aortic Valve Gradient and Effective Orifice Area. Bicuspid and tricuspid patients both demonstra-
ted a significant change in mean aortic gradient and EOA from baseline to discharge. Baseline mean aortic gra-
dient was different for the bicuspid and tricuspid cohorts with no difference between groups at discharge. Baseline 
and discharge measurements between the groups were not different for mean EOA. Data is core-lab adjudicated.
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vs 36.4%; Moderate: 45.2% vs 35.3%, Mild: 9.7% vs 17.4%; Unknown/Not reported: 6.5% vs 10.9%; bicuspid 
vs tricuspid P=NS for all). Site-reported aortic annulus diameter (23.8±2.4mm for bicuspid, 22.8±4.8mm 
for tricuspid; P=0.095) and LVEF (50.9±15.3% for bicuspid, 54.8±13.0% for tricuspid; P=0.112) were similar 
for both groups. There were 11 (35.4%) aortic root aneurysms reported in the bicuspid cohort of the 
RESPOND registry.
Procedural Success and Details
Both the bicuspid and tricuspid cohorts demonstrated high rates of procedural success. Predilation was 
performed significantly more often in the bicuspid cases than in the tricuspid cases (80.0% [24/30] for 
bicuspid, 53.0% [500/943] for tricuspid; P = 0.0035). Correct positioning of a single prosthetic valve in the 
proper anatomical location occurred in 100% of the bicuspid cases - there were no cases of migration, em-
bolization, or deployment of a second valve. Repositioning was attempted in 10 bicuspid patients (32%) 
and 299 tricuspid patients (31%). If attempted, repositioning was successful in 9 of 10 attempts (90%) 
for bicuspid patients and in 287 of 299 attempts (96.0%) for tricuspid patients. The bicuspid and tricus-
pid cohorts had a similar distribution of valve sizes (27mm: 39% for bicuspid, 34% for tricuspid; 25mm: 
39% for bicuspid, 40% for tricuspid; 23mm: 23% for bicuspid, 26% for tricuspid; P=NS for all). (Figure 2) 
Haemodynamic Performance The mean AV gradient was statistically different between bicuspid and tri-
cuspid patients at baseline (48.7±17.0mmHg for bicuspid, 37.6±15.3mmHg for tricuspid; P<0.001) but was 
similar at discharge (11.8±5.1mmHg for bicuspid, 10.8±4.5mmHg for tricuspid; P=0.211). The mean EOA 
measurements were also different at baseline and similar at discharge between the groups; both cohorts 
demonstrated a significant increase in effec-
tive orifice area (Baseline EOA: 0.6±0.2cm2 
for bicuspid, 0.7±0.2cm2 for tricuspid; 
P=0.008. Discharge EOA: 1.7±0.4cm2 for 
bicuspid, 1.8±0.5cm2 for tricuspid; P=0.204). 
(Figure 3) At hospital discharge, PVL was 
not significantly different for bicuspid vs 
tricuspid patients (Mod/Severe PVL: 0% for 
bicuspid, 0.3% for tricuspid; Mild PVL: 13.8% 
for bicuspid, 7.5% for tricuspid; Trace PVL: 
17.2% for bicuspid, 10.9% for tricuspid; None: 
69% for bicuspid, 81.2% for tricuspid; P=NS). 
(Figure 4)
Safety
All-cause mortality at 30 days was not different between bicuspid and tricuspid groups (3.2% for bicus-
pid, 2.2% for tricuspid; P=0.509). There were no significant differences between other principal safety 
outcomes at 30 days such as all stroke (3.2% for bicuspid, 3.0% for tricuspid; P=1.000), major vascular 
complications (6.5% for bicuspid, 2.8% for tricuspid; P=0.231), and pacemaker implantation (22.2% in 
pacemaker-naïve patients for bicuspid, 35.3% for tricuspid; P=0.162). (Table 2)
Figure 4. Paravalvular Aortic Regurgitation at Discharge. No 
severe PVL in either bicuspid or tricuspid group. 86.2% of the 
bicuspid cohort and 92.1% of the tricuspid cohort had none/
trace PVL. Data is core-lab adjudicated.
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Undersizing in Bicuspid Anatomy
Annulus diameter measurements were performed by site and valve sizing was determined at the discre-
tion of the operator. Of the 31 patients with bicuspid anatomy, four had significant (>10%) undersizing by 
annulus diameter. PVL and haemodynamic results in these 4 patients were good. (Table 3) 
DISCUSSION
The principal finding of this study is that outcomes for patients with bicuspid aortic valves who under-
went TAVI with the Lotus Valve in the “real-world” RESPOND registry were comparable to those with 
tricuspid aortic valves receiving the Lotus Valve. The bicuspid cohort was significantly younger, which 
aligns with other descriptions of aortic stenosis in bicuspid valves (1), and the bicuspid cohort presented 
with significantly less coronary artery disease. There was no significant difference in clinical outcomes 
between bicuspid and tricuspid patients, including mortality, stroke, bleeding, vascular complications, 
and acute kidney injury. Device success in bicuspid patients was 100%, with no cases of migration, embo-
lization, placement of a second valve, or annular rupture. Consistent with the low rates of PVL with Lotus 
in tricuspid anatomy, bicuspid patients in RESPOND had 0% moderate/severe PVL and only 13.8% mild 
PVL, as well as good haemodynamics.
30-Day Outcomes BicuspidN=31
Non-bicuspid
N=965 P-value
All-cause mortality 3.2 (1/31) 2.2 (21/955) 0.509
Cardiovascular 3.2 (1/31) 2.0 (19/955) 0.476
Non-cardiovascular 0.0 (0/31) 0.2 (2/955) 1.000
Stroke 3.2 (1/31) 3.0 (29/955) 1.000
Disabling 3.2 (1/31) 2.2 (21/955) 0.509
Non-disabling 0 (0/31) 0.8 (8/955) 1.000
All-cause mortality and disabling stroke 6.5 (2/31) 4.0 (38/955) 0.361
Vascular Complications 12.9 (4/31) 8.6 (82/955) 0.339
Major 6.5 (2/31) 2.8 (27/955) 0.231
Life-threatening or disabling bleeding 6.5 (2/31) 2.1 (20/955) 0.150
PM Implantation for PM-Naïve Patients 22.2 (6/27) 35.3 (292/828) 0.162
MI (>72 hours post-procedure) 0.0 (0/31) 0.6 (6/955) 1.000
Acute Kidney Injury (Stage 2 or 3) 3.2 (1/31) 2.5 (24/955) 0.555
Table 2. Principal Safety Results at 30 Days.
Patient Valve Size (mm)
Area derived annulus 
diameter (mm)
Mean Aortic Gradient (mmHg)
PVL
Baseline 30 Days
1 27 30.0 61.6 NR NR
2 27 31.6 53.6 12.9 Mild
3 25 28.0 48.2 15.8 None
4 27 30.0 22.9 12.0 Trace
Table 3. Four cases of undersizing in bicuspid valves. 
212 Chapter 18
PA
RT
 V
Challenges of TAVI in Bicuspid Anatomy
Due to the high level of calcification and eccentric geometry in patients with bicuspid anatomy, TAVI in 
bicuspid valves may be subject to an increased risk of complications related to irregular and incomplete 
expansion of the prosthetic valve (9). Asymmetrical expansion of valves has been observed as high as 38% 
with the S3 valve in bicuspid anatomy (10) and Zegdi et al.describes noncircular stent deployment as 81% 
more frequent in bicuspid vs tricuspid aortic valves (11). Non-circular or irregular valve expansion may 
impact valve hemodynamics and durability. Valve haemodynamics following TAVI, including mean gra-
dient and effective orifice area, were no different between bicuspid and tricuspid valves in RESPOND, de-
spite a range of eccentricity from 1.11-1.48 in the bicuspid group. (Supplementary Table 1) This similarity 
may be attributed to the independent mobility of the Lotus valve leaflets. The Lotus valve is designed such 
that the leaflets are not sutured to the valve frame, and are therefore not affected by noncircular valve 
expansion. Furthermore, heavy calcification and eccentricity of the native annulus increases the risk of 
device malapposition and consequently of PVL. In a comparative analysis from the German TAVI Registry 
of bicuspid vs tricuspid valves, the risk for moderate or greater aortic regurgitation (AR) was higher in 
patients with bicuspid anatomy receiving CoreValve or Sapien (12). Mylotte et al similarly reported a high 
incidence of post-implant AR in 139 bicuspid patients undergoing TAVI with Sapien XT and CoreValve 
(AR grade ≥2 was 28.4%) (13). 
In tricuspid anatomy, the Lotus Valve has low rates of PVL due to the Adaptive Seal feature. This seal re-
duces PVL by conforming to irregular anatomic surfaces, which may be a crucial attribute for minimizing 
PVL in bicuspid anatomy. In this analysis PVL was similar between tricuspid and bicuspid patients; there 
were no cases of moderate or severe PVL in patients with bicuspid valves, and even mild PVL was seen in 
only 13.8%. This result is consistent with the findings of Yoon et al for PVL with current generation TAVI 
in bicuspid valves (8). Device success is lower overall for bicuspid TAVI-patients as compared to tricuspid 
TAVI patients (8). 
Bicuspid patients are at increased risk for malfunctioning valves post-TAVI due to high leaflet co-apta-
tion, leaflet fusion, as well as extensive and asymmetric calcification (7). The Lotus Valve is fully reposi-
tionable and retrievable, allowing precise positioning in asymmetric anatomy, and avoiding risk of device 
migration or embolization. Deployment via gradual mechanical expansion also minimizes the risk of 
annular rupture. Despite frequent aortopathy (35.4% [11/31] of patients with bicuspid valves in RESPOND 
had aortic root aneurysms), no cases of dissection were seen with the Lotus Valve in RESPOND. The data 
from this subanalysis support these potential advantages of the Lotus Valve for bicuspid patients as there 
were no cases of migration, embolization, deployment of a second valve, or annular rupture. 
Valve Sizing in Bicuspid Anatomy
For the RESPOND registry, sizing of the valve was at the discretion of the implanter. Some clinicians 
have hypothesized that routine undersizing may be beneficial in bicuspid anatomy, allowing fixation and 
sealing within the leaflets, with more complete and symmetrical expansion of the valve frame to optimize 
haemodynamics and potentially enhance long-term durability. In this analysis four patients received 
valves that had >10% undersizing; all four had good outcomes with respect to PVL and valve haemody-
namics. Other studies have shown a tendency to oversize TAVI devices in bicuspid anatomy in an effort 
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to circularize the annulus, prevent malpositioning, and reduce PVL even though oversizing may increase 
the risk of rupture (8). The combination of controlled mechanical expansion and the Adaptive Seal of the 
Lotus Valve may provide a benefit in addressing these challenges. Specific sizing for bicuspid anatomy 
with the Lotus Valve will require further investigation.
Study Limitations
The primary limitation of this study is the small size of the analysis population. Additionally, RESPOND 
is a single-arm registry, and not a randomized study. Aortic valve calcification and preliminary identifica-
tion of bicuspid anatomy were site-reported, although central CT analysis was used to confirm bicuspid 
anatomy and echocardiography data was analyzed by an independent core laboratory. In RESPOND, 3% 
of patients were identified as having bicuspid aortic valve stenosis; however, other studies have shown an 
incidence of approximately 20% (2). It is possible that in this study, and others, that initial identification 
via echo failed to capture all patients with functional bicuspid anatomy, underestimating the true num-
ber of bicuspid patients in the TAVI population. At the time of this study, the largest available Lotus Valve 
was 27mm, which limits the results to patients with smaller annular diameters.
Conclusions
TAVI with the Lotus valve in patients with bicuspid aortic valve anatomy treated within the RESPOND 
registry was associated with good procedural, clinical, and haemodynamic outcomes.
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SUPPLEMENTAL MATERIAL
Patient Bicuspid type
Aortic Valve 
Area (mm2)
Annulus   
Maximum    
Diameter 
(mm)
Annulus
 Minimum 
Diameter 
(mm)
Eccentricity 
Index
Aortic Valve 
Calcification
1 Type 1 L-R 562.3 31.4 23.2 1.35 None
2 Type 1 L-R 578.5 32.2 22.6 1.42 Mild
3 Type 2 R-N 550.3 28.9 24.9 1.16 Mild
4 Type 1 L-R 549.5 28.1 24.4 1.15 Moderate
5 Type 1 L-R 520.5 28.5 22.9 1.24 Moderate
6 Type 1 L-R 413.2 26.0 20.8 1.25 Moderate
7 Type 0 601.0 32.7 23.2 1.41 Moderate
8 Type 1 L-R 507.3 28.4 22.8 1.25 Moderate
9 Type 1 L-R 523.0 30.3 21.5 1.41 Moderate
10 Type 0 488.4 29.9 21.0 1.42 Moderate
11 Type 1 L-R 372.0 26.0 18.3 1.42 Moderate
12 Type 0 399.4 23.6 21.3 1.11 Moderate
13 Type 1 L-R 430.0 24.8 21.8 1.14 Moderate
14 Type 1 R-N 305.4 21.8 17.7 1.23 Moderate
15* Type 1 L-R 705.8 33.8 26.3 1.29 Severe
16 Type 0 394.7 26.9 18.8 1.43 Severe
17 Type 1 L-R 423.1 25.3 21.0 1.20 Severe
18 Type 1 L-R 380.7 26.7 18.1 1.48 Severe
19 Type 1 L-R 429.3 28.2 19.2 1.47 Severe
20 Type 1 L-R 537.8 30.7 22.7 1.35 Severe
21 Type 1 L-R 521.7 28.1 23.4 1.20 Severe
22 Type 0 486.9 27.9 22.2 1.26 Severe
23* Type 1 L-R 536.0 28.7 23.9 1.20 Severe
24 Type 1 L-R 476.6 25.2 23.8 1.06 Severe
25 Type 1 R-N 571.7 29.1 25.2 1.15 Severe
26* Type 1 L-R 661.6 30.5 27.1 1.13 Severe
27 Type 1 L-R 545.2 28.7 24.2 1.19 Severe
28 Type 1 L-R 484.3 28.3 22.2 1.27 Severe
29 UNK UNK UNK UNK UNK UNK
30 UNK UNK UNK UNK UNK UNK
31* UNK UNK UNK UNK UNK UNK
Supplemental table 1.  CT Measurements for Patients with Bicuspid Valves *Indicates case where Lotus Valve 
was undersized.
Epilogue
 Summary and discussion
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In the past decade, transcatheter aortic valve implantation (TAVI) has matured to the mainstay treatment 
for patients with severe symptomatic aortic stenosis (18). The technology was first tested and approved in 
patients who were inoperable or at high risk for death or complications with surgical aortic valve replace-
ment (SAVR) (3-5), but expanded to intermediate risk patients(6-8). Importantly the multidisciplinary 
heart team that includes cardiac surgeons, interventional cardiologists, imaging specialists, geriatricians 
and anesthesiologists should determine the optimal treatment strategy for elderly patients with severe 
AS (17).
Valve manufacturers are continuously improving their designs in order to improve success rate and safety 
of the procedure. In the process, TAVI is becoming easier to use and the workflow is fastened and a ‘same-
day-discharge’ scenario appears feasible.
Over the past decade different TAVI platforms have become commercially available and offers the physi-
cian a tailored approach to treat severe aortic stenosis in patients at elevated operative risk. 
Pre-procedural multi-modality imaging is essential for proper patient and device selection. In particular 
the multi-slice computed tomography of the arterial tree and aortic valve provides crucial information. 
Chapter 1 dives into the current landscape of new-generation transcatheter heart valves and touches 
upon sizing strategies (19). The Lotus valve is the only system that is deployed by mechanical expan-
sion. Lotus is the only platform with true reposition and retrieval ability. These unique features make it 
attractive in complex anatomies where there is insecurity about the valve size or with exuberant amounts 
of calcium in the aortic root. Chapter 2 gives a detailed description of the Lotus valve concept and runs 
through the steps of implantation. 
Early reports of new-generation transcatheter heart valves show excellent performance (20-22). Obvious-
ly, the diverging concepts have their inherent advantages and disadvantages, which are discussed in this 
thesis. 
Part I – Conduction disorders
As with surgical aortic valve replacement, TAVI is associated with the occurrence of new - and aggrava-
tion of existing - conduction disorders. 
The anatomical landing zone of a transcatheter heart valve lies beneath the native aortic valve annulus in 
the left ventricular outflow and in close proximity to the cardiac conduction system (10,23,24). Sufficient 
radial expansion is a prerequisite for stability and optimal performance of the bioprosthesis. As such, 
radial force is exhibited to the conducting bundles and might inflict damage. The fate of these acquired 
conduction disturbances are subject of intense research. 
It is noteworthy that most of the new conduction disorders are already observed during minimal LVOT 
interaction by guidewires and catheters, and thus before the bioprosthesis is de facto deployed. The 
majority of these newly developed conduction disturbances may resolve, although others persist or even 
deteriorate after the valve deployment (25). The fate of these conduction abnormalities has not been 
completely elucidated but may affect patient safety and hospitalization policy. TAVI practice is moving 
towards earlier discharge. This may pose challenges in patients who developed conduction disturbanc-
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es during or after TAVI. In Chapter 3 we hypothesized that the interventricular conduction time (i.e. 
QRS-duration) may represent a valuable predictor for permanent conduction disorders by retrospective 
assessments of daily ECG’s following TAVI. We discovered that patients with a stable small QRS-dura-
tion may develop transient conduction blocks but almost always completely recovered and thus did not 
require a permanent pacemaker. Conversely, patients with prolonged QRS-prolongation at baseline or 
persistent after the procedure were at risk for life-threatening conduction blocks and need for permanent 
pacing. The daily ECG helped thus identify the patients whose conduction was recovering and became 
eligible for an early discharge from the hospital. This finding warrants further prospective validation in 
large cohorts. 
Up to 20% of patients have a right bundle branch block (RBBB) before the TAVI procedure and are at 
particularly high risk for the development of high-grade AV block and need for permanent pacing (26). In 
Chapter 4 we studied whether transcatheter bioprosthesis selection could contribute to avoid the need 
for permanent pacing after TAVI in these patients (27). Although all devices were associated with more 
need for pacemakers in these patients with RBBB,  the mechanically expanded Lotus valve was associat-
ed with the highest risk. This finding underlines the necessity to take this interplay into account before 
selecting a transcatheter heart valve rather than using the same device in all clinical scenarios. 
Transcatheter heart valves rely on radial expansion to anchor within the aortic root. Current sizing of 
transcatheter heart valves typically considers the dimensions at the level of the basal aortic valve an-
nulus. However, the conduction system surfaces below the annulus in the left ventricular outflow tract 
(LVOT). The LVOT is often smaller than the annulus. Consequently, sizing relative to the annulus might 
thus often result in more dramatic oversizing relative to the LVOT dimensions. Chapter 5 confirms that 
oversizing relative to the LVOT in the presence of a deep implantation is associated with more frequent 
need for permanent pacing (28). We hypothesize that adjusted valve sizing algorithms that also take into 
account the LVOT dimensions may reduce the need for permanent pacemakers.  
Part II – Vascular complications
TAVI requires large bore arterial access for the introduction of the valve delivery systems. Sheath sizes 
range from 14 to 20 French (5-7 mm). Arteriotomy closure most often requires percutaneous suture based 
devices. In the early TAVI experience major vascular complications occurred in approximately 12% of 
patients (29), of which two-thirds were due to failed arteriotomy closure (30). Despite rigorous improve-
ments of TAVI over the past decade - including growing experience, improved access techniques, and 
smaller profiled devices -  major vascular complications remain high (6,7). Chapter 6 and 7 describe the  
MANTA closure device, a novel collagen plug-based system (31,32). The Manta technology is intuitive, 
precludes technically demanding pre-closure with sutures and provides almost immediate hemostasis. 
Chapter 8 describes the multi-center CE mark trial with the Manta device including 50 patients from 9 
centers who required large-bore vascular access closure (33). There was only one major vascular compli-
cation and hemostasis was rapid and reliable. Ultrasound follow-up confirmed arterial vessel patency up 
to 60 days after closure. Randomized trials comparing the MANTA with suture-based closure devices will 
have to confirm whether collagen-based technology yields better outcomes. 
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Part III – Neurological events
Neurological events may complicate TAVI including disabling stroke affecting independent living and 
impairing quality of life. The first randomized controlled trials with TAVI demonstrated an early penalty 
of major stroke at 30 days in 5% of patients versus 1.1% with conservative management (i.e. medical ther-
apy and balloon aortic valvuloplasty) (3). Early head-to-head studies showed comparable stroke rates for 
TAVI versus SAVR (3.8 vs. 2.1% with Edwards Sapien and 4.9 vs. 6.2% with Corevalve) (4,5). Despite device 
iteration, procedural refinements and growing experience the overall stroke rate stagnated as was shown 
in recent trials including intermediate risk populations (TAVI 3.2% vs. SAVR 4.3%) (6). 
Clinically overt strokes and transient ischemic attacks represent but the tip of the iceberg. Subtle changes 
in neurocognitive performance are often missed by genuine physical examination (34-36). Indeed, brain 
injury may occur in up to 93% of patients following TAVI (37) . Silent infarcts may not be trivial as they are 
associated with cognitive and functional decline and increased risk for stroke (38). As the focus of TAVI 
is moving to lower risk patients who are younger and have a longer life expectancy the relevance of these 
subclinical brain lesions may only increase. 
More than half of  the early strokes after TAVI occur within 48 hours of the procedure (12,39,40) and have 
a trombo-embolic origin (39,41). Histopathology studies of debris captured by filters in the major extra-
cranial cerebral arteries during TAVI have undisputedly established the presence of cerebral emboliza-
tion of thrombotic material and tissue derived debris during TAVI in nearly all patients (13). This finding 
paved a clear path for cerebral protection during TAVI. Chapter 9 provides a comprehensive overview 
of currently available embolic protection devices and the results from clinical studies (42). Although the 
concept of embolic protection seems sound, compelling clinical benefit is lacking (43-45). All randomized 
controlled trials relied on surrogate endpoints involving the occurrence of new brain injury by MRI as-
sessment. Unfortunately, power calculation fell short and the trials suffered from a high drop-out rate in 
terms of the follow up brain imaging. Chapter 10 discusses the Erasmus MC driven multi-center random-
ized MISTRAL C trial on the effects of filter-based embolic protection system (46). Debris was caught in 
all patients who underwent TAVI, and the filters resulted in fewer and smaller brain lesions and preserved 
neurocognitive function. The current generation filter based embolic protection is limited by covering 
only three of the four cerebral vascular contributors leaving the left vertebral artery unprotected as was 
indicated by the absence of any effect in the posterior brain lobes. Of note, approximately a quarter of 
new brain lesions seem to be located in the cerebellum and brainstem which are largely vascularized by 
the left vertebral artery (47).
We expanded our research with a feasibility study including selective filter protection of the left vertebral 
artery to confirm for the first time the embolization of debris towards the left vertebral territory during 
TAVI (Chapter 11) (48). Future studies are warranted to evaluate the outcome of complete cerebral 
embolic protection. The challenge will be to define proper surrogate endpoints (e.g. lesions on brain-MRI, 
neurocognitive performance) and sufficient power as was proposed by a recent academic research con-
sortium consensus document (49). 
In Chapter 12 we explain that cerebral embolization of thrombotic and tissue related material is inherent 
to left sided structural heart interventions as it also occurred with catheter-based mitral intervention 
(50). 
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Part IV – Technical considerations
TAVI implies a complex interplay between the transcatheter heart valve stented frame within the aortic 
root. Part IV of this thesis zooms in on the technical considerations to optimize transcatheter valve im-
plantation. 
An optimal landing zone for a transcatheter heart valve would be a circular shaped tube slightly narrower 
than the intended prosthesis size to achieve a stabile position with adequate sealing. In reality a stenotic 
aortic valve represents an asymmetric more elliptic landing zone with an irregular surface. Incomplete 
sealing will result in paravalvular leaks during the diastolic phase. Significant paravalvular leaks are asso-
ciated with premature mortality and should be avoided whenever possible (51,52). 
Sealing fabric, repositioning features, metallic properties introducing adequate radial force and balloon 
postdilatation may help prevent paravalvular leaks but sometimes at the expense of conduction disorders 
or even fatal complications such as annular or LVOT rupture or aortic dissection.
Chapter 15 demonstrates a cohort with a diverging pallet of aortic root calcium distribution and sub-
sequent stent frame eccentricity of the CoreValve transcatheter heart valve (53). Up to one third of the 
implanted bioprosthesis had an eccentric shaped stent frame which correlated with the amount of calci-
fication and was associated with more paravalvular leak. 
TAVI is now increasingly performed under local anesthesia. As a consequence, TAVI relies merely on 
contrast aortography to evaluate adequate positioning and paravalvular leaks and transesophageal echo-
cardiography is fading out of every day procedural workflow. Chapter 16 demonstrates the importance 
of contrast aortography with TAVI using a repositionable and fully-retrievable mechanically expanded 
transcatheter heart valve. The data show a strong relation between implantation depth of the stented 
frame below the aortic annulus and subsequent need for a permanent pacemaker. Furthermore sealing of 
the bioprosthesis appeared irrespective of the implantation depth. Also, contrast aortography correlated 
satisfactorily with transthoracic echocardiography in terms of aortic regurgitation assessment. 
Part V – Future perspectives
Degenerative aortic stenosis and left ventricular systolic dysfunction increase ventricular afterload, are 
more frequent in the elderly and often coexist. Afterload reducing agents such as beta-blockers and re-
nin-angiotensin-aldosterone system modulators are the cornerstone of pharmacological management for 
patients with symptomatic heart failure. Aortic valve replacement to resolve an aortic stenosis reduces 
the left ventricular afterload. Current guidelines recommend careful monitoring for moderate aortic 
stenosis (16,17). The fate of moderate aortic stenosis in patients with LV systolic dysfunction is unknown. 
Conceivably, moderate aortic stenosis will affect the overall loading of the left ventricle as illustrated by 
the valvulo-arterial impedance (54). We found significant prognostic implications of moderate aortic 
stenosis in patients with impaired left ventricular systolic function (Chapter 17) (55). The rate of death, 
aortic valve replacement or hospitalization for heart failure exceeded 60% at 4 years of follow-up. Male 
sex, higher transaortic velocities and symptomatic heart failure were important predictors of events. 
Most clinical events occurred during the first year after diagnosis. Early TAVI might improve the overall 
prognosis and quality of life and is the subject of an ongoing randomized trial (56).  
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Bicuspid aortic valve stenosis has so far been excluded from randomized TAVI trials. Several interna-
tional collectives reported acceptable clinical outcomes with TAVI as an off-label treatment for severe 
bicuspid AS (57). Initial experience was hampered by a high rate of at least moderate paravalvular leaks. A 
recent report suggested that the incidence of significant PVL might be less with new-generation tran-
scatheter heart valves as compared to the earlier generations (58). 
Chapter 18 reports post-market study data of clinical and echocardiographic outcomes of TAVI with the 
mechanically expanded Lotus valve in patients with bicuspid aortic valve stenosis as compared to pa-
tients with tricuspid aortic valve stenosis.  Both the clinical outcome and the rate of more than trivial PVL 
were comparable between the two entities, in contrast to studies with earlier generation valves (57,59).  
Conclusion and future directions
This thesis contemplates current challenges of TAVI and focuses on three important entities. Conduction 
disorders remain a frequent issue. Daily ECG analysis after the procedure may help predict the fate of 
acquired conduction abnormalities at an earlier stage and identify the patients who would benefit from 
(early) permanent pacemaker implantation.
Access site management relies on suture-based techniques and has inherent limitations. Collagen plug 
based closure is a different mechanism, may be easier to adopt and globally reduce vascular complica-
tions.
Brain injury seems omnipresent after TAVI and is difficult to reconcile with the  “primum non nocere” 
principle. Filter based embolic protection hold promise to mitigate the effects of cerebral embolization, 
especially if complete protection is achieved.
TAVI has now matured into a simplified procedure under local anesthesia and the performance of the 
latest transcatheter valve iterations approach or even supersede what can be achieved with a surgical 
bioprosthesis. Bicuspid aortic disease, severe aortic regurgitation and moderate AS in heart failure are 
potential new indications for TAVI. Furthermore, TAVI is attractive for treatment in patients at lower risk 
who are younger and have a longer life expectancy. 
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Degeneratieve aortaklepstenose is een progressieve aandoening met een piek in de oudere populatie. 
Hoewel voorheen chirurgische aortaklepvervanging door middel van een open-hart operatie de stan-
daard behandeling voor deze patiënten was, is dit landschap aan het veranderen. Vijftien jaar geleden 
voerde professor Alain Cribier voor het eerst een minder invasieve behandeling voor deze aandoening uit, 
de kathetergebonden aortaklepimplantatie (transcatheter aortic valve implantation - TAVI). Initieel werd 
deze methode uitgevoerd bij patiënten die inoperabel werden beschouwd of waarbij het risico op het 
optreden van overlijden of ernstige complicaties bij een chirurgische aortaklepvervanging te hoog werd 
ingeschat, maar inmiddels is TAVI uitgegroeid tot de hoeksteen van de behandeling. Terwijl de techniek 
van TAVI steeds verder wordt verfijnd, verschuift de toepassing van TAVI naar patiënten met een inter-
mediair operatierisico. Het besluit om een chirurgische aortaklepvervanging of een TAVI uit te voeren 
bij een individuele patiënt vindt plaats in een multidiscplinair hartteam, bestaande uit thoraxchirurgen, 
interventiecardiologen, beeldvormingscardiologen, geriaters en anesthesisten. Hoewel het concept van 
TAVI tot de verbeelding spreekt en ogenschijnlijk minder invasief zou zijn dan chirurgische aortaklepver-
vanging worden bij deze methode nog altijd complicaties gezien. In dit proefschrift zal in eerste instantie 
in worden gegaan op de belangrijkste complicaties die rondom TAVI optreden en worden mogelijke 
oplossingen tegen het licht gehouden om zodoende de procedure te verfijnen. In tweede instantie zal dit 
proefschrift zich richten op de toepassing van TAVI voor andere indicaties dan louter ernstige degenerati-
eve aortaklepstenose.
Het ontwerp van kathetergebonden klepsystemen wordt door fabrikanten continu verfijnd ten behoeve 
van de werkzaamheid en veiligheid van TAVI. Over de laatste jaren is hierdoor een veelvoud aan klepsys-
temen beschikbaar gekomen waardoor artsen in staat zijn om de behandeling af te stemmen op individu-
ele patiënten. Tegelijkertijd wordt de procedure eenvoudiger te hanteren en wordt het ziekenhuisopname 
rondom de ingreep verkort waardoor scenario’s zich aandienen waarbij de patiënt op dezelfde dag van de 
procedure nog het ziekenhuis verlaat. 
Een essentieel onderdeel van de ingreep is beeldvorming voorafgaand aan de procedure om zodoende de 
juiste behandeling en klepsysteem voor de patiënt te kiezen. Voornamelijk ‘multi-slice computed tomog-
raphy’ (MSCT) van de arteriële vaatboom en aortaklep omvatten cruciale informatie. Hoofdstuk 1 omvat 
een beschrijving van de huidige generatie klepsystemen en methoden om de juiste klepmaat en type te 
selecteren.
De Lotus klep is momenteel het enige klepsysteem waarbij implantatie plaatsvindt door mechanische 
expansie. Ook is Lotus het enige systeem waarbij de klep in zijn volledigheid gerepositioneerd en zelfs 
uit de patiënt kan worden teruggetrokken. Deze unieke eigenschappen maken dat dit klepsysteem de 
voorkeur geniet boven andere klepsystemen wanneer het gaat om complexe anatomie waarbij onzeker-
heid bestaat over de klepdimensies of bij ernstige verkalking van de aortawortel. Hoofdstuk 2 omvat een 
gedetailleerde omschrijving van het concept van de Lotus klep en geeft een stapsgewijze beschrijving van 
de implantatie. 
De eerste resultaten van nieuwe generatie klepsystemen zijn veelbelovend. Vanzelfsprekend hebben de 
uiteenlopende specificaties hiervan zowel voor- als nadelen, welke uitvoerig worden besproken in dit 
proefschrift. 
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Deel I – Geleidingsstoornissen
Net als met chirurgische aortaklepvervanging is TAVI geassocieerd met het optreden van nieuwe, 
alsmede toename van bestaande geleidingsstoornissen van het hart. Dit kan ertoe leiden dat patiënten 
afhankelijk worden van een pacemaker.
Anatomisch gezien is de plek waar de klepprothese wordt geïmplanteerd, namelijk tussen de aortaklep 
annulus en de linker ventrikel uitstroombaan, dicht gelegen bij het elektrische geleidingssysteem van 
het hart. Voldoende radiaire expansie is een voorwaarde voor een stabiele kleppositie en functionaliteit 
van de klepprothese. Dientengevolge wordt radiaire kracht op het geleidingssysteem uitgeoefend en kan 
schade optreden. De implicaties van deze nieuw ontstane geleidingsstoornissen vormen de basis van 
geraffineerd onderzoek. 
Het is belangrijk om te realiseren dat de meeste nieuwe geleidingsstoornissen reeds ontstaan bij min-
imaal contact met de linker ventrikel uitstroombaan door bijvoorbeeld voerdraden of katheters en 
waarbij de klepprothese dus nog niet daadwerkelijk geïmplanteerd is. De meerderheid van deze nieuwe 
geleidingstoornissen zijn tijdelijk van aard, maar sommigen zijn permanent of nemen zelfs toe nadat de 
procedure voltooid is. De betekenis van deze nieuwe geleidingsstoornissen zijn nog niet volledig opgehel-
derd, maar deze zouden waardevolle informatie kunnen bevatten om de veiligheid van de patiënt in te 
schatten en hierop ziekenhuisrichtlijnen aan te passen. 
De verfijning van TAVI heeft ertoe geleid dat patiënten steeds sneller na de procedure naar huis worden 
ontslagen. Het optreden van geleidingstoornissen na TAVI vormen hiervoor een belangrijke hindernis. 
In Hoofdstuk 3 onderzoeken wij of de interventriculaire geleidingstijd (i.e. de QRS-duur op het ECG) 
een waardevolle voorspeller zou kunnen zijn voor het optreden van permanente hooggradige geleid-
ingsstoornissen met uiteindelijk noodzaak voor een pacemaker. Het betreft een retrospectieve analyse 
van dagelijks verkregen ECG’s van patiënten na TAVI. Wij stelden vast dat patiënten met een stabiele 
korte QRS-duur ook voorbijgaande hooggradige geleidingsstoornissen kunnen ontwikkelen, maar dat 
deze nagenoeg altijd tijdens opname herstelden en dat zij dus uiteindelijk geen pacemaker nodig zullen 
hebben. Daarentegen hadden patiënten met een persisterend verlengde QRS-duur een hoog risico op het 
ontwikkelen van hooggradige geleidingsstoornissen en dus noodzaak voor een pacemaker. Het dagelijks 
verkrijgen van een ECG hielp ons om patiënten te identificeren waarbij het geleidingssysteem herstelde 
en dus vroeg uit het ziekenhuis konden worden ontslagen. Deze bevinding zal nog in een groter prospec-
tief cohort gevalideerd moeten worden. 
Een rechter bundeltakblok komt bij ~20% van de patiënten die een TAVI procedure moeten ondergaan 
voor, en zij zijn hiermee bij uitstek kwetsbaar voor hooggradige geleidingsstoornissen en noodzaak 
voor een pacemaker. In Hoofdstuk 4 bestuderen wij of het selecteren van een bepaald klepsysteem kan 
bijdragen om de noodzaak voor een pacemaker te omzeilen. Hoewel bij deze patiënten met pre-existent 
rechter bundeltakblok alle klepsystemen geassocieerd waren met een hogere kans op noodzaak voor een 
pacemaker, was dit risico het hoogst met de Lotus klep. Deze bevinding benadrukt dat het samenspel tus-
sen het type klepsysteem en een reeds aangetast geleidingssysteem in overweging genomen moet worden 
voordat een bepaald klepsysteem gekozen wordt. 
Klepprothesen zijn afhankelijk van radiaire expansie om zich te verankeren in de aortawortel. De huidige 
maatselectie voor klepprothesen richt zich op de dimensies van de aortaklep annulus. Echter, het geleid-
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ingssysteem ligt enkele millimeters onder de annulus het meest aan de oppervlakte, in de linker ventrikel 
uitstroombaan (LVOT). De LVOT is doorgaans nauwer dan de aorta annulus. De consequentie is dat 
als de maatselectie berust op de annulus er behoorlijke ‘oversizing’ plaatsvindt ter hoogte van de LVOT. 
Hoofdstuk 5 bevestigd dat ‘oversizing’ ter hoogte van de LVOT in combinatie met een diepere implantatie 
geassocieerd is met frequentere noodzaak voor een pacemaker. Wij suggereren hiermee dat aangepaste 
maatselectie (waarbij rekening gehouden wordt met de dimensies van de LVOT) zou kunnen bijdragen 
aan het reduceren van het aantal benodigde pacemakers. 
Deel II – Vasculaire complicaties
TAVI vereist een grote arteriële (slagaderlijke) toegang voor het introduceren van het klepsysteem. De 
sheathgrootte varieert hierbij van 14 tot 20 French (5-7 mm). Het sluiten van de arteriële toegang wordt 
over het algemeen verricht door middel van systemen waarmee een hechting op de bloedvatwand kan 
worden geplaatst, zogenoemde ‘suture-based’ systemen. Tijdens de initiële ervaringen met TAVI werden 
bij 12% van de patiënten majeure vasculaire complicaties gezien, waarvan twee-derde het gevolg waren 
van een niet-succesvolle sluiting van de arteriële toegang. Ondanks significante verbeteringen van TAVI 
in de afgelopen 10 jaar – waaronder groeiende ervaring, verbeterde methodes voor het verkrijgen van 
arteriële toegang en klepsystemen met kleinere profielen – blijft de incidentie van majeure vasculaire 
complicaties hoog. 
Hoofdstuk 6 en 7 beschrijven MANTA, een vernieuwend systeem waarbij de arteriële toegang wordt 
gesloten met een collageen-plug (‘collagen-based’ sluiting). De MANTA technologie is intuïtief, vereist 
geen technisch uitdagende sluiting voorafgaand aan de index-procedure, en zorgt voor bijna directe 
hemostase. Hoofdstuk 8 beschrijft de multi-center CE-markering trial met het MANTA systeem met 50 
patiënten uit 9 verschillende centra bij wie het sluiten van grote arteriële toegang noodzakelijk was. Er 
was slechts één majeure vasculaire complicatie en de hemostase was doorgaans vlot en betrouwbaar. 
Controle-echo bevestigde een intacte arterie tot op 60 dagen na sluiting. Gerandomiseerde studies 
waarbij MANTA wordt vergeleken met ‘suture-based’ systemen zullen moeten gaan aantonen of ‘colla-
gen-based’ systemen ook hun weerslag hebben op belangrijke klinische uitkomstmaten. 
Deel III – Neurologische complicaties
Na TAVI treden soms neurologische complicaties op, zoals een invaliderende beroerte, met vanzelf-
sprekend veel impact op de zelfstandigheid en kwaliteit van leven. Bij de eerste gerandomiseerde trials 
met TAVI werden 5% majeure beroertes gezien op 30 dagen na de TAVI procedure, tegenover 1.1% bij de 
patiënten die conservatief werden behandeld (medicamenteus en ballon-valvuloplastiek). 
De eerste studies die TAVI vergeleken met chirurgische aortaklepvervanging toonden vergelijkbare inci-
denties van beroerte (respectievelijk 3.8% vs. 2.1% met Edwards Sapien en 4.9% vs. 6.2% met CoreValve). 
Ondanks verbeterde klepsystemen, verfijning van de procedure en groeiende ervaring is de incidentie 
van beroertes gestagneerd, wat onlangs nog werd bevestigd in patiëntenpopulaties met een intermediair 
operatierisico (TAVI 3.2% vs. chirurgische aortaklepvervanging 4.3%). 
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Klinisch waarneembare beroertes en ‘transient ischemic attacks’ (TIA’s) vormen slechts de top van de 
ijsberg. Subtiele veranderingen in neurologisch functioneren worden doorgaans gemist bij een standaard 
lichamelijk onderzoek. Inderdaad treed bij tot 93% van de patiënten na TAVI op MRI waarneembare 
schade aan het brein op. Deze ‘stille’ infarcten zijn mogelijk niet irrelevant, aangezien zij geassocieerd zijn 
met cognitieve en functionele achteruitgang en bovendien een verhoogd risico geven op een beroerte in 
de toekomst. Aangezien de focus van TAVI zich verplaatst naar patiënten met een lager operatierisico en 
een langere levensverwachting zal de relevantie van deze subklinische hersenschade vermoedelijk alleen 
maar toenemen. 
Meer dan de helft van de vroeg optredende beroertes na TAVI treden binnen 48 uur na de procedure op, 
en zijn trombo-embolisch van aard. Histopathologisch onderzoek van het debris dat tijdens TAVI werd 
opgevangen in de grote hersenbloedvaten heeft aangetoond dat embolizatie van trombotisch materiaal 
naar het brein bij nagenoeg alle procedures voorkomt. Deze bevinding maakte vrij baan voor cerebrale 
protectie tijdens TAVI. Hoofdstuk 9 omvat een uitgebreid overzicht van de huidig beschikbare cerebrale 
protectiesystemen en de resultaten hiervan uit klinische onderzoeken. 
Hoewel het concept van cerebrale protectie zeer uitnodigend is, blijven overtuigende klinische resultaten 
vooralsnog uit. Gerandomiseerde studies naar TAVI met en zonder cerebrale protectie richtten zich op 
surrogate eindpunten zoals het optreden van nieuwe laesies op MRI. Helaas werden te weinig patiënt-
en in deze studie geïncludeerd om een effect aan te tonen en bovendien verschenen veel patiënten niet 
voor de vervolgonderzoeken na TAVI. Hoofdstuk 10 bediscussieert de door het Erasmus MC gedreven 
gerandomiseerde multi-center MISTRAL C trial waarin de effecten van ‘filter-based’ cerebrale protectie 
werden onderzocht. Bij alle patiënten die TAVI ondergingen werd in filters in de grote hersenbloedvaten 
debris opgevangen. Het gebruik van de filters resulteerde in minder en kleinere laesies op de MRI scan 
na TAVI en tevens behouden neurocognitieve functies. De huidige generatie ‘filter-based’ cerebrale 
protectie beschermt slechts drie van de vier grote hersenbloedvaten, waarbij de linker arteria vertebralis 
onbeschermd blijft, wat teruggezien werd in het uitblijven van een beschermend effect in de achter-
ste hersenkwabben. Dit sluit aan bij eerdere studies waarbij een kwart van de nieuwe breinlaesies (bij 
patiënten zonder cerebrale protectie) gelokaliseerd was in het cerebellum en de hersenstam, waarvan de 
linker arteria vertebralis een belangrijk aanvoerend bloedvat is.
Wij breidden ons onderzoek uit door de linker arteria vertebralis selectief te beschermen, waarmee voor 
het eerst werd bevestigd dat debris ook via deze route emboliseert tijdens TAVI (Hoofstuk 11). Toekoms-
tige studies zijn noodzakelijk om te evalueren of complete cerebrale protectie daadwerkelijk betere klin-
ische uitkomsten oplevert. Een belangrijke uitdaging ligt in het juist definiëren van surrogate eindpunten 
(bijv. laesies op cerebrale MRI, neurocognitief functioneren) en het includeren van voldoende patiënten. 
Er is onlangs een consensus document opgesteld waarin dit duidelijk staat gedefinieerd.
In Hoofstuk 12 benadrukken wij dat cerebrale embolizatie van trombotisch- en weefselmateriaal inherent 
is aan alle linkszijdige structurele interventies aan het hart, aangezien het ook voorkomt bij katheterge-
bonden interventies aan de mitralisklep. 
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Deel IV – Technische overwegingen
TAVI omvat een complex samenspel tussen het stentframe van de klepprothese en de aortawortel. Deel 
IV van dit proefschrift zoomt in op technische overwegingen om de klepimplantatie te optimaliseren. 
Een optimale landingszone voor een klepprothese zou een circulaire buis zijn, met een iets nauwere 
diameter dan de beoogde maat van de klepprothese zodat een stabiele positie met adequate afdichting 
rondom de klepprothese wordt verkregen. In de realiteit is een stenotische aortaklep een asymmetrische 
elliptische landingszone met een irregulair oppervlak. Inadequate afdichting rondom de klepprothese 
resulteert in paravalvulaire lekkage tijdens de diastolische fase. Significante paravalvulaire lekkage is 
geassocieerd met vroegtijdig overlijden en moet daarom voorkomen worden voor zover mogelijk. 
Materiaal rondom de klepprothese voor optimale afdichting, mogelijkheid tot repositioneren, eigen-
schappen van het stentmateriaal met adequate radiaire kracht en ballon postdilatatie kunnen bijdragen 
aan het voorkomen van paravalvulaire lekkage. Echter gaan deze eigenschappen soms ten koste van het 
optreden van geleidingsstoornissen of zelfs fatale complicaties zoals annulus of LVOT ruptuur of aorta-
dissectie. 
Hoofdstuk 15 toont een cohort patiënten met uiteenlopende mate van verkalking van de aortawortel en 
dientengevolge een excentrisch stentframe na implantatie van de CoreValve klepprothese. Tot een-derde 
van de geïmplanteerde klepprothesen hadden een excentrisch gevormd stentframe, wat correleerde met 
de hoeveelheid calcificatie en op zijn beurt met meer paravalvulaire lekkage. 
TAVI wordt in toenemende mate toegepast onder lokale verdoving. Hierdoor is TAVI steeds meer afhan-
kelijk van angiografie om de positie en paravalvulaire lekkage te beoordelen en wordt transoesophageale 
echocardiografie (slokdarmecho) tijdens de procedure nog zelden gebruikt. Hoofdstuk 16 toont het 
belang van angiografie tijdens TAVI met een repositioneerbare en volledig uitneembare mechanisch geëx-
pandeerde klepprothese. De resultaten tonen een sterke relatie tussen de implantatiediepte van het stent-
frame onder de aorta-annulus enerzijds en de noodzaak voor een pacemaker anderzijds. Bovendien bleek 
de afdichting rondom de klepprothese adequaat ongeacht de implantatiediepte. Ook was de beoordeling 
van paravalvulaire lekkage op angiografie en transthoracale echocardiografie sterk gecorreleerd. 
Deel V – Toekomstperspectief
Degeneratieve aortaklepstenose en verminderde systolische linker ventrikel functie verhogen de after-
load van het hart. Beide aandoeningen komen vaker voor bij ouderen en bestaan vaak ook tegelijkertijd. 
Afterload verlagende medicatie zoals betablokkers en medicijnen die aangrijpen op het renine-angio-
tensine-aldosteron-systeem vormen de hoeksteen van de medicamenteuze behandeling van patiënten 
met symptomatisch hartfalen. Aortaklepvervanging bij patiënten met een ernstige aortaklepstenose is 
ook een methode om de linker ventrikel afterload te verlagen. Bij patiënten met een voorstadium hiervan 
waarbij de stenose nog matig is adviseren de huidige richtlijnen om deze patiënten zorgvuldig te mon-
itoren. De implicaties van een matige aortaklepstenose in het bijzijn van een verminderde systolische 
linker ventrikel functie zijn nog onbekend. Het is aannemelijk dat een matige aortaklepstenose zijn 
weerslag heeft op de algehele belasting van de linker ventrikel zoals geïllustreerd wordt door de valvu-
lo-arteriële impedantie. Wij toonden belangrijke prognostische implicaties aan van een matige aortak-
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lepstenose bij patiënten met een verminderde systolische linker ventrikel functie (Hoofdstuk 17). Het 
gecombineerde eindpunt - dood, aortaklepvervanging of ziekenhuisopname voor hartfalen - trad op bij 
meer dan 60% van de patiënten na 4 jaar follow-up. Belangrijke voorspellers voor het optreden van het 
eindpunt waren: mannelijk geslacht, hogere gradiënten over de aortaklep en symptomatisch hartfalen. 
De meeste klinische eindpunten traden op binnen een jaar na het vaststellen van de diagnose. Vroegtij-
dige behandeling met TAVI zou de algehele prognose en kwaliteit van leven van deze patiënten kunnen 
verbeteren, en dit wordt momenteel onderzocht in een gerandomiseerde studie.
De aortaklep bestaat gewoonlijk uit drie klepbladen (tricuspide). Aortastenose is een degeneratieve ziekte 
die gekarakteriseerd word door valvulaire endotheelschade, inflammatie en calcificatie. Degeneratie 
van de aortaklep ontwikkeld zich over vele jaren en komt vaak pas op oudere leeftijd aan het licht. In 2 
tot 5 procent van de algehele bevolking heeft de aortaklep in aanleg slechts twee klepbladen (bicuspi-
de). Bicuspide kleppen zijn kwetsbaarder voor degeneratieve aortaklepstenose en hierdoor presenteren 
patiënten hierbij zich vaak op jongere leeftijd met symptomen. TAVI is mogelijk uitdagender bij patiënten 
met een bicuspide aortaklepstenose. Patiënten met een bicuspide aortaklepstenose werden geëxcludeerd 
voor de grote gerandomiseerde TAVI trials. Enkele internationale collectieven rapporteerden acceptabele 
klinische uitkomsten met TAVI als een off-label behandeling voor ernstige bicuspide aortaklepstenose. De 
eerste klinische ervaringen werden belemmerd door frequent optreden van ten minste matige paravalvu-
laire lekkage. Een recentere studie suggereerde dat de incidentie van significante paravalvulaire lekkage 
minder zou zijn met de nieuwe-generatie klepsystemen in vergelijking met de eerdere generaties. 
Hoofdstuk 18 toont de resultaten uit een post-market studie welke zich richtte op de klinische en echo-
cardiografische uitkomsten van TAVI met de mechanisch geëxpandeerde Lotus klep bij patiënten met 
een bicuspide aortaklepstenose tegenover patiënten met een tricuspide aortaklepstenose. Zowel de 
klinische uitkomsten als het optreden van belangrijke paravalvulaire lekkage waren vergelijkbaar tussen 
de twee entiteiten, in tegenstelling tot studies met eerdere generatie klepsystemen. 
Conclusie en nieuwe uitdagingen
Dit proefschrift overdenkt de huidige uitdagingen van TAVI en focust op drie belangrijke entiteiten. 
Geleidingsstoornissen blijven een belangrijk probleem. Analyse van dagelijks verkregen ECG’s na de 
procedure kan een vroege voorspelling doen over de uiteindelijke gevolgen van nieuw ontstane geleid-
ingsstoornissen zodat patiënten die baat hebben bij een (vroege) pacemaker implantatie geïdentificeerd 
kunnen worden. 
Het sluiten van de arteriële toegang voor TAVI wordt nog hoofdzakelijk verricht met behulp van ‘su-
ture-based’ methoden, maar deze hebben belangrijke beperkingen. Collageen ‘plug-based’ sluiting past 
een andere techniek toe. Deze methode zou makkelijker toe te passen zijn en het zou vasculaire compli-
caties kunnen terugdringen. 
Cerebrale schade lijkt onvermijdelijk na TAVI en is moeilijk te rijmen met het “primum non nocere” (“als 
eerste zult gij niet schaden”) principe. ‘Filter based’ cerebrale protectie is een veelbelovende methode om 
cerebrale embolizatie te voorkomen, vooral als volledige protectie kan worden bereikt. 
TAVI is uitgegroeid tot een gesimplificeerde procedure die onder lokale verdoving plaats kan vinden en de 
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werkzaamheid van de huidige klepsystemen benadert of overstijgt zelfs de chirurgische klepvervanging. 
Bicuspide aortaklepziekte, ernstige aorta insufficiëntie en matige aortaklepstenose in combinatie met 
hartfalen zijn potentieel nieuwe indicaties voor TAVI. Bovendien vormt TAVI een aantrekkelijke behan-
deling voor patiënten met een lager operatierisico welke doorgaans jonger zijn en een langere levensver-
wachting hebben. 
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Research activities
Year Workload (ECTS)
General academic and research skills
NIHES - Diagnostic research 2015 0.8
NIHES - Biostatistics for clinicians 2015 1.3
NIHES - Regression analysis 2015 1.6
Rules and organization of clinical research (BROK) course 2015 1.5
Good-clinical practice (GCP) course 2015 0.3
Scientific integrity 2015 0.3
English writing course 2016 3.0
NIHES - Prediction modelling course 2016 0.9
In-depth courses
COEUR - Arterial thrombosis in acute ischemic stroke 2014 0.2
COEUR - Vascular epidemiology 2014 1.5
COEUR - Diagnostic Imaging 2014 1.5
COEUR - Cost, quality and value in cardiovascular interventions 2015 0.3
COEUR day 2015 0.4
Conferences and symposia
NVVC conference 2015 0.9
EuroPCR conference 2015 4.8
ESC conference 2015 4.8
London valves conference 2015 3.6
NVVC conference 2015 0.9
CRT meeting 2016 1.2
ACC conference 2016 1.2
NVVC conference 2016 0.9
EuroPCR conference 2016 4.8
DRES summit 2016 0.9
Supervising practicals and Master theses
Supervising writing a systematic review of 2nd year medical students 2015-2016 0.6
Supervising research of 2nd year medical students 2015-2016 0.9
Supervising research of 4th year medical student 2015-2016 0.3
Lectures for technical university students 2016 0.6
Total 40
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Presentations
No. of presentations
Oral presentations
Dutch society of cardiology (NVVC) Spring conference, Noordwijkerhout, 
The Netherlands 2015 1
EuroPCR  conference, Paris, France 2015 2
European society of cardiology (ESC) conference, London, United Kingdom 2015 1
London valves conference, Berlin, Germany 2015 2
Dutch society of cardiology (NVVC) Autumn conference, Noordwijkerhout, 
The Netherlands 2015 1
Dutch society of cardiology (NVVC) Spring conference, Noordwijkerhout, 
The Netherlands 2016 1
EuroPCR conference, Paris, France 2016 3
Dutch revascularization and electrophysiology summit (DRES), Nijkerk, 
The Netherlands 2016 1
London valves conference, London, United Kingdom 2016 1
Poster presentations
Trancatheter cardiovascular therapeutics (TCT) conference, San Francisco, 
United States of America 2015 1
Cardiovascular research technologies (CRT) conference, Washington DC, 
United States of America 2016 1
American college of cardiology (ACC) conference, San Francisco, 
United States of America 2016 1
Trancatheter cardiovascular therapeutics (TCT) conference, Denver, 
United States of America 2017 1
Total 17
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